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Abstract 
C-reactive protein (CRP) is known to dissociate to its monomeric subunits (mCRP) in vivo. 
Furthermore, hyperglycaemia associated with diabetes mellitus (DM) results in glycation of 
serum proteins to a various extent based on their half-life and glycability. The research 
described here focuses on modified forms (glycated and monomeric) of the acute phase 
reactant, CRP, in the serum of DM patients with elevated levels of CRP. 
The susceptibility of CRP to the glycation was investigated in vitro. Human CRP was treated 
using various glucose concentrations and durations, and the glycation status and putative 
glycation sites determined by mass spectrometry. Analysis of glucose treated samples 
shows that CRP can be glycated and the glycation extent is both time- and glucose 
concentration-dependent. Between one and three glucose molecules were found to be 
condensed on the protein after a period equivalent to its serum half-life, suggesting the 
possibility of glycation occurring in vivo under high glucose conditions. Among the 
identified putative glycation sites, K13 was found to be the most susceptible lysine residue 
in CRP toward glycation. 
Human serum samples from participants with DM and elevated CRP levels (>100mg/L, 
n=24) were investigated for the presence of monomeric and glycated CRP variant. 
Monomeric CRP was detected in all investigated serum samples, with an average mCRP 
content of 0.093 mg/L, however no correlation was found between serum levels of mCRP 
and pCRP. The mCRP showed the ability to reversibly bind phosphocholine, moreover the 
mCRP displayed a molecular weight of 23,026 Da as determined by mass spectrometry. All 
24 diabetic samples were negative for the presence of glycated CRP, suggesting the half-
life of the protein is insufficient to cause a detectable level of glycated CRP.
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Chapter 1: Introduction 
1.1 Human C-reactive protein 
1.1.1 C-reactive protein and innate immunity 
Innate immunity is the first line of host defence against invading microorganisms and tissue 
injury, it plays a crucial role in the activation of acquired immunity and the maintenance of 
tissue repair. The innate immune system has a cellular and a humoral arm and comprises 
all mechanisms that do not have immunological memory including: physical barriers, 
phagocytes, inflammatory mediators releasing cells and molecules such as pathogen 
recognition receptors, complement proteins, acute phase proteins, and cytokines. All these 
mechanisms serve to prevent pathogens infections, eliminate damaged host cells, and 
initiate the inflammatory process (Cray et al., 2009). Later aspects of induced innate 
responses are dependent on cytokines and chemokines, which are generated by activated 
cells (as monocytes, macrophages, endothelium, and T-cells). These proinflammatory 
mediators, including interleukin-6 (IL-6), IL-1 and tumour necrosis factor-α (TNF-α), have 
numerous effects throughout the body including initiating the acute phase response which 
is a core part of the innate immune response (Cray et al., 2009). One of the most interesting 
features of the acute phase response is the change in the concentrations of many plasma 
proteins, known as the acute phase proteins (APP) which are proteins whose plasma 
concentration increases or decreases by at least 25% during inflammation (Cray et al., 
2009). 
C-reactive protein (CRP) was the first APP described (in the early 1930s). It is of significant 
interest in humans as its plasma concentration may increase up to 1000 fold in response to 
infection or inflammation. Therefore, it is extensively used as a marker of disease activity 
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(Black et al., 2004). CRP is a part of the humoral arm of the innate immune system and plays 
a vital role as a pattern recognition molecule, it involved in the differentiation of self (host 
molecules) from non-self molecules (antigens) by recognising pathogen-associated 
molecular patterns (CRP ligand on pathogen surfaces). However, CRP may also have 
impacts on adaptive immunity (Janeway & Medzhitov, 2002, Szalai, 2002). 
1.1.2 Historical background 
In 1930, William S. Tillett and Thomas Francis noticed a precipitation reaction in the serum 
of patients acutely infected with pneumococcus pneumonia when pneumococcal C-
polysaccharide fraction was added to it (Tillett & Francis, 1930). The precipitation reaction 
did not occur in serum obtained from patients who had recovered from the disease, nor in 
clinically healthy individuals. The researchers further demonstrated this reaction occurred 
in the serum of patients in the early phases of certain acute infectious diseases, such as 
bacterial endocarditis and acute rheumatic fever (Tillett & Francis, 1930). In 1933, Ash 
confirmed and extended the observations of Tillet and Francis to involve diseases resulted 
from gram-negative bacteria. Ash used the term "C-reactive substance" to describe the 
substance responsible for the precipitation reaction with the pneumococcal polysaccharide 
C fraction in the serum (Ash, 1933). Several years later, Abernathy and Avery (1941) 
established that the so-called C-reactive substance was a protein, and they were the first 
who used the phrase "C-reactive protein" in describing its properties, they also illustrated 
that the precipitation reaction with C-polysaccharide of the pneumococcus pneumonia was 
a calcium-dependent reaction (Abernethy & Avery, 1941). In 1947, human C-reactive 
protein (CRP) was first crystallised, whilst the first report of the medical applicability of a 
CRP test in monitoring rheumatic activity in rheumatic patients appeared in 1950 
(Anderson & McCarty, 1950, McCarty, 1947). In 1955, Roantree and Rantz stated that the 
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CRP test rarely gave a false positive result, and the most important feature of the test was 
that there was no need for interpretation of the normal range, as any positive reaction was 
considered abnormal (Roantree & Rantz, 1955). Several years later, Parker et al. (1962) 
concluded that CRP is of limited importance in viral infections (Parker et al., 1962). In 1971, 
Volanakis and Kaplan identified the ligand for CRP in C-polysaccharide to be a 
phosphocholine moiety in teichoic acid which is part of the pneumococcal cell wall 
(Volanakis & Kaplan, 1971). In the 1990s, investigators recognised that inflammation 
contributes to the development of cardiovascular diseases (CVD) and suggested the 
possibility of using CRP as a marker to predict the risk for development of CVD in patients 
(Lagrand et al., 1999; Ridker, 1998; Ross, 1993). 
1.1.3 Biological functions of C-reactive protein 
The primary biologic functions of CRP are determined by its ability to recognise pathogens 
and damaged cells of the host and to mediate their elimination by activating the 
complement system and phagocytic cells (Szalai, 2002). The capacity of human CRP to 
recognise and opsonise pathogens and damaged cells is mediated by the ligand-binding 
sites that present on the recognition face of the molecule; this face attaches with high 
avidity to the ligand decorated surfaces, figure 1-1 (Pepys & Hirschfield, 2003). After 
binding the opposite side of the molecule (the effector face) can bind C1q (a subunit of the 
C1 enzyme complex that activates the complement system) or possibly Fc-gamma 
receptors (FcγRs, a group of receptors found on the surface of certain cells and bind IgG 
and other ligands to induce phagocytosis of the opsonised cell ; figure 1-1; Pepys & 
Hirschfield, 2003). Activation of complement system via binding to C1q, and the binding to 
FcγRs are the two functions that assumed to be mediated by the effector face of the ligand-
complexed CRP molecule (Du Clos & Mold, 2011). The ability of CRP to increase the 
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clearance of host apoptotic or/and necrotic cells and nuclear antigens suggests another 
function, prevention of autoimmunity (Du Clos & Mold, 2011). 
 
 
Figure 1-1 Proposed physiological function of CRP. One face of the CRP binds to ligand-
decorated surfaces, the other face binds C1q to activate the complement system or to FcγR 
to facilitate phagocytosis; reproduced from Hage & Szalai, 2007. 
 
1.1.3.1 Activation of the complement system 
The complement system is a set of plasma proteins that can be activated either by 
pathogens or by a pathogen-bound antibody, leading to a cascade of reactions that occurs 
on the surface of pathogens, and generates active components with various effector 
functions (Janeway et al., 2005). Complement can be activated via three pathways: the 
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classical pathway (CP), the lectin pathway (LP), and the alternative pathway (AP); (Janeway 
et al., 2005). In all three pathways, the major complement component C3 is cleaved and 
activated by C3-convertase into C3a and C3b; see figure 1-2 (Janeway et al., 2005). The CP 
is initiated by C1q binding to antigen-antibody complexes or other molecules (including β-
amyloid and CRP; Orsini et al., 2014). After the binding, the C1r and C1s proteases cleave 
the C4 and C2, which subsequently result in the formation of the C3-convertase (C4b2b) as 
shown in figure 1-2; (Orsini et al., 2014). The LP is initiated by mannose-binding lectin 
(MBL), ficolins, or collectin-11 binding to carbohydrates or other molecules. After the 
binding, the MBL-associated serine proteases (MASPs), MASP-1 and MASP-2, cleave C4 and 
C2 forming the same C3-convertase as the CP; see figure 1-2 (Orsini et al., 2014). The C3-
convertase generated from CP or LP cleaves the C3 into C3a, which acts as potent 
anaphylatoxin, and C3b, which binds to the complex forming the C5 convertase (C4b2a3b) 
(Orsini et al., 2014). The activation of the alternative pathway occurs by spontaneous 
hydrolysis of C3 to form the C3 (H2O). This molecule then associates factor B and factor D 
to creates the AP C3-convertase (C3bBb) similar to that generated from CP and LP which in 
turn splits the C3 into C3a and C3b, with the latter creating a new C3 convertase (AP 
amplification loop, dotted line in figure 1-2) and creating more C3bBb3b complex (AP C5 
convertase) (Orsini et al., 2014). Increased levels of C3b results in the formation of the C5-
convertase, which cleaves the C5 into C5a, a powerful anaphylatoxin, and C5b. The C5b 
binds to the cell surface and interact with C6, C7, C8 and C9 to generate the complex C5b-
9 which is called the membrane attack complexes (MAC); see figure 1-2 (Orsini et al., 2014). 
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Figure 1-2 Schematic presentation of the activation of the complement system. The 
complement system can be activated via three pathways; the classical pathway, the lectin 
pathway, and the alternative pathway; Orsini et al., 2014.  
 
Complement plays a key role in both innate and acquired immunity. Its proper activation is 
essential for defence against pathogens and elimination of apoptotic and necrotic cells. 
Nevertheless, excessive or inappropriate activation of this system contributes to the 
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pathogenesis of many chronic inflammatory diseases, including atherosclerosis (Salazar et 
al., 2014). 
CRP complexed with its ligand (ligand-CRP) on the surface of the pathogen or damaged host 
cell can activate the classical complement system, through recognition of this complex by 
C1q (Agrawal & Volanakis, 1994, Volanakis, 2001). The resulting ligand-CRP-C1q interaction 
leads to the formation of C3 convertase, which in turn leads to the decoration of the ligand 
surface with the opsonising C3 and C4 complement fragments (Volanakis, 2001). CRP-
mediated activation appears to be limited to this initial stage involving C1-C4 (i.e. classical 
complement pathway), with limited formation of C5 convertase and MAC, due to inhibition 
of the alternative complement pathway (Agrawal, 2005). It has been postulated that the 
activation of the classical complement pathway and attenuation of the alternative 
complement pathway by CRP is due to the direct binding of CRP to the Factor H, an 
alternative complement pathway inhibitor (Sjöberg et al., 2006, Jarva et al., 1999). 
Activation of the classical complement pathway by ligand-bound CRP, therefore, mediates 
the anti-inflammatory functions of CRP (such as phagocytosis of apoptotic cells and 
protection from bacterial infections) but not the proinflammatory functions that require 
C5 convertase (Agrawal, 2005, Black et al., 2004, Du Clos, 2013). 
1.1.3.2 Binding to FcγR receptors 
The effector face of CRP is also assumed to bind FcγRs on the surface of numerous cell types 
including macrophages, leukocytes, mast cells and platelets (Salazar et al., 2014). FcγRs 
plays a co-ordinating role in immune responses; they are essential in phagocytosis, 
antibody-dependent cellular cytotoxicity, antigen presentation and inflammation (Rosales 
& Uribe-Querol, 2013). There are three families of these receptors, FcγRI, FcγRII, and FcγRIII 
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(Rosales & Uribe-Querol, 2013). Pentameric CRP (pCRP) primarily binds to the FcγRIIa 
(CD32) (Bharadwaj et al., 1999) and to a lesser extent to the FcγRI (CD64), whereas 
monomeric CRP (mCRP) binds FcγRIII (CD16), while FcγRIIb (CD32b) recognises both pCRP 
and mCRP (Salazar et al., 2014). The differences in the expression and function of the FcγR 
isoforms may explain the diverse activities of CRP as shown in table 1-1 (Salazar et al., 
2014). Binding of CRP to FcγR receptors activates the effector cells, resulting in 
phagocytosis of CRP-opsonised particles and the release of inflammatory cytokines such as 
IL-1α, IL-6 and TNF-α (Salazar et al., 2014).  
 
Table 1-1 Functions of CRP according to FcγR class and their effector cells. Adapted from 
Salazar et al., 2014. 
 
CRP can bind to these receptors even in the absence of its ligand. However, this binding 
will produce a relatively a limited release of TNF-α, IL1-β and IL-6 from peripheral blood 
mononuclear cells (lymphocytes, monocytes or macrophages) while binding with ligand-
Receptor-type CRP 
isoform 
Effector cell-Functions 
FcγRI (CD64) 
pCRP 
Monocyte- induce the release of cytokines 
Macrophages-mediates phagocytosis  
 
FcγRIIa (CD32A) 
Monocyte- induce the release of cytokine 
Macrophages- induce expression of lipoprotein lipase and 
mediate phagocytosis 
Platelets- inhibit platelet binding to neutrophil 
FcγRIIb (CD32B) 
 
pCRP 
or mCRP 
Endothelial cells- inhibits bradykinin and insulin-mediated 
activation of eNOS 
FcγRIII (CD16) 
mCRP 
Monocyte- induce the release of cytokines 
Macrophages- induce expression of lipoprotein lipase 
Platelets- promotes binding of neutrophils and Induces 
synthesis of IL-8 and MCP-1 
Endothelial cells- induces expression of endothelial 
adhesion molecules 
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complexed CRP increase the plasma concentration of these cytokines significantly (Salazar 
et al., 2014). In addition to phagocytosis and cytokine release, the interaction of CRP with 
peripheral blood mononuclear cells has been reported to induce tumoricidal activity, 
respiratory burst and hydrogen peroxide production (Volanakis, 2001).  
1.1.4 C-reactive protein ligands 
Human CRP binds mainly to phosphocholine-containing ligands in a calcium-dependent 
manner (Volanakis & Kaplan, 1971). Phosphocholine is commonly found in phospholipids 
of cell membranes, native and modified plasma lipoproteins and complex phospholipids of 
capsular and somatic components of bacteria, fungi, and parasites (Thompson et al., 1999). 
In healthy cell membranes, the phosphocholine residues are inaccessible to CRP, and the 
binding only occurs in cases of damaged and apoptotic cells when disruption of the cell 
membrane exposes the phosphocholine to CRP (Marnell et al., 2005, Volanakis & Wirtz, 
1979). Moreover, the binding affinity of CRP to phosphocholine-containing ligand increases 
when there are multiple phosphocholine residues on the membrane, as there are multiple 
phosphocholine-binding sites in each CRP pentamer (Szalai, 2002). 
Other CRP ligands that depend on calcium for binding include histones, chromatin, small 
ribonucleoproteins, fibronectin (an extracellular matrix protein), laminin (basement 
membrane protein), and phosphorylated polysaccharide (Black et al., 2004, Marnell et al., 
2005, Shrive et al., 1996). CRP can also bind to polycationic species such as poly-L-lysine, 
poly-L-arginine, poly-L-ornithine, and protamine sulfate in a calcium-independent manner 
(Ablij & Meinders, 2002). 
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1.1.5 Structure of C-reactive protein 
CRP is a member of short pentraxin family proteins which is characterised by a cyclic 
pentameric structure (Shrive et al., 1996). CRP is made up of five identical globular subunits 
(protomers) as shown in figure 1-3, each subunit has 206 amino acids and molecular mass 
of 23 kDa (Shrive et al., 1996). These amino acids form a single polypeptide chain that 
folded into two antiparallel β-strands with a flattened jelly roll topology; see figure 1-3 
(Salazar et al., 2014, Shrive et al., 1996). The protomers are noncovalently associated and 
arranged in a symmetrical cyclical pattern around a central pore, to form a pentamer with 
an outside diameter of about 102 Å and a central pore diameter of 30 Å and protomer 
diameter of 36 Å (Volanakis, 2001).  
 
 
Figure 1-3 The three-dimensional structure of C-reactive protein. CRP consist of five 
identical protomers arranged around a central pore (left). The protomer made from single 
polypeptide chain folded into two antiparallel β-strands forming a flattened jelly roll 
topology (right). 1B09 (Thompson et al., 1999) created with PyMol (DeLano, 2002). 
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The crystallographic data indicate that in the assembled CRP pentamer, all protomers have 
the same orientation (Shrive et al., 1996), and the molecule has two faces: a ‘recognition’ 
face that binds to the ligands and an ‘effector’ face which mediate CRP functions (Marnell 
et al., 2005, Szalai, 2002). 
1.1.5.1 The ligand recognition face of CRP 
The ligand recognition face of CRP binds ligands such as phosphocholine in the presence of 
calcium ions (Shrive et al., 1996). Each CRP subunit has a single phosphocholine-binding 
site, and the assembled CRP pentamer can, therefore, bind with high avidity to surfaces 
that present multiple ligands in proximity (Culley et al., 2000). The phosphocholine binding 
site of the CRP protomer has a hydrophobic pocket formed by residues Leu64, Phe66, and 
Thr76, in addition to Glu81 which is located on the other side of the hydrophobic pocket as 
shown in figure 1-4 (Shrive et al., 1996). Adjoining to this pocket, there are two calcium 
ions close to each other, see figure 1-4 (Shrive et al., 1996).  
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Figure 1-4 The ligand recognition face of CRP subunit with phosphocholine and the calcium 
ions. The phosphocholine is displayed in raspberry and the calcium ions displayed as blue 
spheres. The residues Leu64, Phe66, Thr76 and Glu81 of the hydrophobic pocket are 
displayed in magenta. Two of the oxygens of the phosphate group of phosphocholine 
directly coordinates with the two calcium ions while the third oxygen group is pointed 
away. The opposite side of phosphocholine molecule, the methyl groups of choline interact 
with Phe66 residue, while the nitrogen of choline interacts with the side chain of Glu8. 
Image of 1B09 (Thompson et al., 1999), created with PyMol (DeLano, 2002). 
 
The first calcium ion is coordinated by residues Asp60, Asn61, Glu138, Asp140 and the main 
chain carbonyl of Gln139 (Shrive et al., 1996), these residues provide one oxygen ligand 
with calcium ion (Shrive et al., 1996). The second calcium ion is 4 Å distance from the first 
one and coordinated by Glu138, Asp140 and Gln150 and Glu147, these residues provide 
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one oxygen ligand with the calcium ion except for Glu147 which provide two coordination. 
Therefore, both calcium ion is equally coordinated with protein chelation being five each 
(Shrive et al., 1996, Thompson et al., 1999). Figure 1-5 illustrates the calcium ions 
coordination with the surrounding residues.  
 
 
Figure 1-5 Illustrative scheme represents calcium ions coordination with the surrounding 
amino acid residues. Each dashed line represents single coordination. 
 
A crystallographic analysis of CRP complexed with phosphocholine demonstrated that the 
choline moiety of phosphocholine lies within the hydrophobic pocket. The methyl groups 
of choline interact with the exposed face of the hydrophobic Phe66 residue, whilst the 
positively charged quaternary nitrogen of choline interacts with the side chain of Glu81. 
The opposite side of phosphocholine molecule, two of the oxygens of the phosphate group 
of phosphocholine directly coordinates with the two calcium ions whilst the third oxygen 
group is pointed away as shown in figure 1-4 (Black et al., 2004, Shrive et al., 1996, 
Thompson et al., 1999). Mutational studies demonstrated the importance of the 
hydrophobic pocket in CRP-phosphocholine binding. The Phe66 residue appears to be the 
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major determinant of CRP-phosphocholine binding, whilst Thr76 plays a role in the 
topology of the hydrophobic pocket because its replacement with Tyr results in a 
significantly reduced avidity for phosphocholine-containing ligands, ostensibly because the 
bulky side chain of Tyr partially obstructs the pocket (Volanakis, 2001). 
1.1.5.2 The Effector face of CRP 
Opposite the recognition face of CRP is the effector face, where complement C1q bind and 
FcγRs assumed to bind (Black et al., 2004). This face is characterised by the presence of an 
α-helix and a deep groove as shown in figure 1-6 (Shrive et al., 1996). The α-helix is formed 
from 168–176 residues, and found to be folded against one of the two β-sheets of the 
subunit. The groove is formed on one side by the carboxyl-terminal end of the α-helix along 
with the 177–182 loop (figure 1-6), the other side of the groove is formed by parts of the 
amino and carboxyl termini of the protomer (Shrive et al., 1996). The groove is deep and 
narrow at its origin in the centre of protomer, but becomes wide and shallow as it extends 
toward the pore of the pentamer (Shrive et al., 1996). It has been speculated that the C1q-
binding site and perhaps the FcγR binding site is associated with the wide shallow end of 
the groove (Volanakis, 2001). 
Mutagenesis experiments have demonstrated that the Asp112 residue is the major 
determinant for recognition of C1q by CRP (Agrawal & Volanakis, 1994, Agrawal et al., 
2001). Asp112 is located within the shallow end of the groove toward the centre of the 
pentamer pore (see figure 1-6); therefore the five Asp112 residues of CRP pentamer will 
form a negative ring lining the pentamer pore (Thompson et al., 1999). It is proposed that 
the positively charged head of C1q engage with the predominantly negatively charged 
central pore that formed by the five clefts present one on CRP pentamer. The C1q head 
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extends across the central pore of CRP and interacts with two of the five protomers of the 
pentamer. The optimal C1q binding is accompanied by slight conformational changes in the 
CRP structure, these conformational changes appear to differ depending on the ligand to 
which CRP is bound (Agrawal, 2005, Black et al., 2004). The C1q unit has six globular heads 
suggesting that more than one CRP molecule is required to be in close proximity for 
complement activation, this may suggest that ligands decorated surfaces facilitate bringing 
of CRP pentamers close together to bind to the C1q heads (Agrawal, 2005).  
 
 
Figure 1-6 Surface representation of CRP showing the cleft viewed approximately from 
within the central pore of the CRP pentamer. The α-helix and the 177-182 loop that forming 
one side of the groove are displayed in red. The residues involved in C1q binding are 
illustrated in green. Image of 1B09 (Thompson et al., 1999), created with PyMol (DeLano, 
2002).  
 
In addition to Asp112, Tyr175 is also an important determinant for C1q binding to 
complexed CRP, and both of them (Asp112 and Tyr175) are assumed to be the contact 
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residue. Substitution of Tyr175 with Ala results in reduced or complete loss of C1q-binding 
activity depending on the ligand to which CRP was bound (Agrawal et al., 2001). Glu88 
appears to influence the conformational change of C1q necessary for activation of the 
complement, while Asn158 and His38 probably contribute to the geometry of the site 
(Agrawal et al., 2001). In contrast, Lys114 appears to reduce binding of C1q to CRP because 
substitution of this residue with negatively-charged, neutral, or nonpolar amino acids 
resulted in greatly improved C1q binding and complement activation, this indicates that 
the extended positively-charged side chain of Lys114 interferes with the interaction 
between C1q and Asp112 (Agrawal & Volanakis, 1994). The configuration of the CRP groove 
is not changed by the presence or absence of calcium ions at the recognition face (Ramadan 
et al., 2002). This in agreement with the findings that both calcium-independent CRP 
complexes and artificial trimers of CRP pentamers are capable of binding C1q (Agrawal et 
al., 2001). 
1.1.5.3 The structural difference between calcium-bound and calcium-depleted CRP 
The presence of calcium in CRP protomers is not only crucial for ligand binding, but also 
increases the stability and maintains the integrity of the protein (Ramadan et al., 2002). 
Early studies show that calcium-bound CRP resists denaturation caused by high 
temperatures and high urea concentrations (Heaton et al., 1999). In calcium-bound 
protomers, the 140-150 loop is folded inward and held tightly against the main body of the 
protein, mainly by the Glu147 residue. Furthermore, the Arg47 residue further stabilises 
the 140-150 loop by forming two hydrogen bonds to the main chain carbonyls of Ser151 
and Ser149, which surround calcium binding Gln150; this conformation protects the 145-
147 site, a protease cleavage site, from proteolytic degradation (Ramadan et al., 2002, 
Shrive et al., 1996). In the absence of calcium, the 140-150 loop becomes mobile, and CRP 
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can be cleaved at two sites: Asn145-Phe146 by nagarse protease, and Phe146-Glu147 by 
pronase (Kinoshita et al., 1989). The movement of the 140-150 loop away from the CRP 
protomer may also give rise to an increased binding affinity for polycations which are 
calcium-independent ligands (Ramadan et al., 2002, Thompson et al., 1999). 
1.1.6 Different forms of C-reactive protein 
1.1.6.1 Monomeric C-reactive protein 
The native pentameric CRP (pCRP) can be dissociated irreversibly into monomeric CRP or 
modified CRP (mCRP) under conditions of heat, altered pH, and urea with calcium chelation 
(Potempa et al., 1987). These modified CRP were found to run faster in gel electrophoresis, 
and were characterised by a reduced solubility, and lower isoelectric point than the native 
CRP (Potempa et al., 1987). The mCRP expresses new epitopes (neoepitopes) which are 
typically hidden in the native pCRP, and therefore mCRP has different biological features 
(Ablij & Meinders, 2002, Potempa et al., 1987). 
There is now strong evidence to demonstrate that pCRP dissociation can take place under 
physiological conditions after binding to cell membranes, and the mCRP has been detected 
in various tissues throughout the body (Salazar et al., 2014, Thiele et al., 2015). The mCRP 
is commonly considered as a tissue-based protein rather than as a soluble circulating 
protein, it is seldom found in circulation by the common detection and quantification 
methods possibly because of its limited solubility (Salazar et al., 2014, Thiele et al., 2015). 
The pCRP dissociation has been observed on the membranes of apoptotic cells and 
activated platelets in atherosclerotic plaque, and the dissociation appears to be initiated 
by binding of pCRP to the exposed lysophosphatidylcholine (LPC) on the cell surface of 
injured tissue (Salazar et al., 2014, Thiele et al., 2015). LPC, which is produced by the action 
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of phospholipase A2 on cell membrane phosphatidylcholine, appears to be important in 
this process (Salazar et al., 2014, Thiele et al., 2015). The primary step in this dissociation 
is the formation of a hybrid intermediate molecule with partial structural change termed 
mCRPm, mCRPm possess mCRP antigenicity but retains the native pentameric 
conformation, this molecule (mCRPm) rapidly detaches from the cell membrane and finally 
dissociates into mCRP (Ji et al., 2007, Salazar et al., 2014). Independent mCRP synthesis is 
also another possible mechanism, CRP mRNA has been reported in numerous extra-hepatic 
tissues including adipocytes, smooth muscle cells, and inflammatory cells within 
atheromatous plaques. However, whether the synthesised CRP is assembled into pCRP or 
expressed as the mCRP isoform is still unclear (Salazar et al., 2014). In fact, there is evidence 
that CRP mRNA in U937 macrophages of atherosclerotic lesions is processed into mCRP 
isoform rather than pCRP (Salazar et al., 2014). 
The mCRP receptors are not well characterised, but it has been suggested that mCRP can 
bind to the FcγRIIIb (CD16) receptor on the neutrophil surface. However, when the binding 
of mCRP to FcγRIIIb is inhibited by anti-CD16 antibodies, full inhibition of mCRP actions was 
not obtained suggesting the existence of additional receptors (Salazar et al., 2014). 
1.1.6.2 Fibril-like C-reactive protein 
Freshly purified CRP in a neutral buffer solution (pH 7.4) form short strand fibrils after a 
few days of storage, probably by the face-to-face stacking of pCRP and electrostatic 
interactions between pCRP molecules; these strands continue to grow in length with 
increasing duration of storage (Wang et al., 2002). Wang et al. (2002), reported fibril-like 
structure in both calcium-containing and calcium-free buffers, the ionic strength of 
Chapter 1: Introduction  Human C-reactive protein 
19 
 
solutions appear to be a key determinant as the solutions with high ionic strength result in 
less fibril-like structures (Wang et al., 2002). 
1.1.6.3 Glycosylated C-reactive protein 
Das et al., (2003), identified a glycosylated version of CRP in several pathological conditions 
including systemic lupus erythematosus, acute lymphoblastic leukaemia, tuberculosis, 
visceral leishmaniasis, Cushing's syndrome, osteogenic sarcoma, and osteogenic sarcoma. 
The glycosylated version of CRP was identified in the serum samples collected from patients 
with the above conditions by utilising digoxigenin kits, neuraminidase treatment and 
binding with lectins. The presence of N-linked sugar moiety was confirmed by N-glycosidase 
F digestion. The presence of sialic acid, glucose, galactose and mannose has been 
demonstrated by gas-liquid chromatography, mass spectroscopic and fluorimetric analysis 
(Das et al., 2003). 
The researchers were also demonstrated that the glycosylated CRP shows a variation in 
glycosylation pattern in each studied pathological condition, they also suggested two 
potential glycosylation sites on the CRP groove floor. The researchers demonstrated that 
these glycosylated CRP have variable binding characteristics with plasma glycoprotein and 
antibodies, including human IgG and anti-CRP antibody and plasma fibronectin, due to 
minute structural differences in the CRP as a result of glycosylation (Das et al., 2003). 
1.1.7 CRP synthesis and gene expression 
CRP is primarily produced by hepatocytes, and is mainly controlled at the transcriptional 
level through IL-6 signals, and enhanced synergistically by IL-1β signalling (Black et al., 2004, 
Marnell et al., 2005). The CRP gene located on the short arm of chromosome 1 (Black et al., 
2004). Both IL-6 and IL-1β control expression of several acute phase proteins through 
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activation of the transcription factors STAT3 (signal transducer and activator of 
transcription 3), Rel proteins, and C/EBP family members C/EBPβ and C/EBPδ. These 
transcription factors bind to response elements in the CRP promoter (Black et al., 2004, 
Marnell et al., 2005). Clinical trials demonstrated the importance of IL-6 as a principal 
inducer of CRP synthesis as the treatment with an anti-IL-6 receptor antibody cause a 
dramatic decrease in CRP levels (Lazzerini et al., 2015, Nishimoto et al., 2000). After 
transcription, CRP mRNA is translated to protomers that assemble to form CRP pentamer 
in the endoplasmic reticulum. The pentamers are largely retained in the endoplasmic 
reticulum-bound by two resident carboxylesterases. During the acute phase of the 
inflammatory response, the half-time for the release of CRP from the endoplasmic 
reticulum is largely accelerated. The pronounced acceleration of CRP secretion is 
apparently due to the reduced affinity of one of the carboxylesterases to CRP, thus result 
in increased serum CRP levels (Ablij & Meinders, 2002, Volanakis, 2001). 
Apart from hepatocytes, CRP synthesis has been reported to occur in many extra-hepatic 
cell including: lymphocytes, macrophages, adipose tissue, smooth muscle cells, aortic 
endothelial cells, epithelial cells from nasal polyps, epithelial cells of the upper respiratory 
tract, and tubular epithelial cells in the kidney (Ablij & Meinders, 2002, Black et al., 2004). 
The specific mechanisms by which the synthesis at these sites is regulated are not known. 
Although extra-hepatic CRP may mediate local effects, it is unlikely that it substantially 
affects the serum levels of CRP (Ablij & Meinders, 2002, Black et al., 2004). 
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1.1.8 The serum concentration of C-reactive protein in health and disease 
Many studies have reported the serum concentration of CRP in apparently healthy adults 
of the general population. Shine et al. (1981) studied 468 healthy adult volunteers using 
radioimmunoassay, the volunteers showed median CRP concentration of 0.8 mg/L, with 
90% of the values being less than 3.0 mg/L and 99% being less than 10 mg/L (Shine et al. 
1981). These results are similar to those obtained from a more recent study carried out on 
13,000 healthy individuals across Europe, in which the median concentration ranged from 
0.6-1.7 mg/L, and the 90th percentiles from 3.2-8.0 mg/L (Imhof et al., 2003). Another 
study on 22,000 healthy adults from the United States show median values of less than 
1.52 mg/L; and the 90th percentiles less than 6.61 mg/L (Rifai & Ridker, 2003). While 
studies on Asian population give a much lower result (Kao et al., 2006, Yamada et al., 2001). 
The slight difference in CRP values between populations may be due to genetic as well as 
environmental factors (physical activity, lifestyle, and dietary factors); (Kao et al., 2006). 
CRP is the most sensitive among the APPs. During the acute phase response to infection or 
inflammation, CRP concentration increases rapidly within the first 4-6 hours, doubling at 
least every 8 hours and reaching its peak after 36-50 h. With very intense stimuli, the CRP 
concentration can rise to more than 500 mg/L, i.e. 1000 times the average value; other 
APPs rarely increase by more than fourfold (Hogarth et al., 1997, Jaye & Waites, 1997, 
Vigushin et al., 1993). 
The half-life of serum CRP is 19 hours independent of its concentration in serum and the 
pathophysiological circumstances that cause the elevation. Therefore the only determinant 
of circulating CRP concentration is the rate of synthesis, which in turn reflects the intensity 
of the pathological process that stimulated the CRP production (Vigushin et al., 1993). 
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Therefore measuring CRP can provide information about the presence and intensity of an 
inflammatory process, and help to differentiate inflammatory from non-inflammatory 
conditions (Póvoa, 2002). If the stimulus that causes increased production completely 
ceases, the circulating CRP concentration will fall rapidly. However, CRP serum 
concentration can remain high, even for very long periods of times if the underlying 
pathology of the elevation persists (Vigushin et al., 1993). 
Elevation in serum concentration of CRP is seen in infections (bacterial, viral, and fungal 
infection), inflammation and tissue damage. In infectious diseases, the highest elevations 
of CRP concentrations are seen in bacterial infections, with levels exceeding 200 mg/L in 
case of severe conditions. In contrast, viral infections are less likely to cause a substantial 
elevation. Therefore, CRP can be used to differentiate between viral and bacterial infection 
(Chew, 2012). However, this generalisation is not always true, as sometimes uncomplicated 
infections with adenovirus, measles, mumps and influenza are associated with high serum 
CRP levels while some chronic bacterial infection as tuberculosis and leprosy, cause only a 
modest elevation (Póvoa, 2002). There is limited information about CRP response in 
parasitic infections, but some protozoan parasitic diseases such as malaria, pneumocystosis 
and toxoplasmosis characterised by a marked increase in serum CRP level (Póvoa, 2002). 
Serum CRP concentration is also markedly elevated in most of the inflammatory diseases 
and measuring CRP concentration in these diseases can give valuable information about 
the extent of activity and severity of disease state. However, the behaviour of CRP is not 
the same with all inflammatory diseases such as SLE, dermatomyositis, Sjögren’s syndrome, 
or ulcerative colitis have a normal or only slightly elevated CRP despite the presence of a 
severe disease state. The reason for this contradiction remains speculative (Vermeire et al., 
2004). Even in inflammatory conditions that are not associated with elevated CRP levels, 
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the measurement may still useful to differentiate between disease exacerbation and 
complication with infection, as these patients are still able to mount a major CRP response 
in the presence of infection (Póvoa, 2002). 
There are several other conditions that lead to a substantial increase in CRP concentrations, 
these include trauma, surgery, burns, tissue necrosis, and advanced cancer (Gabray & 
Kushner, 1999, Vigushin et al., 1993), even vigorous exercise and some psychiatric diseases 
are associated with mild CRP changes (Póvoa, 2002). 
1.1.9 Applications of CRP as a clinical marker 
CRP has many analytical properties that support its use as a clinical marker, particularly, 
the rapid change follows the onset of the inflammation, the long half-life compared to 
other markers of inflammation, a broad range of abnormal values and availability of easy 
and sensitive methods for its measurement (Pepys & Hirschfield, 2003). CRP can be 
measured in plasma, serum and detected in various body fluids (including cerebrospinal, 
synovial, pleural and ascitic fluids), and there is no diurnal variation in its serum 
concentration; therefore the measurement can be done without concern for the time of 
collection (Pepys & Hirschfield, 2003). 
Elevation of CRP is not specific of any particular disease as it happens in all diseases 
involving tissue damage or inflammation; however, because of its extreme sensitivity CRP 
can be used as an adjunct to clinical assessment in many situations including the followings 
(Aguiar et al., 2013, Hirschfield & Pepys, 2003, Reeves, 2007): 
1. Screening for the organic disease to support the clinical diagnosis 
2. Monitoring response to treatment of infection and inflammation  
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3. Detection of intercurrent infection in inflammatory diseases characterised by 
modest or absent CRP response 
4. Prediction in CVD. 
1.1.10 Methods of measurements 
CRP levels have been measured utilising a variety of methods. The most common methods 
of measurement include; latex agglutination, immunonephelometry, immunoturbidimetry, 
and enzyme immunoassay (Deodhar, 1989, Urdal et al., 1992). These immunological 
methods of measurement depend on the formation of antigen-antibody complexes when 
anti-CRP antiserum reacts with its antigen (CRP in patient’s serum). These complexes 
(which proportionally reflect the concentration of CRP) can scatter incident light; in turn, 
this scattering of the light can be measured by different methods including turbidimetry 
(measuring the reduction of light passing through a reaction mixture) or nephelometry 
(measuring the light scattered by a reaction mixture); (Deodhar, 1989, Urdal et al., 1992). 
Nephelometry is the most widely used method as it is stable, reproducible, rapid (results 
can be obtained in less than 30 min), sensitive (≤ 0.04 mg/L) and relatively inexpensive 
(Enguix et al., 2001). 
There are two major types of CRP assay; standard or high-sensitivity CRP (hs-CRP) assay. 
The standard assay has a limit of detection of approximately 10 mg/L and can be used for 
any clinical condition with a serum CRP concentration above this limit. The hs-CRP assay 
range is from < 1.0 mg/L to ≤ 10.0 mg/L; this assay can be used for an apparently healthy 
individual with serum CRP concentrations of less than 10 mg/L (Faraj & Salem, 2012). The 
advent of the hs-CRP assay led to numerous studies that showed utility in individuals at risk 
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for cardiovascular disease, metabolic syndrome, and other chronic diseases associated with 
a low level of inflammation (Du Clos, 2013). 
1.1.11 Demographic, behavioural and lifestyle factors that affect baseline CRP 
Baseline values of CRP are influenced by a wide variety of factors including: age, obesity, 
smoking, and other factors. Increasing age was associated with increased serum level of 
CRP in several studies of different gender groups. A large population study, including 
individuals aged from 25 to 74 years by Hutchinson et al. (2000) found the median CRP 
concentration is approximately doubled with age, from ∼1 mg/L in the younger age groups 
to ∼2 mg/L in the older age group and the levels tended to be higher in females (Hutchinson 
et al., 2000). Further evidence from a 20 year follow-up study in men aged 60-79 showed 
that 57% of the median serum CRP levels increased between the 60-64 year age group and 
the 75-79 year age group (Rumley et al., 2006). Caparevic and Kostic also showed that 
healthy women over 56 years have higher levels of serum CRP compared with healthy 
women younger than 45 years of age (Čaparević & Kostić, 2007). 
Many studies have demonstrated a strong positive correlation between serum CRP 
concentration and obesity (Timpson et al., 2005, Visser et al., 1999). As obesity is associated 
with a higher CRP concentration compared to lean control subjects, weight reduction 
results in a decrease in CRP concentration regardless of the type of intervention, with a 
roughly linear relationship (Dietrich & Jialal, 2005, Selvin et al., 2007). Elevated serum CRP 
levels are associated with abdominal obesity, which is a measure of general obesity, 
independent of body mass index (BMI). CRP concentration is higher in individuals with 
abdominal obesity, compared to control subjects with the same BMI (Lapice et al., 2009). 
It has been hypothesised that a chronic low-grade inflammatory state is associated with 
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obesity; however, the origin of this inflammation and the underlying molecular 
mechanisms that explain its occurrence are not completely understood. Pro-inflammatory 
cytokines are postulated to play a central role (Rodríguez-Hernández et al., 2013). 
Infiltrating macrophages in expanded adipose tissue and adipocyte secrete a number of 
pro-inflammatory cytokines including IL-6 and TNF-α. It found that adipocytes may produce 
as much as one-third of the total IL-6 in circulation. IL-6, in turn, activates CRP expression 
from hepatocytes, as a consequence, obese individuals tend to have slightly elevated 
serum CRP levels (Rodríguez-Hernández et al., 2013). 
Smoking also results in a high serum CRP concentration as evidenced by many studies, for 
example, a study of 2,920 British men aged 60-79 showed that current smokers have 
significantly higher CRP levels (2.53 vs 1.35 mg/L) than to non-smokers (Wannamethee et 
al., 2005). The level of serum CRP in smokers is dose-dependent, such that CRP 
concentration is positively correlated with the number of cigarettes smoked per day 
(Melbye et al., 2007, O'Loughlin et al., 2008). Furthermore, the relationship between 
smoking and the high CRP concentration appears to be temporal, as smoking cessation for 
long periods (≥5 years) can significantly improve CRP concentration (Ohsawa et al., 2005, 
Wannamethee et al., 2005). This finding suggests that the risk reduction of CVD by smoking 
cessation could be reflected by the reduction in CRP level (Ohsawa et al., 2005). 
Other factors that may cause a small elevation in CRP levels include ethnicity, low 
socioeconomic status, high fat and low fibre consumption, hormonal replacement therapy, 
pregnancy, poor physical fitness or low levels of physical activity (Kushner et al., 2006, Nanri 
et al., 2007). 
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1.1.12 C-reactive protein as a low-grade inflammatory marker 
Historically, only serum CRP values above 10 mg/L were considered clinically important 
(Morley & Kushner, 1982), today a mildly elevated serum CRP levels higher than those in 
most normal subjects is now believed to represent low-grade inflammation, and may 
underlie chronic complex diseases such as diabetes, dyslipidaemia, atherosclerosis, and 
metabolic syndrome. Recent studies have shown the importance of minor CRP elevation in 
the prediction of CVD. Ridker and colleagues have suggested clinical categories for baseline 
serum CRP values in predicting the risk of future cardiovascular events (Ridker, Paul M. et 
al., 2003). 
• Low-risk group: less than 1.0 mg/L 
• Intermediate risk group: 1.0 to 3.0 mg/L 
• High-risk group: above 3.0 mg/L 
Thus, CRP is now also considered as a marker of low-grade inflammation alongside its 
traditional role as an acute phase protein. 
1.1.13 CRP and cardiovascular disease 
1.1.13.1 Evidence from epidemiological studies 
Since the 1990s, several epidemiological studies have shown a link between the circulating 
CRP and incidence of a variety of CVD (Lagrand et al., 1999). Arima et al. (2008) followed 
2589 adult aged 40 years and older for 14 years in a population-based prospective cohort 
study. The researchers found that the risk of coronary heart disease (CHD) in the highest 
CRP quartile group was three times higher than that in the lowest CRP group even after 
adjusting the other cardiovascular risk factors such as age, gender, BMI, smoking habits, 
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alcohol intake and regular exercise (Arima et al., 2008). Zieske et al. also found that 
elevated CRP levels are independently associated with atherosclerosis in young people 
(Zieske et al., 2005). Furthermore, Williams et al. (2008) showed that the elevated CRP 
levels in patients with CHD can predict hospitalisation due to heart failure independent of 
a prior history of heart failure, medication use, and severity of CHD; therefore CRP can add 
prognostic information and predict morbidity and mortality in CHD patients. Ridker et al., 
(2002), stated that serum CRP was the stronger predictor of future cardiovascular events 
(myocardial infarction, ischaemic stroke, or death from cardiovascular causes) than plasma 
low-density lipoprotein cholesterol (LDL-C). Ridker et al., (2002), followed 27,939 healthy 
women for eight years for the occurrence of the first cardiovascular events. They found 
that the relative risk of a first cardiovascular event according to increasing quintiles of CRP 
level as compared to the lowest quintile, were 1.4, 1.6, 2.0, and 2.3, whereas the 
corresponding relative risks in increasing quintiles of LDL-C level compared with the lowest 
were 0.9, 1.1, 1.3, and 1.5 (Ridker, et al., 2002). 
CRP is not only a predictor of CVD, but also can be a therapeutic target, as demonstrated 
by JUPITER trial (Justification for the Use of Statins in Primary Prevention), which showed a 
significant reduction in the incidence of major cardiovascular events through lowering 
serum CRP levels by using statin therapy (Rosuvastatin) among people without 
hyperlipidemia. This finding emphasises the vital role that CRP plays in CVD prevention 
(Ridker, 2003). Some researchers in the field consider that CRP is more than just an 
inflammatory marker, but also a direct cause of CVD (Li, Jian-Jun & Fang, 2004, Stumpf & 
Hilgers, 2009). 
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1.1.13.2 Role of CRP in atherosclerosis and atherothrombosis 
Atherosclerosis is a multifactorial disease affecting the endothelial lining of medium and 
large-sized arteries, and usually develops several years before the manifestation of any 
clinical symptoms. The main risk factors for atherosclerosis include dyslipidaemia, smoking, 
hypertension and diabetes mellitus, all these factors are associated with low-grade 
inflammation (Packard & Libby, 2008). In atherosclerosis, the LDL-C which is transmigrated 
across the vascular endothelium and deposited in the intima undergo oxidation by local 
reactive oxygen species (Heinecke, 2006). Oxidised LDL (Ox-LDL) stimulates endothelial 
cells to express adhesion molecules (vascular cell adhesion molecule 1 (VCAM-1), 
intercellular adhesion molecule 1 (ICAM-1) and E-selectin), cytokines (IL-1, IL-8, TNF-α) and 
chemokines (monocyte chemoattractant protein 1 (MCP-1)). These molecules make 
vascular endothelial surfaces ‘sticky’, so that white blood cells such as monocytes adhere 
to the endothelium. Once the monocytes adhere to the activated endothelium, they 
migrate through it into the subendothelial space. Within the intima, the monocytes mature 
into macrophages where many of them can differentiate into macrophages, which express 
scavenger receptors enabling them to ingest Ox-LDLs, and subsequently transform into 
foam cells as shown in figure 1-7 (Heinecke, 2006, Packard & Libby, 2008). Foam cells 
accumulate and form ‘silent’ fatty streaks. If the process continues, smooth muscle cells 
from the vascular intima can migrate into the subendothelial intima, proliferate and form 
a fibrous cap which surrounds the atherosclerotic plaque (see figure 1-7). The plaque may 
grow large enough to reduce the blood flow or the fibrous cap may weaken and rupture, 
exposing the underlying thrombogenic tissues causing the contents of the plaque to spill 
out into the lumen of the blood vessel, impeding blood flow, and resulting in severe clinical 
manifestation according to the site of occlusion (Packard & Libby, 2008). The clinical 
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manifestation may be in the form of angina pectoris, myocardial infarction, sudden cardiac 
death, cerebrovascular disease (transient ischaemic attacks, stroke) or peripheral vascular 
disease. 
 
Figure 1-7 Initiation and progression of the atherosclerotic lesion. Atherosclerosis begins 
with dysfunctional endothelial cells and the retention of LDL-C in the subendothelial space. 
The retained LDL-C are modified (e.g. by oxidation) and promotes activation of endothelial 
cells to express monocyte interaction/adhesion molecules leading to attachment and 
transmigration of monocytes into the intimal space. The monocytes differentiate into 
macrophages, which express receptors that mediate the uptake of modified LDL and 
converting it into foam cells. Subsequently, smooth muscle cells migrate into the 
subendothelial space and form a fibrous cap which surrounds the atherosclerotic plaque. 
Reproduced from Heinecke, 2006.   
 
Inflammation plays a fundamental role in all phases of atherosclerosis, as evidenced by the 
continuous presence and accumulation of monocyte-derived macrophages and T 
lymphocytes in fatty streaks and advanced atherosclerotic lesions (Ablij & Meinders, 2002). 
Both activated complement and CRP are present in atherosclerotic lesions (Ablij & 
Meinders, 2002). CRP may be more than just an inflammatory marker of increased 
cardiovascular risk, several in vitro and in vivo studies claim that CRP has an active role in 
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the endothelial dysfunction, atherosclerotic plaque formation, progression and rupture 
that result in atherothrombotic events. CRP actively participates in atheroma formation by 
binding modified LDL of the type that accumulates in atherosclerotic plaques (ox-LDL and 
partly degraded LDL) and facilitates their uptake by macrophages by opsonisation thus 
enhancing foam cell formation, a typical feature of atherosclerotic plaques (Osman et al., 
2006). Aggregated and/or ligand complexed CRP activates complement, thus promoting 
inflammation in the plaques; therefore, CRP can be proinflammatory. CRP and activated 
complement are found in all acute myocardial infarction lesions, and they can significantly 
increase the infarct size in experimental models (Pepys & Hirschfield, 2003). Furthermore, 
CRP up-regulates the expression of endothelial adhesion molecules (ICAM-1, VCAM-1, and 
E-selectin) through binding of FcγRII and activation of the NF-κB pathway (Pasceri et al., 
2000, Verma et al., 2003). CRP also stimulates MCP-1 expression from endothelial cells. 
MCP-1 and other chemoattractant factors cause monocytes that have adhered to 
endothelial cells to migrate across the endothelial cells (Pasceri et al., 2001). Elevated 
serum CRP levels are also associated with reduced expression and activity of endothelial 
nitric oxide synthase (eNOS), thus reducing nitric oxide production in endothelial cells. 
Nitric oxide plays crucial roles in many biological processes including regulation of vascular 
tone, inhibition of smooth muscle cells proliferation, leukocyte adhesion, and platelet 
aggregation. Inhibition of nitric oxide synthesis by CRP, therefore, leads to vasoconstriction 
and promotes endothelial cell dysfunction and apoptosis (Osman et al., 2006, Salazar et al., 
2014). CRP can also promote the synthesis of matrix metalloproteinases (MMPs), 
proteolytic enzymes responsible for remodelling the extracellular matrix, which is 
implicated in plaque rupture and thrombosis. Elevated MMP levels may contribute to 
plaque instability, which may explain the heightened risk of coronary events in subjects 
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with elevated serum levels of CRP (Cimmino et al., 2013, Montero et al., 2006). CRP has 
been also linked to thrombosis by stimulating the release of tissue factor (a potent stimulus 
for the extrinsic pathway of coagulation) from peripheral blood monocytes, endothelial 
cells and smooth muscle cells (Cermak et al., 1993, Cirillo et al., 2005). In addition, CRP 
increases the expression and activity of plasminogen activator inhibitor-1 (PAI-1), a marker 
of atherothrombosis and impaired fibrinolysis in human aortic endothelial cells (Devaraj et 
al., 2003). These postulated mechanisms support the rule of CRP in clinical 
atherothrombosis in addition to its role in atherosclerosis progression. CRP has been shown 
to induce the production of endothelin-1 (a potent endogenous vasoconstrictor) and IL-6 
from endothelial cells. IL-6, in turn, stimulates CRP production by the liver (Verma, Li et al., 
2002). CRP inhibits bone marrow-derived endothelial progenitor cell survival and 
differentiation, these cells play a role in promoting angiogenesis in ischaemic tissue, 
therefore, their inhibition results in impaired maintenance of vascular integrity (Verma et 
al., 2004). CRP also assumed to induce overexpression of angiotensin type 1 receptor in 
vascular smooth muscle cells in vitro and in vivo and stimulates vascular smooth muscle 
migration, proliferation, neointimal formation, and reactive oxygen species production 
(Verma et al., 2004). 
1.1.13.3 Doubts about the in vitro experiment 
There are some doubts about the validity of the in vitro investigation of CRP effects on 
endothelial cells. Commercial preparations of recombinant human CRP produced in E. coli 
may contain contaminating bacterial endotoxins such as lipopolysaccharide (LPS), as well 
as sodium azide as a bacteriostatic preservative. LPS is known to activate endothelial cells, 
while azide is generally cytotoxic; the presence of these substances may interfere with in 
vitro investigation of CRP effects on endothelial cells. For this reason, all the published work 
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that has been done using commercially-sourced CRP of incompletely defined provenance 
and purity were criticised since results may be attributed to LPS or azide rather than CRP 
itself (Pepys & Hirschfield, 2003, Hirschfield & Pepys, 2003). Taylor and associates 
examined the literature up to 2005, and found that only two studies detailed the use of 
azide-free CRP was used. One of these two studies demonstrated a modulatory effect of 
CRP on monocyte adhesion to human endothelial cells (Taylor et al., 2005). The LPS 
contamination aspect has been better investigated, with at least four studies employing a 
Detoxi-GelTM column for endotoxin removal, with SDS-polyacrylamide gel electrophoresis 
and/or Limulus assay for endotoxin level estimation. The results of these studies support 
the role of CRP in atherogenesis (Pasceri et al., 2001, Venugopal et al., 2002, Venugopal et 
al., 2003, Verma, Wang et al., 2002). The remainder of the previous studies were however 
potentially affected either by LPS or azide contamination. Many researchers tried to prove 
the results of previous studies, Dasu and co-workers used azide-free CRP preparations 
purified by Detoxi-GelTM column in Toll-like receptor 4 (TLR4) knockdown endothelial cells 
to abrogate the effect of LPS as TLR4 is the receptor for sensing LPS and consequent 
signalling. CRP incubation induced secretion of pro-inflammatory cytokines (IL-8, IL-6, IL1-
β) and PAI-1 from knockdown endothelial cells and inhibited eNOS activity (Dasu et al., 
2007). Other studies using heat-inactivated CRP (which has no effect on endotoxin activity), 
abolishes the pro-atherogenic effects of CRP (Devaraj et al., 2009, Singh et al., 2005). 
Bisoendial et al. have stated that the trace amount of endotoxin present in recombinant 
human CRP following additional purification steps is insufficient to contribute to the pro-
atherogenic effects (Bisoendial et al., 2005). These studies may confirm that the biological 
effects of CRP on endothelial cells are independent of endotoxin, a common contaminant 
in commercial CRP preparations. 
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1.1.14 CRP and metabolic syndrome 
Metabolic syndrome (Mets) can be defined as the presence of three or more of the 
following criteria: Central obesity, Dyslipidemia (elevated triglycerides and/or reduced 
levels of HDL cholesterol), High blood pressure, and High fasting glucose (Grundy et al., 
2004). Mets associated increased risk of mortality as a result of the systemic inflammatory 
state, increased risk of CVD or type two diabetes mellitus that found in Mets patients. 
Therefore, measurement of inflammatory markers such as CRP in patients with Mets can 
help in the prediction of the hazardous outcome of this syndrome (Huffman et al., 2009, 
Vidyasagar et al., 2013). 
Increased serum CRP levels (more than 3 mg/L) have been found in patients with Met, and 
a positive correlation has been found between serum CRP level and each of the component 
of Mets (Huffman et al., 2009, Vidyasagar et al., 2013). It is suggested that the elevated CRP 
concentrations seen in patients with severe Mets may reflect IL-6 production by adipocytes 
(Fröhlich et al., 2000). Large scale, population-based studies have concluded that CRP 
concentration >3 mg/L in patients with Mets confers greater risk for developing 
cardiovascular disease (Freeman et al., 2002, Ridker et al., 2008). This led to the 
recommendation of considering CRP as a clinical criterion for metabolic syndrome 
definition because it adds prognostic information with regard to the risk of CVD, and 
improves the early detection of risk for future diabetes and CVD in these individuals 
(Devaraj et al., 2009, Ridker et al., 2004). 
 
Chapter 1: Introduction  Human C-reactive protein 
35 
 
1.1.15 CRP and diabetes mellitus 
Numerous studies have hypothesised that chronic low-grade inflammation plays a role in 
the pathogenesis of both type 1 and type 2 diabetes, and a moderately increased levels of 
CRP were found in both types of diabetes (Schalkwijk et al., 1999, Kilpatrick et al., 2000, 
Pickup & Crook, 1998, Duncan et al., 2003). The increased levels of CRP in diabetes are not 
caused by the development or presence of diabetic complications but might precede these 
(Schalkwijk et al., 1999, Chase et al., 2004). High CRP levels were found to be an 
independent predictor of risk for the development of type 2 diabetes mellitus even after 
adjustment for coronary risk factors, BMI, fasting insulin levels, smoking and other factors 
(Freeman et al., 2002, Pradhan et al., 2001). Prolonged exposure to hyperglycaemia is 
known to stimulate the release of the pro-inflammatory cytokines from adipocytes, 
monocytes and other cells, which can increase the production of CRP in the liver (Ingle & 
Patel, 2011, Goh & Cooper, 2008). Moreover, diabetic individuals are at high risk of 
developing other inflammatory conditions including atherosclerosis and heart disease, 
which associated with high levels of CRP (Messier et al., 2004, Lee et al., 2015). CRP may 
also give information about glycaemic control; CRP found to be higher in type 2 diabetic 
patients with high haemoglobin A1c (HbA1c) as compared to those with recommended 
HbA1c level (Capuzzi & Freeman, 2007, King et al., 2003). 
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1.2 Protein glycation 
1.2.1 Introduction 
Protein glycation is a process that involves non-enzymatic attachment of a reducing sugar 
or sugar derivative to a reactive protein residue (Rabbani & Thornalley, 2012). The reducing 
sugars are sugars with a free aldehyde or ketone groups, this includes the common 
monosaccharides such as glucose, galactose, glyceraldehyde, fructose, and ribose. In the 
human body, glucose, the most important source of fuel, is the most abundant 
monosaccharide making it the main glycating sugar present in the body (Aragno & 
Mastrocola, 2017). Glucose exists almost entirely in the pyranose (ring-closed) form, with 
less than 0.4% in the furanose ring form, and less than 0.02% in the open-chain aldehyde 
form (Bubb, 2003). Only the acyclic form of glucose can react with the reactive protein 
residues during glycation reaction, this is because the open-chain form possesses the 
reactive carbonyl group (Aragno & Mastrocola, 2017). Other sugars and sugar derivatives 
such as galactose, fructose, ribose, sialic acid, mannose, glucose 6-phosphate, and 
glyceraldehydes are more reactive than glucose and have been used in vitro glycation 
experiments, sometimes to hasten the process of glycation (Arasteh et al., 2014). The main 
targets of glycation in the proteins are the ε-amino groups of lysine residue side chains and 
N-terminal amino acid residues (Ansari & Ali, 2011, Rabbani & Thornalley, 2012). Glycation 
of arginine residues is also seen as a major feature of protein glycation in physiological 
systems, and there is also evidence for cysteine glycation (Rabbani & Thornalley, 2012, 
Münch et al., 1999). Protein glycation reactions are relatively non-specific, not mediated 
by enzymes and usually resulting in protein damage and reducing functionality, it differs 
from the enzymatic glycosylation, an essential post-translational modification required for 
the molecule to function (Spiro, 2002). Glycation was first identified by Louis Camille 
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Maillard in 1912; therefore, glycation reactions is also referred to as ‘Maillard reactions’ 
(Maillard, 1912). Protein glycation has been studied most extensively in foods; the 
formation of glycation reaction products is responsible for the brown colour formation and 
loss of protein quality in cooked and stored foods (Ulrich & Cerami, 2001). The realisation 
of the importance of the glycation in the human body began after the studies on 
haemoglobin A 1c (HbA1c), a naturally occurring minor fraction of human haemoglobin that 
is elevated in diabetics (Koenig et al., 1976). HbA1c is glycated haemoglobin in which the 
glucose molecule is condensed on N-terminal of valine residue of the beta chain of 
haemoglobin (Welsh et al., 2016). The measurement of the elevation of HbA1c in diabetics 
allowed the assessment of the glycaemic control integrated over several weeks (Koenig et 
al., 1976). In the human body, protein glycation can take place under normal physiological 
conditions, but the reaction is accelerated in hyperglycemia as seen in diabetes especially 
in an uncontrolled state (Arasteh et al., 2014). In addition to the haemoglobin, in vivo 
glycation has been described in other proteins such as; serum albumin, ferritin, 
apolipoprotein, collagen, insulin, histone, IgM, IgG, and the lens protein crystallin (Arasteh 
et al., 2014, Ansari & Ali, 2011). 
1.2.2 The chemistry of protein glycation 
The process of protein glycation can be divided into three distinguishable phases: the initial 
stage, the intermediate stage and the late stage (Wang & Ho, 2012).  
During the initial stages, the carbonyl group of the reducing carbohydrates reacts with the 
nitrogen atom of the ε-amino group on lysine or arginine or the N-terminal amino group by 
the nucleophilic attack (Wang & Ho, 2012). The product of this reaction is a reversible 
glycosylamine which dehydrates to form unstable Schiff base (aldimine) as shown in figure 
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1-8, the formation of the Schiff base is fast but highly reversible (Rabbani & Thornalley, 
2012). The Schiff base then undergoes a rearrangement to form a more stable ketoamine 
named Amadori product (such as fructosamine if the reaction is between glucose and lysine 
residues) as shown in figure 1-8 (Rabbani & Thornalley, 2012). Formation of Amadori 
product from the Schiff base (the forward reaction) is much faster than the reversed 
reaction so that the Amadori adducts tend to accumulation on the protein (Rabbani & 
Thornalley, 2012). This process (Amadori rearrangement) is thought to be facilitated by 
localised acid-base catalysis if there is a basic residue in the proximity from the target amino 
residue on which the Schiff base has formed (Ulrich & Cerami, 2001).  
 
 
Figure 1-8 Protein glycation pathway. Protein glycation reactions can be divided into three 
stages: the initial stage involves condensation of glucose with primary amines to give a 
Schiff base, which rearranges to an Amadori product, the intermediate stage during which 
the α-oxoaldehydes are formed from the degradation of glucose, Schiff base or Amadori 
product, and the late stage that result in the formation of the advanced glycation end 
products via several pathways, including direct degradation of Amadori products or protein 
modification by dicarbonyl compounds. 
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During the Intermediate stage, the Amadori products or the Schiff base can degrade via 
non-Amadori rearrangement reactions to α-oxoaldehydes (dicarbonyl compounds) as 
shown in figure 1-8, these compounds more potent glycating agents than glucose (Rabbani 
& Thornalley, 2012). The most important α-oxoaldehydes are glyoxal (GO), methylglyoxal 
(MG), and 3-deoxyglucosone (3-DG), see figure 1-9; (Rabbani & Thornalley, 2012). GO is 
formed from several reactions including the oxidative fragmentation of Schiff base via the 
Namiki pathway (Wang & Ho, 2012), the 3-DG can be produced from non-oxidative 
fragmentation and hydrolysis of Amadori product (Wang & Ho, 2012). GO and 3-DG can be 
also produced as a result of metabolic degradation of D-glucose; the auto-oxidation of 
glucose in the presence of metal can produce GO (Wolff pathway); (Jakuš & Rietbrock, 
2004), while 3-DG can also be produced from fructose-3-phosphate, an intermediate of the 
Polyol pathway in which glucose is reduced to sorbitol by aldose reductase (Lal et al., 1995). 
Methyl glyoxal can be formed from further degradation of 3-DG generates by retro-aldol 
condensation (Wang & Ho, 2012). α-oxoaldehydes are more reactive glycating agents than 
glucose due to their lack of cyclic structure and comparatively smaller size (Rabbani & 
Thornalley, 2012). 
 
Figure 1-9 Reactive dicarbonyl species. Glyoxal, methylglyoxal and 3-deoxyglucosone are 
highly reactive α-oxoaldehydes and precursors for the formation of advanced glycation end 
products. 
Chapter 1: Introduction  Protein glycation 
40 
 
During the late stage, heterogeneous group of compounds, collectively termed the 
advanced glycation end products (AGEs), are formed (Rabbani & Thornalley, 2012). The 
Amadori product or Schiff base can slowly undergo further dehydration, cyclisation, 
oxidation and rearrangement to form AGEs (Rabbani & Thornalley, 2012). Dicarbonyls 
compounds, formed from the intermediate stage of glycation, potent precursors for AGEs, 
can interact with proteins or other amino-containing molecules to produce AGEs at a much 
higher reaction rate than does the reducing sugar itself (Rabbani & Thornalley, 2012, 
Thorpe & Baynes, 2003). Examples of these AGEs are Nε-carboxymethyl lysine (CML), 
carboxyethyl lysine (CEL), pentosidine, glucosepane, and others such as methylglyoxal 
lysine dimer (MOLD), glyoxal- lysine dimer (GOLD), 3-deoxyglucosone-derived imidazolium 
cross-link (DOGDIC), methylglyoxal-derived imidazolium cross-link (MODIC) and glyoxal-
derived imidazolium cross-link (GODIC), see figure 1-10 (Cho et al., 2007, Sell et al., 2005, 
Ulrich & Cerami, 2001).  
 
Figure 1-10 AGEs Structures. The structures of some of the known AGEs 
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Except for CML these are all cross-links between two amino acid residue side chains within 
proteins. GOLD and MOLD are lysine-lysine cross-links, whereas pentosidine, glucosepane, 
DOGDIC, MODIC and GODIC are lysine-arginine cross-links (Cho et al., 2007, Sell et al., 
2005). 
1.2.3 Biological effects of protein glycation 
Protein glycation and the resulting AGEs have varied deleterious effects on the proteins 
and biological systems. Modification of the side chains of lysine and arginine residues by 
glycation is likely to affect the protein interaction of with other molecules such as ligands, 
substrate or the cell receptors (Avery & Bailey, 2005). Moreover, the cross-links between 
amino acid residues within the protein as a result of AGEs formation could alter the shape, 
restrict the movement, and affect the mechanical properties of the protein (Avery & Bailey, 
2005). Furthermore, the interaction between AGEs and the receptor for AGEs (RAGE, non-
specific cellular receptors belong to the immunoglobulin super-family of cell surface 
molecules) can increase oxidant stress and induce a cascade of inflammatory reactions, 
these interactions (AGEs-RAGE) plays a significant role in diabetic complications (Sparvero 
et al., 2009, Stern et al., 2002). 
The rate of glycation of any protein is dependent on the glucose concentration and the 
duration of exposure (the biological half-life) of the protein to the glycating agent (Olufemi 
et al., 1987). Therefore, the degree of glycation of proteins in diabetic patients is 
significantly greater than in non-diabetic patients because of the persistent hyperglycaemia 
in those patients (Negre-Salvayre et al., 2009). Many studies indicate that the increased 
rate of protein glycation in diabetic patients and the accumulation of the AGEs play an 
important role in diabetic complications such as diabetic nephropathy, retinopathy, 
neuropathy and cardiovascular diseases (Negre-Salvayre et al., 2009, Thornalley et al., 
1999). The proteins with a longer half-life, such as collagen and lens crystalline, are more 
implicated with glycation mediated effects than the short-lived proteins because of the 
longer exposure time (Thornalley et al., 1999). The accumulation of the AGEs on the long-
lived proteins are implicated in several chronic complications, for example cataract 
formation as a result of accumulation of AGEs on lens crystalline (Ulrich & Cerami, 2001), 
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while glycation of collagen may contribute to atherosclerosis and coronary disease, poor 
peripheral circulation, and other lesions (Ulrich & Cerami, 2001). AGEs are involved not 
only in diabetic complications but also in pathophysiology of other conditions such as 
neurodegenerative diseases (Alzheimer’s and Parkinson disease); (Grillo & Colombatto, 
2008), renal failure (Thornalley, 2006), some types of liver disease (Hyogo & Yamagishi, 
2008), and the normal ageing (Grillo & Colombatto, 2008). The accumulation of AGEs in 
tissues and their interaction with RAGE are the main mechanisms that explain glycation-
related pathophysiology (Fournet et al., 2018, Nawale et al., 2006).   
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1.3 Research aims and objectives 
The high levels of circulating blood sugar found in diabetic patients can cause protein 
glycation, however, the effect of the glycation reaction on CRP remaining unexplored. In 
addition, recent studies have shown that a monomeric isoform of CRP, formed as a result 
of a dissociation process of CRP, plays a pro-inflammatory harmful role in the progression 
of diseases. 
The overall aims of this research were first to provide insight, via the production and 
characterisation of in vitro produced glycated CRP, into the susceptibility of CRP to the 
glycation reaction. Secondly, this research aims to clarify whether glycated and monomeric 
modified forms of CRP are present, detectable and quantifiable within the serum of 
diabetes patients (type 1 and 2) with elevated levels of CRP, with a view to assessing the 
relationship between pentameric, monomeric and glycated CRP in diabetes mellitus. 
The specific objectives required to fulfil these aims are as follows:  
1. Preparation of in vitro glycated samples of CRP conjugated with glucose through the 
Maillard reaction, and study the effects of the concentration and exposure time to 
glucose on the extent of glycation of the target protein using electrospray mass 
spectrometry and other biochemical methods. 
2. Identification of the potential glycation sites of CRP treated with various 
concentrations of glucose for a varying time interval, and determination of the 
favourable glycation site using the tandem mass spectrometry, this will also involve 
optimisation of the enzymatic digestion method and glycated CRP samples 
preparation for tandem mass analysis. 
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3. Investigation of the microenvironment of the potential glycation sites including; the 
distance to the nearby acidic and basic residues in the 3D structure of the protein, 
the exposed surface area of the potential glycation sites and their pKa values. 
4. Identification, then quantification of the modified (monomeric and glycated) 
isoforms of CRP in the serum of diabetes patients (type 1 and 2) with elevated CRP 
levels and assessing the relationship between pCRP, mCRP and the glycated 
isoform. This will involve separation of CRP isoforms using affinity chromatography, 
identification of the glycated form and the site(s) of glycation using the mass 
spectrometry, separation of the monomeric form of the protein using size exclusion 
chromatography followed by quantification by ELISA.
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2.1 Introduction 
2.1.1 Overview 
Glycation involves the non-enzymatic addition of reducing sugars and/or reactive sugar 
derivatives to the protein reactive residues. This modification alters the three-dimensional 
structure of proteins and consequently their physical and functional properties. Glycation 
affects a wide variety of proteins in human serum at a rate greatly accelerated during 
hyperglycaemia and derived disorders. C-reactive protein (CRP) is a classic acute phase 
protein which plays a vital role in infection, inflammation, and tissue damage. CRP is a 
clinically important molecule. However, the effect of glycation of this protein remains 
unexplored. We aim to shed light on this subject, and this chapter discusses modifying CRP 
with various concentrations of glucose for different intervals, and identification of the post-
translational modifications of CRP resulting from non-enzymatic glycation, determined via 
electrospray mass spectrometry. 
2.1.2 Analytical techniques used for detection of glycated proteins 
Glycation reactions are a complicated group of processes, with primary and secondary 
reactions potentially resulting in a heterogeneous group of compounds. The end products 
depend on the glycating agent involved, its concentration, the exposure time and reaction 
conditions (Eble et al., 1983, McPherson et al., 1988, Austin et al., 1987). The complex 
nature of the reaction and the diversity in the reaction endpoint makes glycation reaction 
monitoring a challenging task (Priego Capote & Sanchez, 2009). Multiple analytical 
methods have been utilised for the detection and characterisation of glycation products, 
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including colourimetric methods (such as the thiobarbituric acid, nitroblue tetrazolium and 
hydrazine-based), immunological assays (enzyme-linked immunosorbent assays, Western 
blotting or radioimmunoassays), electrophoretic methods (single and two dimensional gel 
electrophoreses), chromatographic (boronate affinity chromatography), and mass 
spectrometric-based methods (Lacinová et al., 2010, Priego Capote & Sanchez, 2009). The 
choice of method depends on the nature of information required; however, a combination 
of more than one method may be needed to derive the required information. The focus 
will be limited to the analytical methods utilised in this chapter. 
2.1.3 Polyacrylamide Gel Electrophoresis 
Polyacrylamide gel electrophoresis (PAGE) is an analytical method used to separate 
proteins in a sample based on their mobility through a sieving gel matrix under the 
influence of an applied electrical field (Hames, 1998). PAGE is relatively simple, fast and 
highly reproducible. PAGE can provide information about the molecular weight, subunit 
structures, electrical charges, amount and purity of polypeptides or proteins in the sample 
depending on the particular technique used (Hames, 1998). 
The critical element in the PAGE system is the gel itself. Polyacrylamide gels are 
polymerised from monomeric acrylamide and N, N’-methylene-bisacrylamide (Hames, 
1998). In the presence of suitable initiator compounds (ammonium persulfate, 
tetramethylethylenediamine), the acrylamide polymerises to form long polyacrylamide 
chains, cross-linked by N,N'-methylene bisacrylamide to form a three-dimensional network 
with uniform pores (Hames, 1998). The size of the pores within the gel is governed by the 
total amount of acrylamide used per unit volume and the cross-linker ratio (Bass et al., 
2017). Gels with higher acrylamide concentration (e.g., 20%) have smaller pores, meaning 
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the gel impedes the movement of larger proteins to a greater degree than those of smaller 
molecular weight but better resolves those of lower molecular weights (Bass et al., 2017). 
To obtain an optimal resolution of a sample component a “stacking” gel is cast over the top 
of the “resolving” gel (Bass et al., 2017). The stacking gel (where the samples are loaded) 
has a lower pH and reduced acrylamide content, hence larger pores (Bass et al., 2017). This 
allows the sample component to be concentrated into a tight ‘band’ during the first few 
minutes of electrophoresis prior to entering the resolving portion of a gel, where proteins 
are separated according to their molecular weight (Bass et al., 2017). 
PAGE comprises a number of different techniques each with its uses, advantages and 
limitations. Native-polyacrylamide gel electrophoresis (native-PAGE) separates proteins, in 
their native form, based on their charge, shape and size (Hames, 1998). In native-PAGE the 
protein is loaded in non-reducing and non-denaturing conditions to preserve the secondary 
and tertiary structure of the protein in the sample; thus native-PAGE preserves the 
proteins’ function, structure and activity and can be used, for example, alongside detection 
of the proteins biological activity (Hames, 1998). 
In contrast to native-PAGE, where three independent molecular properties influence the 
electrophoretic mobility of the proteins, sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) separates proteins almost exclusively based on their size 
(Hames, 1998). In this technique, sodium dodecyl sulfate (SDS), an anionic detergent, is 
incorporated in sufficient excess to denature the protein and produce a linear polypeptide 
chain covered with a uniform negative charge of SDS molecules (Hames, 1998). Samples 
are heated to a high temperature (typically 95 °C for 5 minutes) in the presence of 
denaturants such as beta-mercaptoethanol to further denature the protein, removing the 
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three-dimensional structure. The denatured proteins migrate through SDS gel based 
primarily on their size, and hence SDS-PAGE is used to estimate the molecular weights of 
proteins (Hames, 1998). 
Isoelectric focusing (IEF) is an electrophoretic technique used to separate proteins across a 
pH gradient based on their isoelectric point (PI); (Friedman et al., 2009). During IEF, proteins 
migrate under the influence of an electric field through an immobilised pH gradient until a 
given protein reaches a pH within the gel at which their net charge is zero; this is the PI of 
this protein. Determination of PI by IEF can separate minor charge variants resulting from 
protein post-translational modifications (Friedman et al., 2009). 
Protein glycation increases the mass of the protein based on the net number of sugar 
molecules incorporated to a given protein subunit. Protein glycation could result in the 
formation of further cross-linked structures in the later reaction stages, with significantly 
higher mass than their non-cross-linked counterparts. SDS-PAGE has the potential to reveal 
changes in the molecular weight of glycated and cross-linked species due to the net 
increase in mass (Ghosh et al., 2013, Galván-Moroyoqui et al., 2016, Bai et al., 2012, 
Ledesma-Osuna et al., 2008, Chen et al., 2012). Native-PAGE can reveal the changes in the 
charge properties of glycated proteins, where glycated proteins will migrate more quickly 
toward the positive pole of the gel under native conditions (Wijetunge & Perera, 2014, 
Btissam et al., 2017, Handa & Kuroda, 1999). The increased electrophoretic mobility of 
glycated proteins has been attributed to the increase in the net negative charge of glycated 
proteins due to the attachment of sugar residues to the amino groups of the protein 
(Wijetunge & Perera, 2014, Handa & Kuroda, 1999). This change in the net charge is more 
significant when proteins are glycated with phosphorylated sugars such as glucose-6-
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phosphate and fructose bisphosphate (Yaylayan et al., 1994), or with carboxyl-containing 
sugars such as glucuronic acid (Aoki et al., 1999). Incorporation of negatively charged 
sugars derivatives adds extra negative charges and increase the net negative charge of the 
protein; this will increase their electrophoretic mobility through Native-PAGE. IEF also has 
been used to separate glycated proteins. The increase in the net negative charge of 
glycated proteins results in a decrease in the PI, which supports the occurrence of glycation 
(Luthra & Balasubramanian, 1993). 
2.1.4 Western Blotting 
Western blotting is an analytical technique to identify a particular antigen in the midst of a 
complex mixture of proteins, based on the interaction between an antibody and its specific 
antigen. Western blotting has diverse applications including; detection and quantification 
of specific proteins, estimation of protein molecular weight, and in some cases the 
determination of post-translational modifications (Blancher & Jones, 2001, Bass et al., 
2017). 
The first step in western blotting is to separate the proteins in the sample by gel 
electrophoresis, commonly SDS-PAGE. Separated proteins are transferred to a membrane 
by electroblotting; this immobilises the separated proteins and provides a durable surface 
for probing with antibodies (Bass et al., 2017). Electroblotting is typically achieved by 
placing the membrane in direct contact with the gel and immersing this sandwich in a 
buffer solution (wet transfer). After applying a lateral electrical current, the negatively 
charged protein will transfer from the gel to produce a mirror image on the membrane 
(Bass et al., 2017, Mahmood & Yang, 2012). 
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The two most commonly used membranes in western blotting are nitrocellulose and 
polyvinylidene difluoride (PVDF). The nitrocellulose membranes have the advantage of the 
low background regardless of the detection method, lower cost, and ease of use as it does 
not require an activation step. However, it is fragile when dried and not suitable for 
stripping and re-probing. On the other hand, PVDF membranes are more durable, allowing 
stripping and re-probing the blots and more convenient to store. Their hydrophobic nature 
results in high protein binding capacity, however, as a consequence the background noise 
is also higher. PVDF require pre-soaking with methanol to hydrating the membrane and 
improve transfer and binding (Bass et al., 2017, Mahmood & Yang, 2012). 
After transferring the proteins to the membrane, the unoccupied surface of the membrane 
is ‘blocked’ to prevent nonspecific interaction of antibodies with the membrane. Non-fat 
dry milk is commonly used as it is cheap and widely available. Blocking reduces background 
noise and improves signal-to-noise and hence the sensitivity of the assay (Mahmood & 
Yang, 2012, Bass et al., 2017). Blocked membranes are probed using a primary antibody 
that specifically recognises the target protein. This primary antibody is produced by 
immunising a host with purified target protein (or fragments thereof), and it should be 
thoroughly assessed for specificity and sensitivity for the target protein (Bass et al., 2017). 
Both polyclonal and monoclonal primary antibodies can be used for target protein 
detection. Polyclonal antibodies are more cost-effective, and they provide a greater level 
of sensitivity as they bind to multiple epitopes in the target protein; however, a polyclonal 
antibody can give higher background and have a greater chance of non-specific binding 
(Bass et al., 2017). In contrast, the monoclonal antibody is raised against single specific 
epitope; therefore, they can provide higher specificity for the target antigen with less 
background (Bass et al., 2017). The binding affinity of the monoclonal antibody can be 
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influenced if the target epitope is affected in any way through denaturing or modification 
(Bass et al., 2017). 
The primary antibody-target protein complex is then detected using a secondary antibody, 
typically conjugated to a reporter, usually an enzyme such as horseradish peroxidase (HRP). 
The importance of the secondary antibody is to amplify the detectable signal as several 
molecules of secondary antibodies can bind to the primary antibody (Bass et al., 2017). The 
secondary antibody must be species-specific and isotype-specific (Bass et al., 2017). Finally, 
a suitable substrate is added to react with the secondary antibody’s reporter to produce a 
signal. This signal locates the target protein on the membrane with an intensity 
proportional to the amount of the target protein (Mahmood & Yang, 2012). 
Western blot can be used for the detection of the glycated form of proteins. Monoclonal 
and polyclonal antibodies raised against early glycation adduct (1-deoxyfructosyl lysine) 
(Wu& Steward, 1991), and advanced glycation end products (Nϵ-carboxymethyl-lysine and 
Nϵ-carboxyethyl-lysine) have been produced and found to be specific for the corresponding 
glycation products (Choi & Lim, 2009). On the other hand, protein glycation may result in 
alterations in protein structure which in turn could result in steric hindrance or epitope 
modification and thereby affecting antigen-antibody recognition (Seo et al., 2013). 
2.1.5 Mass spectrometry 
Mass spectrometry is a powerful analytical technique in the field of proteomics and related 
studies (Aebersold & Mann, 2003). It relies on the conversion of analytes into gaseous ions, 
separating them according to their mass to charge ratio (m/z) and recording the abundance 
of each separated ion. Increased information yield is accessed via fragmentation of selected 
precursor ions (De Hoffmann, 2000). Mass spectrometry has a myriad of applications 
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including protein identification and quantification, detection of post-translational 
modifications, determination of protein structure, function, folding and interactions 
(Aebersold & Mann, 2003). 
Different kinds of mass spectrometry instruments are available; with the newest mass 
spectrometers aimed to suit multiple experimental goals. Generally, a mass spectrometer 
consists of an ion source to produce gas phase ions from the sample under investigation, 
one or several mass analysers to separate the generated ions according to their m/z ratio, 
and a detector to count the ions at each m/z value, see Figure 2-1 (De Hoffmann, 2000). 
The most common ionisation methods employed in protein mass spectrometry are Matrix-
assisted laser desorption/ ionisation (MALDI) and electrospray ionisation (ESI; Aebersold & 
Mann, 2003). Both are capable of ‘’soft’’ ionisation and volatilisation of biomolecules into 
gas phase ions without excessive fragmentation (De Hoffmann, 2000) 
 
Figure 2-1 Schematic representation of the components of a mass spectrometer. Mass 
spectrometers can be divided into three fundamental parts; the ion source, the analyser, 
and the detector. The sample can be inserted directly into the ion source, or can undergo 
some type of chromatography en route to the ion source e.g. a high-pressure liquid 
chromatography (HPLC) or gas chromatography (GC); (De Hoffmann, 2000). 
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MALDI ionises analytes from the solid phase, where the analyte is typically mixed with a 
solvent containing organic matrix molecules then dried to form a thin layer in which the 
analyte is embedded within the matrix crystals. Within the source, the analyte is irradiated 
with a pulsed laser beam causing sublimation of the analyte as singly or doubly charged 
ions (De Hoffmann, 2000). The principally singly charged nature of MALDI-generated 
precursor ions results in easy to interpret spectra with limited need for post-analysis 
processing. 
ESI ionises solutes; sample solution is pumped through a capillary with a high voltage 
applied to create a spray of charged droplets; these droplets evaporate, usually by means 
of heat and drying gas, eventually releasing the ions into the gas phase (De Hoffmann, 
2000). ESI typically generates multiply charged ions and is compatible with solution-based 
separation techniques such as liquid chromatography (LC), hence allowing online 
separation of complex samples. A minimised-flow version of ESI, named nano-spray (nESI), 
may be utilised with a low flow rate LC. nESI produces droplets with a smaller diameter 
compared to ESI. This enhances droplet desolvation and thus increases the ionisation 
efficiency of analyte molecules beside minimising the volume of sample needed (Juraschek 
et al., 1999). 
After the ions are produced and transferred into a gas phase, they have to be separated in 
a mass analyser according to their m/z. There are many types of mass analysers each has 
its own characteristics; however, in the proteomic field time of flight (TOF), quadrupoles, 
ion traps and the orbitraps are the commonly used analysers (Aebersold & Mann, 2003). 
More than one analyser type may be joined together in tandem in a single instrument 
platform. This offers the advantage of mass filtering and subsequent ions activation for 
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tandem mass analysis through which additional information about specific ion species can 
be obtained. In tandem mass spectrometry analysis (also called MS/MS) the ionised sample 
is separated in the first mass analyser then ions with a particular m/z value are selected. 
The selected ions are subjected to collisions, commonly with inert gas, the resulting 
fragment ions are separated and their m/z ratios recorded (De Hoffmann, 2000). 
TOF analysers are conceptually the simplest mass analyser; this can be considered as a 
velocity metre. TOF measures the time that ions need to pass through a tube of a fixed 
length under a vacuum (De Hoffmann, 2000). To improve mass resolution and obtain the 
best performance from TOF analyser; an electrostatic mirror (called a reflectron) is used to 
turns the ions around and sends them back a second flight distance to the detector as 
shown in figure 2-2 (Glish & Vachet, 2003). The function of the reflectron is to compensate 
for small differences in the velocities of ions with the same m/z. Therefore, the reflectron 
increases the resolution of TOF spectrometry (Glish & Vachet, 2003). TOF analysers are 
typically fast, sensitive, and theoretically have no upper mass limit, furthermore, increasing 
the path length of a reflectron increase available resolving power (De Hoffmann, 2000). 
 
Figure 2-2 Schematic description of a TOF instrument equipped with a reflectron. Following 
ionisation, the sample ions will pass through TOF drift tube, the larger ions will travel slower 
than smaller ions and the time required for the ions to reach the detector is used to 
determine mass to charge ratio (m/z) of the sample ions. A reflectron is used to focus the 
ions onto the detector and improves the resolution of the instrument. 
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Quadrupole mass analysers consist of four rods assembled in a symmetrical and parallel 
structure as shown in figure 2-3, opposite rods being paired, across which radio frequency 
(RF) and direct current (DC) voltage are applied (De Hoffmann, 2000).  
 
 
Figure 2-3 Diagram of Quadrupole Mass Analyser. At a particular RF and DC voltages, only 
the ion with a given m/z passes through the quadrupole field, reproduced from De 
Hoffmann, 2000.  
 
The applied voltages influence ion trajectories. For a given DC and RF voltages, only ions of 
a particular m/z ratio will pass through the quadrupole while the other ions will be ejected. 
Manipulating the RF and DC voltages, while keeping their ratio constant, allows selection 
of a particular range of m/z ions to the detector, thus the quadrupole act as a ‘mass filter’. 
Moreover, if the RF is the only voltage applied, then a wide range of oscillating ions will 
traverse through the quadrupole and in this case the quadrupole can be used as an ion 
focusing component for the next analyser in tandem mass spectrometers (De Hoffmann, 
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2000). Quadrupole mass analysers are relatively cheap and have high reproducibility. 
However, they have limited resolving power compared to TOF (Aebersold & Mann, 2003). 
Ion traps are another type of analyser, they capture (hold) the ions in a physical volume for 
a period of time, the desired ions are selected, fragmented, and scanned all in the same 
component. Hence, they offer the advantage of tandem MS analysis without having 
multiple analysers (Aebersold & Mann, 2003). 
Many instruments combine mass analysers of different types, referred to as hybrid 
instruments, to gain the strengths of each analyser and/or provide new or enhanced 
capabilities. The quadrupole ion trap-time of flight QIT-TOF, and quadrupole-time of flight 
(Q-TOF) mass spectrometer are two examples of hybrid instruments (Glish & Burinsky, 
2008). 
All the of MS work presented in this thesis was generated using a hybrid Q-TOF mass 
spectrometer; therefore it will be discussed in a little more detail. Q-TOF hybrid mass 
spectrometers were first introduced commercially in the late 1990s and remain popular 
today; typically these are equipped with an ESI or nESI source, although other ionisation 
sources can also be used (Chernushevich et al., 2001, Ens & Standing, 2005). The 
instruments consist of ion focusing and collisional damping devices, a quadrupole mass 
filter, a gas-filled collision cell (which can be of quadrupole or hexapole geometry), and a 
TOF analyser (Chernushevich et al., 2001). The Q-TOF can operate in MS and MS/MS mode; 
in MS mode the ions pass through a series of ion focusing devices and are separated in the 
TOF analyser. In MS mode, the quadrupole operates in RF only mode and functions as an 
ion guide (Chernushevich et al., 2001). In MS/MS, ions of a particular m/z value are selected 
using the quadrupole filter; the selected ion population then passes through the collision 
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cell (RF only q2) that promotes ion fragmentation by collisions with an inert gas. Product 
ions are then separated in the TOF analyser (Chernushevich et al., 2001). Thus, the Q-TOF 
instruments combine the ion guiding and isolating properties of a quadrupole mass filter 
with the high accuracy and performance of the TOF analyser. This combination results in 
accurate mass measurement, high resolution, and the ability to perform tandem mass 
spectrometry MS/MS experiments (Chernushevich et al., 2001). Q-TOF instruments have 
been widely used for qualitative analyses and in the identification of post-translational 
modifications (Aebersold & Mann, 2003, Chernushevich et al., 2001). 
 
2.1.6 Experimental Aims 
CRP is a clinically important molecule; however, no prior work in the literature describes 
the glycation of CRP in vitro nor in vivo. Exploring CRP glycation in a complex biological 
sample (serum, plasma) without prior knowledge about the susceptibility of CRP to 
glycation is a difficult task. Consequently, CRP glycation study was first carried out by in 
vitro experiments with the aim to extrapolate the generated information to the in vivo 
situation, taking into account the factors that affect the glycation process under 
physiological conditions. 
The aim of the work described this chapter was to prepare in vitro glycated samples of CRP, 
and to investigate the susceptibility of the target protein to glycation using electrospray 
mass spectrometry, and other biochemical methods to monitor CRP glycation as a function 
of concentration and exposure time to the glucose, with the aim to extrapolate the 
generated information to in vivo studies. 
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2.2 Materials & Methods 
2.2.1 Reagents and consumables 
Reagents, solutions and proteins used in this chapter and their suppliers are summarised 
in Table 2-1. 
Table 2-1 Reagents, solutions and proteins used in the study. All substances were 
purchased in the highest possible purity from the following suppliers 
Chemicals/proteins  Supplier 
30% T acrylamide/bisacrylamide Sigma-Aldrich 
Acetonitrile (HPLC grade, 99.9%)  VWR International 
Ammonium bicarbonate Sigma-Aldrich 
Anti-mouse IgG (whole molecule) peroxidase antibody Sigma-Aldrich 
Ammonium persulfate (APS) VWR International 
Bromophenol blue VWR International 
Clarity western ECL blotting substrates Bio-Rad 
C-reactive protein (CRP, >99% pure) SCRIPPS Laboratories 
D-glucose (99.5%) Sigma-Aldrich 
Formic acid (96%) Sigma-Aldrich 
Glycerol Sigma-Aldrich 
Glycine Sigma-Aldrich 
InstantBlue™ protein stain Expedeon 
Low range molecular weight markers Bio-Rad 
Marvel dried milk Local supermarket  
Monoclonal anti-C-reactive protein antibody (Clone-8) Sigma-Aldrich 
Ponceau S solution Sigma-Aldrich 
Sodium dodecyl sulfate SDS  Sigma-Aldrich 
Sodium chloride Sigma-Aldrich 
Sodium phosphate dibasic (99%) Sigma-Aldrich 
Sodium phosphate monobasic (99%) Sigma-Aldrich 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
Trifluoroacetic acid (98%) Sigma-Aldrich 
Tris  Sigma-Aldrich 
Triton-X-100 Sigma-Aldrich 
Water (HPLC grade)  VWR International 
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2.2.2 Preparation of Glycated C-Reactive Protein 
C-reactive protein (CRP, 99% pure) was obtained from SCRIPPS Laboratories and supplied 
as a solution in 20 mM Tris, 280 mM sodium chloride, 5 mM calcium chloride, pH 8.0 ± 0.1, 
with sodium azide added as a preservative. Protein concentration was determined by UV 
absorbance at 280 nm (Nanodrop 1000, Thermo Scientific). An extinction coefficient of 1.7 
was used to give the concentration values in mg/mL (De Beer & Pepys, 1982). 
In vitro glycation of CRP was carried out by exposure of the protein at a varying 
concentration of glucose up to 6 days. Aliquots of CRP were diluted to 0.2 mg/mL (8.6 
pmol/µL) using 0, 30, 100, 300, 500 and 1000 mM glucose in 0.2 M phosphate buffer, pH 
7.4, respectively. The aliquot diluted in the 0.2 M phosphate buffer alone was used as a 
control. 
The samples were incubated at 37 °C with continuous shaking (TS-100 Thermo-Shaker, 
bioSan), and a portion was removed from each incubated sample after 19 hours, 3 days 
and 6 days. Unreacted glucose was separated from protein by ultrafiltration using Amicon 
ultra centrifugal filter devices (Millipore) fitted with a 10 kDa molecular weight cut-off 
membrane. The Amicon devices were pre-washed with 500µL of deionised water at 1000 
x g for 5 minutes. After the washing step, the sample was then concentrated down at 14000 
x g for 15 minutes, discarding the filtrate, then reconstituting the concentrate to 500 µL 
with 50 mM ammonium bicarbonate, pH 7.4. This process (“washing out”) was repeated 
three times. The ultrafiltrate was removed, and the volume adjusted to 1 µg/µL (43.4 
pmol/µL) of the protein using ammonium bicarbonate buffer. The samples were stored at 
4 °C until analysis. 
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2.2.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was carried out to 
see if we could detect the glycated forms of CRP based on its mobility through the gel 
compared to that of non-glycated CRP standard. SDS-PAGE was performed according to the 
method of Laemmli (Laemmli, 1970), using a mini format 1-D electrophoresis system (Bio-
Rad Laboratories, Inc.). 
Gels were hand cast with acrylamide concentration of 4% and 15% (v/v) in the stacking and 
resolving gels, respectively (see Table 2-2). Low range molecular weight markers, 
purchased from Bio-Rad, were used for estimation of molecular weight. 5µL of each sample 
(containing 5 µg protein) as prepared in section 2.2.2 was mixed 50% (v/v) with non-
reducing loading buffer containing bromophenol blue (see Table 2-2) to visualise the dye 
front while the gel was running. All samples were heated at 95 °C for 5 minutes before 
being run on the gel. After loading the samples, the gel was placed vertically in a Mini-
PROTEAN Tetra cell attached to a PowerPac Basic electrophoresis apparatus (Bio-Rad 
Laboratories, Inc.). The gel was run at 200V in Tris-glycine-SDS running buffer (see Table 2-
2) for 45 minutes, or until the bromophenol blue tracking dye reached the lower edge of 
the gel. Gels were then removed from the tank, and the proteins in the gel were either 
transferred to a nitrocellulose membrane (Bio-Rad Laboratories) for western blot analysis 
or visualised using Coomassie InstantBlue™ stain. 
The gels were soaked in a sufficient volume of InstantBlue™ Protein Stain to cover the 
membrane for a minimum of 30 minutes at room temperature. The excess dye was washed 
off with deionised water (destaining) once a sufficient level of staining had been achieved. 
Gels were photographed on a FluorChem imager (Alpha Innotech Corporation). 
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Table 2-2 Components and amounts required for SDS-PAGE experiment. The gel, sample 
buffer and the running buffers components are listed, the amounts are also given. 
Gel/ buffer Components  
Resolving Gel 15% 
(given amounts are enough to cast 
two identical 0.75 mm SDS-PAGE gels) 
• 30 % T acrylamide/bisacrylamide 4.013 mL 
• Deionised Water   1.867 mL 
• Tris 1.5 M (pH 8.8)  2 mL 
• SDS 10% (w/v)   80 uL 
• TEMED     6 uL 
• APS 10% (w/v)   60 uL 
Stacking Gel 4% 
(given amounts are sufficient for two 
identical 0.75mm stacks) 
• 30 % T acrylamide/bisacrylamide 0.67 mL 
• Deionised Water   3 mL 
• Tris 0.5M (pH 6.8)   1.25 mL 
• SDS 10% (w/v)   60 uL 
• TEMED    6 uL 
• APS 10% (w/v)   60 uL 
Running Buffer 1L • Tris Base    3.03 g 
• Glycine    14.42 g 
• SDS    1 g 
Non-Reducing sample Buffer • Tris 0.5 M (pH 6.8)  1.25 mL 
• Glycerol    2.5 mL 
• Deionised Water   3.55 mL 
• SDS 10% (w/v)   2 mL 
• Bromophenol Blue 0.5%  0.2 mL 
 
2.2.4 Western blotting 
The samples prepared as described in section 2.2.2 were first subjected to SDS-PAGE as 
described in section 2.2.3 but without staining the gel. After electrophoresis, the gel, a 
nitrocellulose membrane blotting paper (0.2 µm, 7x8.4 cm, pre-cut, Bio-Rad) and filter pads 
(Bio-Rad) were soaked for 1 hour in equilibration buffer (Table 2-3) and then assembled in 
cassette case of the Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad). The assembled 
cassette was placed in the transfer apparatus with an ice pack to prevent overheating 
during the transfer. The running buffer (Table 2-3) were then added, and a magnetic stirrer 
was used to maintain a consistent flow of running buffer throughout the tank. The cell was 
connected to a PowerPac Basic power supply (Bio-Rad). Proteins were transferred from the 
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gel to the nitrocellulose membrane by electroblotting at 350 mA for 1 hour at 4 °C. Post-
transfer, the membrane was stained for 1-5 min with Ponceau S solution (0.1% w/v 
Ponceau S, 5% v/v acetic acid) to determine the quality of the transfer. When bands are 
visible, the membrane was destained by washing with deionised water to attain a clear 
background.  
The membrane was then incubated for 5 hours at room temperature with agitation in a 
blocking solution of Tris-buffered saline (TBS), 2.5 % (w/v) defatted milk powder (see Table 
2-3). Following blocking, membranes were washed sequentially five times for 5 minutes 
each with BLOTTO, (Table 2-3).  
 
Table 2-3 Buffers and solutions used for western blotting transfer and staining. The 
components and their corresponding amounts are given. 
Buffer/Solution Components/Amount 
Running/Equilibration 
Buffer 
• SDS     0.5 g 
• Tris     7.21 g 
• Glycine     1.515 g 
TBS pH 7.4 with HCl • Sodium chloride    150 mM 
• Tris     50 mM 
Blocking Solution • Marvel dried milk    1 g 
• TBS     40 mL 
BLOTTO • Marvel dried milk    0.5 g 
• Triton-X-100    1 mL 
• TBS     50 mL 
Primary Antibody Dilution • Monoclonal anti-CRP antibody  6 µL 
• BLOTTO up to     24 mL 
Secondary Antibody 
Dilution 
• Anti-mouse IgG peroxidase antibody  1 µL 
• BLOTTO up to     40 mL 
ECL Reagent • Clarity peroxidase reagent   7 mL 
• Clarity western luminol/enhancer reagent 7 mL 
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The primary antibody solution was added in a 1:1000 (v/v) dilution in BLOTTO to the 
membrane and incubated overnight at 4 °C with agitation. The primary antibody used was 
a monoclonal mouse anti-C-reactive protein antibody (Clone CRP-8), provided in ascites 
fluid. The antibody concentration reading was 9.1 mg/mL; stocks were stored at -20 °C and 
thawed to room temperature before use. Following incubation with primary antibody, 
membranes were washed as previously with BLOTTO (5 minutes x five washes). Polyclonal 
rabbit anti-mouse IgG antibody, conjugated with HRP, was added to the membrane in a 
1:40,000 dilution in BLOTTO and incubated for 1h at room temperature with agitation. The 
secondary antibody was decanted, and the membrane washed. 
Chemiluminescence (Clarity Western ECL Substrate, Bio-Rad) enabled visualisation of 
immunoreactive bands. HRP peroxide reagent and luminol/enhancer were mixed 1:1 (v/v) 
immediately prior to being added to membranes, then incubated for a minimum of 5 
minutes with gentle agitation. Membranes were wrapped in Saran Wrap (protein side up) 
to prevent drying out and visualised using a FluorChem imager (Alpha Innotech 
Corporation), with exposure times of up to 30 minutes, depending on observed band 
intensity. 
2.2.5 Liquid Chromatography-Mass Spectrometry 
Liquid chromatography-mass spectrometry (LC-MS) of intact protein was carried out to 
detect protein glycation and monitor the reaction as a function of the net gain in the 
molecular weight of the protein following glucose conjugation. The molecular masses of 
the intact proteins in the samples were determined by using Ultimate 3000 nano-flow high-
performance liquid chromatography (HPLC) system (Dionex Ultimate 3000, Thermo Fisher 
Corporation) coupled with a Premier hybrid quadrupole-time of flight mass spectrometer 
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Q-TOF (Waters Corporation). The HPLC system consists of a pump, microflow controller 
and autosampler maintained at 4 °C. Proteins were separated using a C4 analytical column 
(Acclaim PepMap300, ID 75 μm, length 15 cm, particle size 5 μm, pore size 300 Å, Dionex) 
preceded by a C4 guard/trapping column (Acclaim PepMap300, ID 0.3 mm, length 5 mm, 
particle size 5μm, pore size 300 Å, Dionex) to concentrate protein and wash away buffer 
salt. The HPLC solvents were solvent A, consisting of 0.1% formic acid (FA), 5% acetonitrile 
(ACN) and solvent B, consisting of 0.1% FA, 95% ACN. The Q-TOF Premier mass 
spectrometer was equipped with a nano-flow electrospray ionisation source (nESI) which 
produces the electrospray through a PicoTip needle (10 µm i.d., New Objectives, Wobum, 
MA, USA), the electrospray was optimised by adjusting both capillary voltage and the x-y-z 
position of the nESI emitter relative to the front of the Q-TOF sample cone. The software 
used to operate the Ultimate 3000 HPLC system, and the Q-TOF Premier were Chromeleon 
Client version 6.8 (Thermo Fisher Corporation) and MassLynx 4.1 (Waters Corporation), 
respectively. 
For intact protein mass spectrometric analysis, the samples described in section 2.2.2 were 
diluted with solvent A to a final concentration of 5 pmol/μL. Samples were centrifuged for 
3-5 minutes to remove any precipitate, then transferred to autosampler vials (Waters 
Corporation). The vials were loaded onto autosampler, and an aliquot of solvent A was also 
loaded to be used as a blank. 
Sample runs were bracketed by blank runs to ensure full equilibration of columns and to 
minimise system carryover and consequent column contamination. For each HPLC 
separation, 10 pmol (2 µL) of protein solution was injected into the 20 µL loop without prior 
purification. Protein samples were loaded to the guard column over 5 minutes using 95% 
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solvent A, 5% solvent B (30 µL/min). After the trap/wash period, the sample was loaded 
onto the reversed phase column at a split flow rate of 0.35 µL/min. The gradient consisted 
of 2 ramps; 15 minutes (5% - 60% solvent B), then 5 minutes (60-95% solvent B). The column 
was then washed at 95% solvent B for 5 minutes before re-equilibration to the starting 
conditions. 
The HPLC column was coupled online to the Q-TOF mass spectrometer via nESI, with typical 
capillary voltages of 1-2 kV being applied. The Q-TOF was operated in MS mode. The Q-TOF 
parameters were as follow; sample cone and the extractor cone voltages were 45 V and 5 
V, respectively, source and desolvation temperatures 80 and 180 °C, cone gas flow and the 
desolvation gas flow were 50 and 400 L/h, respectively. The collision energy setting was set 
at 5-V. The scan m/z range started at 500 and ended at 2500 in positive ion mode, scan 
time 1 s, 0.1 s interval. Data were collected and processed using MassLynx V4.1 (Waters). 
The multiply charged electrospray spectra were deconvoluted (after background 
subtraction) using the Maximum Entropy 1 package of the MassLynx software, with a 
resolution of 1 Da/channel, a uniform Gaussian width at half height of 0.5 Da, and minimum 
intensity ratios of 33%. 
2.2.6 Calculation of glycoforms distribution percentage, the extent of glycation and glucose 
index 
Depending on peak intensities, the percentage of each glycated form of CRP was estimated 
as an approach to determine the relative quantity of each form of the protein. LC-MS 
analysis of each sample was carried out in triplicate, and the average intensities of the 
peaks in the deconvoluted LC-MS spectra corresponding to different species of CRP were 
calculated. From the calculated average intensities, the percentage of glycated CRP species 
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was determined by dividing the average intensity for each peak corresponding to CRP with 
i number of attached glucose, by the sum of average intensities of all peaks in the spectrum 
that corresponds to the glycated and non-glycated forms. The obtained ratio was multiplied 
by 100. 
% of each CRP glycoform (𝑖 ∗  glucose) in the sample =  
𝐼 (𝑖 ∗  glucose) 
𝑁
∗ 100% 
where (I) is the average intensity of the CRP peak with i number of attached glucose, N is 
the summation of the average intensities of CRP peaks that correspond to different species 
in the spectrum. 
The extent of CRP glycation for each sample was calculated by summing up the individual 
glycoforms percentages. 
Extent of glycation = ∑ % 𝑜𝑓 𝐶𝑅𝑃 𝑔𝑙𝑦𝑐𝑜𝑓𝑜𝑟𝑚𝑠 (𝑖 ∗ 𝑔𝑙𝑢𝑐𝑜𝑠𝑒)
𝑛
𝑖=1
 
To further illustrate the tendency of CRP glycation over incubation time, the average 
glucose index was calculated. 
Glucose Index (G-idx), can be defined as the average number of glucose residues per 
molecule of CRP. It was calculated according to the following equation (Gadgil, 
Bondarenko, Pipes et al., 2007, Miller et al., 2011a): 
G − idx =
 ∑ 𝑖 ∗ 𝐼 (𝑖𝑛𝑡𝑎𝑐𝑡 𝐶𝑅𝑃 + 𝑖 ∗ 𝑔𝑙𝑢𝑐𝑜𝑠𝑒)𝑛𝑖=0
 ∑ 𝐼𝑛𝑖=0  (𝑖𝑛𝑡𝑎𝑐𝑡 𝐶𝑅𝑃 + 𝑖 ∗ 𝑔𝑙𝑢𝑐𝑜𝑠𝑒)
 
where I is the average intensity of various glycated CRP species, and i is the number of 
glucose units attached to in each peak of the deconvoluted spectrum.  
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2.3 Results 
In vitro glycation of CRP was carried out with various concentrations of glucose and 
incubation time to understand the effects of glycating agent and the exposure time in vitro. 
The protein was treated with 30 mM to 1 M glucose (the primary glycating agent in human 
serum) in phosphate buffer at pH 7.4. Phosphate buffer is a commonly used buffer for in 
vitro glycation reactions (Priego Capote & Sanchez, 2009). Since the glycation process relies 
on several factors including the functional lifetime protein (Schleicher & Wieland, 1986), 
the protein was exposed to the glycating agent for a period equivalent to its half-life in the 
human serum at 37 °C. Longer incubation times were used to enable observation of higher 
order glycation products. 
2.3.1 Preliminary characterisation of glycated samples using SDS-PAGE and western blotting 
Glycated CRP samples prepared as per section 2.2.2 were subjected to SDS-PAGE and 
western blotting to assess the impact of in vitro glycation of CRP on its apparent molecular 
weight or interaction with antiserum. 
Figure 2-4 shows the SDS-PAGE mobility of CRP samples incubated at 30, 100, 300, 500 and 
1000 mM glucose for 19 hours (Figure 2-4, A), three days (Figure 2-4, B) and for 6 days 
(Figure 2-4, C). An untreated CRP sample was included as a control (lane 2 in figure 2-4). 
The control sample produced a single band at a molecular weight of ~23 kDa, 
corresponding to the molecular weight of monomeric protein. In all glucose incubated 
samples, a single band was also observed. Following 19 h incubation of CRP with different 
concentrations of glucose, no difference in electrophoretic mobility was observed 
compared to control (Figure 2-4, A). However, after three days of incubation, CRP 
incubated with 500 and 1000 mM of glucose tend to produce a broad and diffused band 
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compared to the control (lanes 6 and 7 in figure 2-4, B). Further increase of incubation time 
to 6 days results in a minor difference in migration patterns of the glucose treated samples, 
where the glycated samples show a slower migration through the gel in parallel with the 
increase in glucose concentration (Figure 2-4, C). The difference in electrophoretic mobility 
was more clear with the samples incubated with 500 and 1000 mM compared to control. 
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Figure 2-4 SDS-PAGE of in vitro glycated CRP Samples. Native CRP (0.2 mg/mL) were 
incubated with 0 mM glucose (Lane 2), 30 mM glucose (Lane 3), 100 mM glucose (Lane 4), 
300 mM glucose (Lane 5), 500 mM glucose (Lane 6), or 1000 mM glucose (Lane 7), n=6. The 
sample incubations were carried out at 37 °C in 0.2 M phosphate buffer, pH 7.4, for 19 
hours (A), 3 days (B), and for 6 days (C). Lane 1 represents the molecular weight markers. 5 
µL of each sample (containing 5 ugs of the protein) were loaded and analysed by 4-15% 
SDS- PAGE, the Gels were stained with Coomassie brilliant blue. 
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A single band was also seen when the glycated samples were subjected to western blotting, 
figure 2-5 is the result of western blotting of CRP samples incubated at 0, 30, 100, 300, 500 
and 1000 mM glucose for 19 hours (figure 2-5, A), three days (figure 2-5, B) and for 6 days 
(figure 2-5, C). The intensity of the bands produced by glycated CRP samples were relatively 
comparable to that produced by non-glycated CRP control suggesting the reactivity of the 
monoclonal anti-CRP antibody toward the glycated samples was comparable to that 
toward the control. 
 
 
Figure 2-5 Western blot of the in vitro glycated samples. Native CRP (0.2 mg/mL) were 
incubated with 0 mM glucose (Lane 1), 30 mM glucose (Lane 2), 100 mM glucose (Lane 3), 
300 mM glucose (Lane 4), 500 mM glucose (Lane 5), or 1000 mM glucose (Lane 6), for a 
period of 19 hours (A), 3 days (B), and for 6 days (C). The primary mAb dilution was 1:4,000. 
The secondary mAb dilution was 1:40,000. Samples were exposed for up to 30 minutes.  
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2.3.2 Characterisation of CRP glycation using LC-MS 
A typical spectrum of untreated CRP as observed by nESI-Q-TOF-MS is shown in figure 2-6, 
A. The charge states of the protein range from 10+ to 21+, after a software-assisted 
deconvolution of the spectrum, the mass spectrum depicted in figure 2-5, B was obtained, 
the deconvoluted spectrum shows a major mean species at 23027 Da, which corresponds 
to the expected mass of a single CRP subunit. 
 
Figure 2-6 Mass spectrum of native non-glycated CRP as measured by nESI-QTOF-MS in 
positive ion modes. A, Combined m/z spectrum after LC-MS analysis of 10 pmole of 
standard non-glycated CRP. The charge states are indicated in the spectrum, and the 
intensities are scaled to the highest peak, B: Deconvoluted LC-MS mass spectrum of CRP 
based on the m/z spectrum presented in figure A. 
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2.3.2.1 LC-MS analysis of CRP samples incubated for 19 hours 
The deconvoluted mass spectra of CRP samples incubated with different glucose 
concentration for 19 hours at 37 °C, pH 7.4. are shown in Figure 2-7. The deconvoluted 
spectrum generated following glycation of CRP with 30 mM glucose, Figure 2.7, A, 
demonstrate the emergence of a new low intensity signal, observed mass 23,189 Da in 
addition to the unmodified protein observed at 23,027 Da. The mass increment of 162 Da 
between emergent and original peak corresponds to the addition of a single dehydrated 
glucose molecule to the protein, suggesting that the new peak is the representative of a 
mono-glycated form of CRP obtained via the Maillard reaction. This mono-glycated CRP 
signal was observed in all other samples incubated for the same duration; increasing peak 
intensity corresponded with increasing glucose concentration (Figure 2-7). 
Incubating the sample with 100 mM glucose resulted in increased intensity of the mono-
glycated form to the double compared to 30 mM sample (Figure 2-7, B). while the spectra 
obtained from the sample glycated by 300 mM of glucose, indicate an additional signal at 
23,351 Da in addition to the mono-glycated signal at 23,189 Da and the unmodified peak 
at 23,027 Da (Figure 2-7, C). This new peak represents a mass increase of 324 Da compared 
to the unmodified protein molecular weight and this equal to the net mass of two glucose 
residues, suggesting that this peak is a di-glycated form of the protein. This di-glycated peak 
is more evident in the sample incubated with 500 mM glucose (Figure 2-7, D), and its 
intensity increased an additional fourfold when the glucose concentration was increased 
to 1 M (Figure 2-7, E). At 1 M glucose, the intensity of the mono and di-glycated forms 
increased significantly, with the signal intensity of the mono-glycated form reaching >70% 
the intensity of the residual unmodified form. Furthermore, a trace signal at 23,513 Da, 
representing conjugation of three glucose molecules, was also observed (Figure 2.7, E). 
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With increasing glucose concentration in the sample, the intensity of the unmodified 
protein signal decreases (Figure 2-7) in parallel with the increasing intensities of the 
glycated forms of the protein.
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Figure 2-7 The deconvoluted mass spectra of CRP samples incubated with different concentrations of glucose for 19 h. A; with 30 mM glucose, 
B; with 100 mM glucose, C; with 300 mM glucose, D; with 500 mM glucose, and E; with 1000 mM glucose. The sample incubations were carried 
out at 37°C in 0.2 M phosphate buffer, pH 7.4 for 19 hours.
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2.3.2.2 LC-MS analysis of samples incubated for 3 days 
After three days of exposure of CRP to different concentrations of glucose, the 
deconvoluted spectra in Figure 2-8 were obtained. 
At 30 mM glucose level (Figure 2-8, A), the peak at 23,189 Da is identified; however, its 
relative intensity is double compared to that from the sample incubated with the same 
glucose concentration but for 19 hours (Figure 2-7, A). On the other hand, a trace signal for 
the di-glycated CRP peak was observed using 100 mM glucose, (Figure 2-8, B). Moreover, 
the sample incubated with 300 mM glucose for 3 days (Figure 2-8, C) showed a peak 
distribution similar to that produced by 1000 mM glucose after 19 h (Figure 2-7, C), with 
conjugation of up to three glucose molecules to the protein. At 500 mM glucose (Figure 2-
8, D), the mono-glycated CRP peak intensity was almost identical to that of the non-
modified protein. Furthermore, a trace signal at 23,675 Da, with a mass difference of 648 
Da, indicates condensation of four glucose molecules. 
At 1 M glucose, the base peak is for the mono-glycated CRP, with the di-glycated form being 
the second most intense peak in the spectrum while the tri-glycated CRP peak is three times 
higher compared to the 500 mM glucose level after same incubation time. The tetra-
glycated CRP is more intense, and a trace signal is observed at 23,837 Da, consistent with 
the addition of five glucose monomers.
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Figure 2-8 The deconvoluted mass spectra of CRP samples incubated with different concentrations of glucose for 3 days. A; with 30 mM glucose, 
B; with 100 mM glucose, C; with 300 mM glucose, D; with 500 mM glucose, and E; with 1000 mM glucose. The sample incubations were carried 
out at 37°C in 0.2 M phosphate buffer, pH 7.4 for 3 day
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2.3.2.3 LC-MS analysis of samples incubated for 6 days 
Following six days incubation, at 30 mM concentration of glucose (Figure 2-9, A), the peak 
that represents the unmodified form of the protein remains base peak in resultant spectra, 
but the distribution between un- mono- and higher glycated forms shifts with increasing 
glucose concentration, with a marked alteration above 300 mM glucose (Figure 2-9, C). The 
intensity of the unmodified peak is barely detectable above background at a glucose 
concentration of 1 M (Figure 2-9, E). 
Reduction in the intensity of the unmodified protein corresponded with the appearance of 
new glycoforms and an increase in the intensity of previously observed glycation peaks. 
The peak representing di-glycated CRP was barely detectable at 30 mM glucose level 
(Figure 2-9, A), but increased six-fold with 100 mM glucose level, alongside the emergence 
of tri-glycated protein signal (Figure 2-9, B). At 300 mM glucose (Figure 2-9, C), the mono-
glycated peak is the prominent peak in the spectrum. However, the intensity of this peak 
gradually decreased in proportion as the glucose concentration further increased; in 
parallel, there was an increase in the intensities of multi-glycated forms with higher glucose 
levels. 
The peaks of the di- and tri-glycated CRP were the major peaks in the deconvoluted 
spectrum of the sample incubated with 500 mM glucose (Figure 2-9, D), the intensity of 
these two peaks exceded fourfold the intensity of the peak corresponding to non-glycated 
CRP. Furthermore, the intensity of tetra-glycated CRP is almost identical to that produced 
by the mono-glycated CRP, and both are more than two fold higher than that provided by 
the unmodified protein (Figure 2-9, D). At this level of glucose (500 mM) signals at 23,837, 
and 23,999 Da were quite evident and represented the addition of five and six glucose 
Chapter 2: Production & characterisation of glycated C-reactive protein Results 
 
78 
 
molecules to the protein, respectively, beside a trace signal at 24,162 Da that could 
represent the addition of seven glucose molecules (Figure 2-9, D). 
At the highest glucose level (1 M), most of the protein is glycated, and a series of glycated 
forms of the protein are seen (Figure 2-9, E). The peaks representing the tri and tetra-
glycated form of the protein dominate the spectrum while the di- and penta-glycated forms 
are the second dominant forms; both are more than two fold higher than the mono-
glycated form. The peak at 24,162 Da is quite evident demonstrating the addition of seven 
glucose molecules to the protein. Additionally, a very low signal at 24,323 Da can be 
recognised at this glucose level to report the condensation of eight glucose molecule to the 
protein (Figure 2-9, D). 
Notably, there is a minor peak with an average mass of 23,080 Da (+53 Da) was a common 
feature in the mass spectra of most of the CRP preparations including the non-glycated 
sample as shown in figure 2-6 B. The above peak is found to follow the pattern of CRP 
glycation; it is thought to be an experimental artefact due to the ingredient impurities or a 
result of a combination modification. The odd mass difference (+53 Da) between the minor 
peak at 23,080 Da and the main peak at 23,027 suggest presence of 1 or 3 ammoniun 
adducts.   
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Figure 2-9 The deconvoluted mass spectra of CRP samples incubated with different concentrations of glucose for 6 days. A; with 30 mM glucose, 
B; with 100 mM glucose, C; with 300 mM glucose, D; with 500 mM glucose, and E; with 1000 mM glucose. The sample incubations were carried 
out at 37°C in 0.2 M phosphate buffer, pH 7.4 for 6 days.
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2.3.3 The percentage distribution of glycoforms and the extent of glycation 
The LC-MS analysis of each sample was carried out in triplicate. The peak intensity for a 
given species averaged and used to calculate the extent of glycation and the proportion of 
each glycoform for each sample, the calculations were based on the assumption that signal 
intensity represents the relative amount of the protein in the sample, the results of these 
calculations are presented in Figure 2-10. 
As shown in Figure 2-10, A, the extent of glycation of CRP incubated for 19 hours increased 
with increasing glucose concentration, from 3.7% of the protein signal at 30 mM glucose to 
48.8% at 1000 mM glucose. At this incubation time, the mono-glycated form is the 
predominant glycated signal, at all glucose concentrations; its percentage increases in 
parallel with increasing glucose concentration from 3.7% at 30 mM of glucose to 35.7% at 
1000 mM. The di-glycated form represented only 1.9% of the protein signal at 300 mM 
glucose, increasing to 3.6% at 500 mM glucose and further increased to 11.1% at 1000 mM 
glucose. The tri-glycated form was seen only at 1000 mM glucose, where it represented 2% 
of the protein signal. 
Increasing the incubation time to 3 days doubled the extent of glycation of CRP compared 
to 19 hours incubation (Figure 2-10, B). Again, the extent of glycation here increased in 
parallel with the increase in glucose concentration. The mono-glycated form is also the 
main glycated form during this incubation period, However, the percentage of the mono-
glycated form started to fall after 500 mM (from 38.4% at 500 mM of glucose to 32.9 at 
1000 mM of glucose), but it remained higher than the second highest glycated form, the 
di-glycated form, which counts 29% of the protein signal. The di-glycated form increased 
from 2.5% at 100 mM glucose and in parallel with the increasing glucose to reach 29% at 
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1000 mM glucose level. The tri-glycated form started at 1.8% at 300 mM and reached 14.7% 
with 1 M glucose. The tetra-glycated form started at 1.2% at 500 mM but increased to 4.9% 
at 1000 mM, condensation of five glucose molecules was seen only at 1000 mM and 
represent 1.2% of the protein. 
After 6 days of the incubation (Figure 2-10, C), heterogeneous mixtures of glycated forms 
were detected, and almost complete removal of the un-glycated CRP peak was observed 
at the highest dose of glucose. Again, the observed glycation occupancy increased with 
increasing glucose concentration. However, the increment is only slight after 500 mM; from 
93% at 500 mM to 97.6% at 1000 mM. The mono-glycated form is the predominant form 
in the samples incubated with 30, 100 and 300 mM of glucose (17.6%, 34.6% and 36%, 
respectively), while the di-glycated form represents the second most prevalent form. At 
500 mM glucose, the di-glycated form becomes the dominant form (26.8%) and followed 
by the tri-glycated form (24.3%). At 1000 mM glucose, the tri and tetra-glycated forms were 
the primary forms (23.7% and 23.6%) while the di-glycated and the tetra-glycated forms 
are the second dominant (16.2% and 15.4%), the mono-glycated form percentage fall to 
6.8%.
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Figure 2-10 The extent of glycation and the percentage of glycoform signal distributions of in vitro glycated samples. CRP samples were incubated 
with different concentration of glucose for A: 19 hours, B: 3 days, C: 6 days. The columns represent the extent of glycation for each sample, the 
values placed at the base of the column while the error bars represent the standard deviation of the extends of glycation. Different coloured 
divisions represent individual glycoform percentages in each sample.
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2.3.4 Glucose Index (G-idx) 
The G-idx, which is the average number of glucose residues per molecule of CRP, was 
calculated as detailed in section 2.2.6 and plotted as a function of time, the results are 
presented in the Figure 2-11. 
 
Figure 2-11 The G-idx of the in vitro glycated samples versus the incubation time. Different 
coloured lines represent the glucose concentrations used to produce glycated isoforms, the 
error bars (too low for the majority of the values) represent the standard deviation of G-
idx 
 
For all the in vitro glycated samples, the G-idx shows a direct relationship with the further 
increase in the incubation time; the longer the incubation time, the larger numbers of 
glucose attached per CRP molecule. 
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G-idx were less than one for the majority of the samples; sample incubated with 1000 mM 
for 19 hours, samples incubated with 500 mM or less for 3 days, and samples incubated 
with 100 mM or less for up to 6 days. More than 1 values were seen only when the samples 
exposed to 1000 mM of glucose for 3 days, or 300 to 1000 of glucose for 6 days. The sample 
incubated with 1000 mM of glucose for 6 days has 3.6 glucose molecules per each CRP 
molecules. 
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2.4 Discussion 
Despite extensive studies having been previously carried out on CRP, no information in the 
literature is available regarding the existence of glycated versions of CRP either in vivo nor 
in vitro. To understand the glycation process in more detail and to be able to interpret the 
mass differences that could be found in vivo, in vitro glycation of CRP has been carried out 
in defined experimental condition with the aim to extrapolate the generated information 
to the in vivo situation. 
The glycation process relies on several factors including the half-life of the protein 
(Schleicher & Wieland, 1986), type of glycation agent and its concentration (Eble et al., 
1983, McPherson et al., 1988), pH, type of buffer and the temperature (Kańska & 
Boratyński, 2002, Smith & Thornalley, 1992). Two factors, whose influence were taken into 
consideration, were the glucose concentration and the incubation time, while other factors 
were kept constant. Different glucose concentrations were used (from 30 mM to 1 M), and 
the incubation time ranged from 19 hours, which is the half-life of the protein in serum, to 
six days, to increase the opportunity of observation of reaction products. The protein-
glucose mixture was prepared using phosphate buffer (pH 7.4), since other buffers or 
different pH may increase protein glycation as a result of denaturation and revealing the 
unexposed potential glycation sites (Lee, et al., 2011). All glycation experiments were 
carried out at 37 °C, similar to the physiological temperature as higher temperature results 
in an increased rate of glycation (Gadgil, et al., 2007). 
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2.4.1 Preliminary characterising of in vitro glycated CRP with SDS-PAGE and western blotting 
SDS-PAGE is one of the simplest and most widely used technique in proteomics, and has 
been used in the analysis of protein glycation for detecting or for separating the glycation 
product for further analysis (Galván-Moroyoqui et al., 2016, Bai et al., 2012, Ledesma-
Osuna et al., 2008, Chen et al., 2012). In SDS-PAGE proteins are separated according to 
their molecular weight, depending on their differential rates of migration through a sieving 
matrix (a gel) under the influence of an applied electric field (Rabilloud et al., 2009). In this 
work, SDS-PAGE has been used to see to assess if there is an apparent increase in the 
molecular weight of the protein after treating it with glucose. 
CRP incubated with different concentrations of glucose for a period equal to the half-life of 
the protein in human serum revealed a single band with no apparent difference in their 
mobility as compared to the control (Figure 2-4, A). When the incubation time was 
increased to three days, broader bands with less distinct edges were associated with the 
samples treated with 500 and 1000 mM of glucose (Figure 2-4, B). These broader bands are 
suggestive of the behaviour of individual molecules as a distribution of molecular masses 
(Ledesma-Osuna et al., 2008, Chen et al., 2012). 
Further increasing incubation time to 6 days resulted in a slight decrease in the 
electrophoretic mobility of the samples treated with the higher glucose concentrations 
(300, 500, and 1000 mM of glucose) as compared to the control (Figure 2-4, C), this 
decrease in electrophoretic mobility is strongly suggestive of an increase in CRP molecular 
weight and, accordingly, the occurrence of glycation. 
SDS-PAGE alone has limited resolution, meaning unless the samples are profoundly 
different in molecular weights and low in complexity it will fail to provide sufficient 
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separation capacity to be used as the sole indicator of glycation. Even in the case of samples 
with low complexity such as our samples, proteins with close molecular weight due to the 
attachment of few glucose molecules will co-migrate, even with the excellent optimisation 
of the separation (Rabilloud et al., 2009). Additional SDS-PAGE experiment was performed 
by loading fewer amounts of the glucose treated samples (data not shown) as an attempt 
to resolve the glycated bands; we were, however, unable to see separate/multiple bands. 
Some workers modified the SDS-PAGE technique (named Flu-PAGE) to detect and identify 
in vitro glycated proteins. In their method the glycated proteins were incubated first with 
a fluorophore-appended boronic acid, then the labelled glycated proteins are subjected to 
electrophoresis and visualised with visible blue light or UV (Morais et al., 2013). This 
method would be a useful alternative to conventional SDS-PAGE if we did not intend to use 
mass spectrometry. 
SDS-PAGE is a useful technique to identify cross-linked AGEs because the significant 
difference in mass between the cross-linked protein and their non-cross-linked counterpart 
results in a noticeable change in the electrophoretic mobility (Galván-Moroyoqui et al., 
2016, Sheng et al., 2018). However, it is not expected to identify a cross-linked structure of 
CRP as the incubation time was limited to six days in pseudo-physiological condition 
(Nawale et al., 2006, Anguizola et al., 2013). 
Western blotting was performed to assess whether the effect of glycation could be 
visualised using the immunoreactivity of CRP with its anti-CRP antibody. Alteration in the 
antigen-antibody binding because of glycation reaction has been reported with several 
proteins (Ma et al., 2013, Seo et al., 2013). The changes in immunoreactivity of targeted 
protein could be attributed to blockage of the lysine residue or the structural changes as a 
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result of protein glycation, leading to either epitope modification or steric hindrance 
thereby affecting the antigen-antibody recognition (Ma et al., 2013). The western blotting 
results show that the anti-CRP antibody have comparable reactivity toward all the glycated 
samples regardless of the incubation time and the glucose concentration used (see Figure 
2-5), and the protein at the higher glucose concentrations/times show similar bands 
intensity compared to the non-glycated CRP control, this would indicate that CRP-antibody 
interaction is not affected by glycation. 
The anti-CRP antibody used in western blotting was a monoclonal anti-CRP antibody (clone-
8) which recognise an epitope located on the denatured and reduced CRP monomer. The 
manufacturer does not reveal which epitope is involved; however, it is reported that 
monoclonal anti-CRP antibody (clone-8) cross-react with an epitope on Hsp60. The epitope 
occupies amino acids sequence from 218-232 on Hsp60 and displays 26.6% amino acid 
identity to CRP amino acid region 77 to 90 (Udvarnoki et al., 2007). This sequence (77-90) 
have only one possible glycation site, K87. If this sequence is where the antibody bind to 
the protein, then either K87 is not glycated or its glycation has no effect on the antibody-
CRP interaction. 
2.4.2 Using LC-MS for the intact analysis of glycated proteins 
Among the multiple analytical methods available to detect proteins glycation (Priego 
Capote & Sanchez, 2009, Lacinová et al., 2010), the mass spectrometric-based techniques 
provide the most direct and reliable approach for detection and characterisation of 
glycated protein. The usefulness of mass spectrometry for both in vivo and in vitro 
monitoring of non-enzymatic glycation of protein has been well documented (Bai et al., 
2012, Farah et al., 2005, Lapolla, et al., 2013, Thornalley, et al., 2000). 
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In this work, a Q-TOF-MS was coupled to nESI ion source, the nESI ion source shows a better 
overall performance for posttranslational modification detection than MALDI-TOF mass 
spectrometer (ter Haar et al., 2011, Nadler et al., 2017). Moreover, the nESI can easily be 
combined with HPLC as the coupling is fast, simple and provides an extraordinarily powerful 
analytical tool (Hart & Gaskell, 2005). The Q-TOF mass spectrometer has been used in MS 
mode, which allows the measurement of the accurate mass of the intact protein and the 
relative abundance of its isoforms (Stastna & Van Eyk, 2012). 
During glycation, the covalent coupling of a glucose moiety to the protein via the Maillard 
reaction, accompanied by loss of a water molecule, lead to a mass increase of 162 Da per 
glucose molecule incorporated to the protein, this characteristic mass shift incurred to 
protein by the Amadori product (Δm 162 Da) can be measured by mass spectrometric 
analysis of the intact protein. Utilising the LC-MS to determine the mass of intact protein 
molecules will detect the glycated protein and monitor the reaction as a function of the net 
gain in the molecular weight of the protein due to its binding to glucose. Determination of 
net increase in the mass of intact protein was the basis of measurement of the degree of 
glycation of many previous studies dealing with the analysis of protein glycation by MS 
(Farah et al., 2005, Thornalley et al., 2000, Lapolla et al., 2013, Leblanc et al., 2016, Gadgil 
et al., 2007). 
The acquired multiply charged m/z spectra of the Q-TOF-MS were deconvoluted using 
maximum entropy function (MaxEnt1) to give the actual molecular mass spectra. MaxEnt1 
preserves the quantitative information of the multiply charged electrospray spectra. The 
intensities of the peaks in the deconvoluted spectra were used to calculate the extent of 
glycation, percentage of each glycoform, and the average number of glucose molecules per 
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molecule of CRP (G-idx). These calculations based on the assumption that limited glycation 
has no to little effect on the ionisation state of proteins and the intensities of the peaks are 
representative of their corresponding species (Yeboah & Yaylayan, 2001). Quantifying and 
understanding the degree of glycation based on peaks intensities has been used in several 
studies and found to be reasonably accurate (Gadgil et al., 2007, Miller et al., 2011b, ter 
Haar et al., 2011, Leblanc et al., 2016). 
2.4.3 LC-MS analysis of the in vitro glycated CRP samples 
The typical spectrum of a non-glycated CRP standard, as acquired by nESI Q-TOF-MS, shows 
a broad distribution of multiply-charged monomer peaks (see Figure 2-6, A). This is one of 
the advantages of utilising the ESI-MS instruments, where the protein can acquire more 
than one charge (usually multiple charges) during the ionisation process, and each different 
charge state will give rise to a separate peak for the same compound in the spectrum. The 
set of peaks will reduce errors during the calculation of the mass and hence give higher 
mass accuracy. 
After software-assisted deconvolution of the acquired m/z spectrum (Figure 2-6, B), the 
main peak at 23027 Da corresponds to the expected mass of CRP unit was obtained 
(Kiernan et al., 2004). CRP is a pentameric protein at physiological pH, composed of five 
identical noncovalently associated subunits (Shrive et al., 1996). However, the finding of a 
single subunit of CRP suggests that the non-covalent interactions between CRP units have 
been disrupted, as might be expected when using a typical ESI buffer system. The acid and 
organic solvent in ESI buffer degrade the quaternary and tertiary structure, unfold the 
protein and expose all their basic side chains to the solvent. However, the non-covalent 
interactions between proteins are usually destroyed in their denatured state (Hilton & 
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Benesch, 2012, Loo, 1997). Furthermore, it was observed that incubating CRP with a 
glucose-free phosphate buffer (standard CRP sample) for a period up to six days did not 
result in any apparent modification in the LC-MS spectrum (data not shown). 
Investigation of glucose-treated CRP by LC-MS at intact protein level demonstrated for the 
first time, that human CRP can be glycated. This can occur to a different extent depending 
on both the incubation time and the glucose concentration used. Overall, the LC-MS 
spectra of the in vitro glycated samples shows charge state distributions similar to that 
produced by control samples, but additional peak(s) were associated with each charge 
state. These new peaks were of varying intensity depending on the incubation time or 
glucose concentration used. Deconvolution of these spectra Indicates that these additional 
peaks represent new forms of the protein due to its glycation. 
Incubating CRP with different concentrations of glucose for a period equal to the half-life 
of the protein in vivo reveal additional peaks in the spectrum besides the original peak that 
represents the non-glycated CRP. CRP with 1 to 3 glucose molecules attached was found 
after 19 hours of incubation with different glucose concentration (see Figure 2-7). 
At 30 mM glucose level (Figure 2-7, A), which is the lowest glucose concentration used, the 
deconvoluted spectrum of CRP shows a low-intensity peak at 23,189 Da beside the major 
peak at 23027 Da that represents the unmodified CRP. The difference in mass of 162 Da 
between the new and the non-glycated CRP peak clearly indicate that the former peak 
represents the mono-glycated CRP. This finding suggests that, despite its short half-life of 
19 hours (Vigushin et al., 1993), CRP could be glycated in a patient with a high glucose level 
as in poorly controlled diabetes. Proteins with a half-life comparable to CRP were also 
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found to be glycated in diabetic patients (Spiller et al., 2017, Sensi et al., 1990, Hammer et 
al., 1989). 
During this incubation period, increasing glucose concentration resulted in a parallel 
increase in the intensity of the mono-glycated form of CRP; this adds further confidence in 
the identity of this peak. Moreover, the samples incubated with higher levels of glucose 
revealed additional peaks representing the progressive addition of glucose residues; the 
peak at 23,351, which seen at 300 mM glucose level and thereafter, has a mass increment 
of 324 Da over the unmodified peak suggests that the peak is the representative of CRP 
conjugated with two glucose molecules, while the signal at 23,513 Da, which was observed 
at 1000 mM glucose, is shifted by 486 Da from the original peak in the spectrum and hence 
represent a condensation of three glucose molecule (Figure 2-7). 
Using the intensities of the peaks to estimate the glycation level, clearly demonstrate the 
increase in the glycation of the protein from 3.7% at 30 mM glucose to 48.8% at 1 M glucose 
level (Figure 2-10, A). The mono-glycated form was the dominant form during this 
incubation period. Because the glycation condition used were identical for all the samples 
including the incubation time, then the increase in the extent of glycation can be solely 
attributed to the increase in glucose concentration. Several in vitro glycation experiments 
on other proteins showed the relationship between increased glycation level and glucose 
concentration. (Farah et al., 2005, Lapolla et al., 1993, Goodarzi et al., 2004). Farah et al., 
incubated insulin preparation with 55, 110, 165, and 220 mM glucose for 24 h at 37 °C, pH 
7.4 with subsequent mass analysis of the resultant products. In their work, mono-glycated 
insulin was detected with the lowest glucose level with increasing intensity with further 
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increasing glucose concentration, while the di-glycated form was noticed only when the 
insulin exposed to 220 mM glucose. 
The glycation process of CRP was not only affected by glucose concentration, but also by 
the incubation time. If we use the CRP sample incubated with the lowest glucose 
concentration, 30 mM, as an example to explain the effect of incubation time we found 
that the extent of glycation of this sample was increased from 3.7% at 19 hour incubation 
to 8.3% after 3 days, and increased further to nearly 20% with further increase the 
incubation time to 6 days (Figure 2-10). The same trend was seen with all other samples. It 
can also be observed that the extent of glycation of CRP exposed 30 mM of glucose (which 
is lowest glucose concentration used in this work but still higher than that those in diabetic 
patients) for a period equal to its half-life in vivo is relatively low and represented by only 
a mono-glycated form. This degree of glycation could be too low to influence the biological 
functionality of CRP mainly because of its short half-life in vivo (Vigushin et al., 1993). In a 
poorly-controlled diabetic, longer half-life proteins such as albumin are glycated by 
condensation of 4-15 glucose molecule while IgG was found to be glycated with 7-28 
glucose (Lapolla et al., 2013), the glycation of both proteins known to affect their 
functionality (Anguizola et al., 2013, Goetze et al., 2011). 
It is observed that samples incubated with glucose for three days favoured the formation 
of mono-glycated CRP even when the protein exposed to 1000 mM of glucose, while 
glycoforms with the higher level of glycation tetra-, penta-glycated CRP represented the 
lowest proportion (see Figure 2-8 and 2-10, B). The mono-glycated CRP is the only detected 
glycated form in the samples incubated with 30 and 100 mM for 19 hours and with 30 mM 
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for 3 days, suggesting that if CRP found glycated in vivo it probably will be a mono-glycated 
form. 
By the sixth day of incubation (see Figure 2-9), there was a shift in the distribution of CRP 
glycoforms toward the highly-glycated forms with higher glucose concentration. The 
predominant glycoform was the mono-glycated CRP for the samples incubated with up to 
300 mM glucose. At 500 mM glucose, the di- and tri-glycated CRP become the most 
dominant (26.8% and 24.3%, respectively) while the mono-glycated CRP decreased to the 
third lowest observed glycoform (17.3%). At 1000 mM of glucose, the tri- and tetra was the 
most observed glycoform, representing 23.7% and 23.6% of total glycoforms, respectively. 
It was observed that the same level of glycation and glycoforms distribution that was 
achieved by longer incubation times can be achieved with higher glucose concentration in 
shorter times. For instance, the samples incubated with 30 and 100 mM of glucose for six 
days produced a mass profile comparable to the samples incubated with 300 and 1000 mM 
but for 19 hours, respectively. This suggests that the degree of CRP glycation achieved after 
six days of exposure to the glucose can be reached after 19 hours if the glucose 
concentration increased to tenfold. 
The G-idx elucidate the dynamic of the glycation process against the time. For constant 
sugar level, the degree of glycation of CRP was found to be augmented by prolonging the 
time of exposure to that level of glucose. The relationships between G-idx of each sample 
and the incubation time show a linear ascending trend, suggesting that the further increase 
in incubation time could result in more glycation. At 1 M glucose level almost all the protein 
is glycated (97.6%) with an average of 3.6 glucose molecule per each CRP molecule (Figure 
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2-11). Increasing the incubation beyond this period will be aimless; however, it could result 
in a further increase in G-idx value as it reflects the heterogeneity of the glycation product. 
Utilising LC-MS to analyse glycated protein at intact level offers several advantages 
including minimal sample pre-treatment, fast detection of glycated forms, provides means 
to estimate the relative quantity of the glycoforms from their intensities in the spectrum 
(Zhang et al., 2008). One drawback of this approach is that it does not result in any 
information regarding the modification site within the amino acid sequence of the protein. 
 
2.4.4 Conclusion 
Investigation of glucose-treated CRP by LC-MS at intact protein level demonstrates, for the 
first time, that human CRP can be glycated to a different extent depending on both 
concentration and time of exposure to glucose. The LC-MS analysis of intact CRP and the 
intensities of the peaks of the glycated forms can be effectively used in the detection and 
determination of the extent of CRP glycation. The extent of CRP glycation seems to be low 
with the formation of only a mono-glycated form when the protein incubated with 30 mM 
of glucose for a period equal to its half-life in vivo. Samples incubated with glucose for 19 
hours and three days favoured the formation of mono-glycated CRP even when the protein 
exposed to 1000 mM of glucose, while glycoforms with the higher level of glycation were 
obtained upon the glycation of CRP with higher glucose levels (0.5 and 1 M of glucose) and 
longer incubation time. Western blotting shows that the glycation of CRP does not affect 
its reaction with the monoclonal anti-CRP antibody. 
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3.1 Introduction 
3.1.1 Overview 
In chapter two, we demonstrated the usefulness of the intact mass measurement by 
electrospray ionisation-mass spectrometry in the identification of the glycated isoforms 
and estimation of the glycation level of the in vitro glycated CRP samples treated with 
different concentrations of glucose for different time intervals. In this chapter, further 
studies were carried out involving enzymatic digestion of the glycated CRP samples with 
trypsin and endoproteinase Glu-C, followed by product ion tandem mass spectrometric 
analysis of the digests, the aim of these experiments were to identify the precis glycation 
sites in CRP. The Mascot search engine was used to identify the glycated peptides and the 
possible glycation site; the product ion spectra of glycated CRP peptides were then further 
interpreted manually, and the neutral losses from the glucose-containing parent and 
fragment ions were employed to sequence the peptides and to confirm the Mascot result 
or identify the modified residues when Mascot fail. 
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3.1.2 Proteomic approaches to identify modification sites by mass spectrometry 
 Analysis of protein post-translational modifications (PTM) such as glycation, using mass 
spectrometry can provide information about the exact location of the modified residues 
(Mann & Jensen, 2003). Intact protein analysis by MS alone does not result in any 
information regarding the precise modification site within the amino acid sequence of the 
protein (Zhang et al., 2008). Tandem mass spectrometry (MS/MS) based experiments which 
involve fragmentation of either the intact, undigested protein (top-down approach) (Zhang 
& Ge, 2011), or of peptides derived from proteolytic digestion of intact proteins (bottom-
up approach) are typically required for the confident assignment of the modification sites 
(Larsen et al., 2006, Silva et al., 2013). 
Top-down and bottom-up approaches are the two major classes of modern MS-based 
proteomics (Zhang & Ge, 2011, Verrastro et al., 2015, Zhang et al., 2008). The top-down 
approach remains nascent and requires a high mass resolution/accuracy instrument such 
as Fourier-transform ion cyclotron resonance (FTICR) MS (Zhang & Ge, 2011). By contrast, 
the well-established bottom-up approach has been commonly employed in the 
identification of glycated proteins and their modified residues (Gadgil et al., 2007, Jahouh 
et al., 2013, Zhang et al., 2008, Wang et al., 2014, Swamy-Mruthinti & Schey, 1997). The 
top-down approach has never been applied in the analysis of non-enzymatically glycated 
proteins (Zhang et al., 2008). This introduction will, therefore, focus on bottom-up 
approaches and the technologies and strategies that have been developed or applied to 
characterise glycated proteins and determine their modification sites. 
The bottom-up approach, which is also named ‘shotgun’ analysis when performed on a 
mixture of proteins (Zhang et al., 2013), involves the following steps: protein digestion by 
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single or multiple enzymes, separation of the generated peptides typically by liquid 
chromatography (LC) and then peptide analysis using by MS and MS/MS (Zhang et al., 2013, 
Rathore et al., 2018). Identification of the protein and mapping of the modification sites 
relies on the resulting peptide m/z values, and their product ion spectra with the assistance 
of database search bioinformatic tools (Tsiatsiani & Heck, 2015). Figure 3-1 shows the steps 
involved in analysing protein through a bottom-up approach. 
 
 
Figure 3-1 Schematic presentation for the general steps in bottom-up proteomics. In 
bottom-up approach the proteins are first digested into peptides prior to separation and 
MS analysis, the resulting peptides may be further fragmented before another step of MS 
analysis, identification of the protein is achieved by the assistance of database search 
bioinformatic tools. 
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3.1.3 Peptide production via enzyme digestion 
The important step during sample preparation for bottom-up experiments is the 
conversion of proteins into appropriately-sized peptides suitable for mass spectrometric 
analysis (Hustoft et al., 2012). Different proteolytic enzymes with varying degrees of 
specificity are currently available for this task (Tsiatsiani & Heck, 2015), and selecting the 
appropriate enzyme depends largely on experimental goals (Verrastro et al., 2015). 
Trypsin is the most commonly protease used in proteomic studies (Tsiatsiani & Heck, 2015, 
Hustoft et al., 2012). It cleaves specifically and efficiently at the C-terminal side of lysine 
and arginine residues except if they are followed by a proline (Hustoft et al., 2012). Because 
of its cleavage specificity and the relative abundance of lysine and arginine; trypsin-
generated peptides are relatively short peptides generally with a basic residue at the C-
terminus, meaning that tryptic peptides carry at least two positive charges in acidic 
medium; one on the N-terminal amine and another on the basic (K or R) residue (Manadas 
et al., 2010). Tryptic peptides are well-separated using conventional chromatographic 
fractionation, and generally produce information-rich and readily-interpretable tandem 
mass spectra that help in peptide identification (Tsiatsiani & Heck, 2015). 
When the comprehensive mapping of PTMs of proteins is the goal of the study, generating 
as close to complete protein sequence coverage as possible is required. However, one 
drawback of trypsin is that in some cases the generated peptides may be too short to be 
sequenced by MS (Swaney et al., 2010, Tsiatsiani & Heck, 2015), resulting in limited protein 
sequence coverage. Therefore, it is often impossible to identify all the post-translational 
modifications decorating a given protein using trypsin alone (Tsiatsiani & Heck, 2015). 
Moreover, the presence of PTMs is known to affect the cleavage efficiency of proteases 
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(Larsen et al., 2006). Protein glycation alters the digestion pattern of trypsin (or other 
enzymes cleaving at K or R residues) and results in the generation of longer peptides as a 
result of miscleavage, since some K and R side chains are modified in the glycation reaction 
with carbohydrates (Larsen et al., 2006, Priego-Capote et al., 2014). Nevertheless, several 
studies concerned with the mapping of glycation sites have utilised trypsin as a sole 
proteolytic enzyme (Brady et al., 2007, Zhang et al., 2008, Silva et al., 2018, Frolov et al., 
2006). Using other proteases that have different cleavage specificities and/or using multi-
protease protein digestion alongside trypsin can increase the protein sequence coverage 
and improve the identification of PTMs (Tsiatsiani & Heck, 2015, Rathore et al., 2018). 
Glu-C specifically cleaves peptide bonds C-terminally to glutamate or aspartate (at a lower 
rate) and Asp-N, cutting N-terminally to asparagine and cysteine, are both suitable 
alternative to trypsin when trypsin cleavage sites are unavailable. Glu-C and Asp-N are less 
reactive than trypsin (Hustoft et al., 2012). However, because of the limited cleavage sites 
for these enzymes, Glu-C and Asp-N generate longer peptides than does trypsin, therefore, 
allowing increased sequence information per peptide (Tsiatsiani & Heck, 2015). Glu-C and 
Asp-N have been used alone or in combination with trypsin to digest glycated proteins for 
identifying the glycation sites by tandem mass spectrometry (Jahouh et al., 2013, Priego-
Capote et al., 2014, Meltretter et al., 2008, Sun et al., 2005). Pepsin, a nonspecific protease, 
was also reported to improve sequence coverage of glycated proteins (Wang et al., 2013). 
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3.1.4 Peptide separation 
Following protein digestion, the resulting peptide mixture is typically separated by HPLC 
before mass spectrometry (Xie et al., 2012). Reversed-phase high-performance liquid 
chromatography (RP-HPLC) is commonly used for separation of the peptides (Aguilar, 2004, 
Manadas et al., 2010, Simpson et al., 2006). RP separation is based on the binding of the 
peptides in aqueous, moderately polar mobile phase to hydrophobic ligands immobilised 
on the stationary phase (commonly n-octadecyl C18); (Manadas et al., 2010). Polar 
peptides elute first, while the hydrophobic peptides interact more strongly with the 
hydrophobic groups in the stationary phase, causing their retention, i.e. the retention time 
of a given peptide is directly proportional to its hydrophobicity (Aguilar, 2004). Elution of 
the peptides from hydrophobic stationary phases is generally achieved by means of 
applying a gradient of increasing organic content (such as acetonitrile or methanol, with an 
ionic modifier such as trifluoroacetic acid or formic acid); (Aguilar & Hearn, 1996). The 
nature of the buffer system used in RP-HPLC allows direct coupling to the MS system, 
making it the preferred separation method in bottom-up proteomics (Tsiatsiani & Heck, 
2015). RP-HPLC not only separates peptides based on their hydrophobicity but also affords 
a means for removal of the polar salts which are deleterious to MS analysis (Zhang & Ge, 
2011). 
Besides RP-HPLC, other separation techniques have been used online or offline, including 
ion-exchange chromatography (most commonly strong cation exchange), hydrophilic 
interaction LC, and IEF. These methods can be used individually or in combination (usually 
with RP-HPLC) to resolve peptides from more complex proteomes in two-dimensional 
liquid chromatography (Manadas et al., 2010, Simpson et al., 2006). 
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3.1.5 Peptide mass fingerprinting 
Peptide mass fingerprinting (PMF) is a method based on MS analysis of the peptides 
generated from proteolytic digestion of a known or unknown protein followed by matching 
of the obtained masses with a list of theoretical peptide masses generated from in silico 
digestion of the protein sequence (Thiede et al., 2005). PMF can be used for protein 
identification and investigating the presence of PTMs. The matched peptide masses 
identify the protein sequence, while the unmatched values could arise from several factors 
including the presence of PTMs (Mann & Jensen, 2003, Holmes & Giddings, 2004). Evidence 
for the occurrence of PTMs upon a specific peptide can be inferred from the resultant mass 
shift between the measured value and theoretical mass (Zhang et al., 2003). Examples of 
some mass shifts (ΔM) resulted from the formation of early and advanced glycation end 
product are listed in Table 3-1. PMF has been applied in the identification of glycated 
peptides and their corresponding proteins using LC-MS (Ames, 2005, Brock et al., 2003), or 
MALDI-TOF MS (Farah et al., 2005, Wa et al., 2007). In some cases, it was even possible to 
predict the modified residue when there is only one lysine or arginine residue in the given 
glycated peptide (Wa et al., 2007). Using LC-MS-based peptide mass fingerprinting, Brock 
et al. determined the major sites of glycation of RNase, incubated with glucose in 
phosphate buffer, are K41, K7, K1, and K37 (Brock et al., 2003). 
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Table 3-1 Summary of possible early and advanced glycation adducts, according to 
literature. A; the possible modification that involves lysine residues, B; arginine residues, 
C; or both lysine and arginine residues due to glycation processes (Vlassara, 1994, Lyons & 
Jenkins, 1997, Thornalley, P. J., 1999). 
Glycation adducts Mass (Da) 
A 
Fructosyl-lysine 162.0528 
Fructosyl-lysine -1H2O 144.0423 
Fructosyllysine -2H2O 126.0317 
Nε-(carboxymethyl hydroxy)-lysine (CML) 72.0211 
Nε-(carboxymethyl)-lysine (CEL) 58.0055 
Pyrraline 108.0211 
B 
Nδ-[5-hydro-5-(2,3,4-trihydroxybutyl)-4-imidazolon-2-yl]ornithine 144.0423 
Tetrahydropyrimidine (THP) 144.0423 
Imidazolone B 142.0266 
Argpyrimidine 80.0262 
Nδ-(5-hydro-5-methyl-4-imidazolon- 2-yl)-ornithine (MG-H1) 54.0106 
Nδ-(5-hydro-4-imidazolon-2-yl)-ornithine (G-H1) 39.9949 
C 1-alkyl-2-formyl-3,4-glycosyl-pyrrole (AFGP) 270.074 
 
While PMF is a fast and simple method, as it does not involve amino acid sequencing of the 
peptide with tandem mass spectrometry (MS/MS). PMF frequently does not provide 
adequate information to determine the glycation site, particularly in cases where the 
peptide has more than one possible modification site. Further, some of the ΔM may be 
poorly diagnostic, preventing confident assignment of glycation from another kind of PTM, 
for instance, the ΔM of 162 could result from nonenzymatic glycation with hexose or 
enzymatic O- and N-glycosylation with hexose (Mann & Jensen, 2003). 
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3.1.6 Tandem mass spectrometry 
Tandem mass spectrometry experiments involve two or more stages of mass analysis, often 
with analyte dissociation steps between subsequent stages. Generally, during the first 
stage, precursor ions of a specific m/z range are isolated, ion activation is performed to 
promote the production of product ions, the m/z values of which are then recorded (Glish 
& Vachet, 2003, El-Aneed et al., 2009). 
Several dissociation methods have been applied to promote precursor ion fragmentation 
(Silva et al., 2013). The most widely available and hence applied fragmentation method is 
collision-induced dissociation (CID); (Zhang et al., 2008, Silva et al., 2013). CID is based on 
the collision between selected precursor ions with inert collision gas molecules (such as 
helium, nitrogen or argon). Dissipation of the resultant kinetic energy takes place via 
vibrational translation. For unimolecular precursor ions, this ultimately results in 
fragmentation of covalent bonds; in the case of peptides the most abundant cleavage sites 
are amide bonds (Zhang et al., 2013, Larsen et al., 2006). CID of peptides, therefore, results 
in general in the predominant formation of two types of product ions; the product ions 
derived from the N-terminal side of the peptide are referred as b-ions, and product ions 
derived from the C-terminus are referred to as y-ions (El-Aneed et al., 2009). The different 
type of peptide backbone fragment ions according to the nomenclature of Roepstorff and 
Biemann are shown in Figure 3-2 (Biemann, 1992). 
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Figure 3-2 Peptide ion fragmentation in tandem mass spectrometry. Six types of backbone 
fragment ions can be generated, a-, b- and c- are the N-terminal fragment ions while x-, y-
, and z-ions are the C-terminal fragment ions. Reproduced from (Biemann, 1992). 
 
For the Q-TOF mass spectrometer, which was used in this study, the peptide precursor ion 
is selected within the first quadrupole (Q1) mass filter, fragmented by CID within the 
collision cell (an RF-only quadrupole), and the resulting fragment ions (principally b- and y-
ions in addition to the residual precursor) are measured by the TOF analyser 
(Chernushevich et al., 2001). 
Alternative fragmentation techniques for MS/MS-based experiments are available (Quan 
& Liu, 2013). Higher energy collisional dissociation (HCD) is a subset of CID whereby the 
precursor ion is accelerated to higher kinetic energy (Quan & Liu, 2013). HCD is principally 
used with Orbitrap analysers (Olsen et al., 2007). It has the advantage of increased ion 
fragments, able to detect and generate immonium ions, and has no low mass cut-off (Olsen 
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et al., 2007, McAlister et al., 2011). Therefore, HCD can provide more informative MS/MS 
spectra for quadrupole ion trap-based instruments (McAlister et al., 2011). HCD generates 
b- and y-ions with a high prevalence of y-ions; b-ions can be further fragmented to a-ions 
or smaller species (Olsen et al., 2007). Other methods to induce fragmentation include: 
electron-capture dissociation (ECD), used mainly with FTICR (Sleno & Volmer, 2004), and 
electron-transfer dissociation (ETD), used with ion trap mass spectrometers and Q-TOF 
instruments (Kim & Pandey, 2012). Both these methods involve electron-driven radical 
species generation from a multiply protonated peptide, followed by N-Cα bond 
dissociation, resulting in c- and z-type products (Kim & Pandey, 2012). ECD and ETD allow 
identification of PTMs that are labile under CID. Uptake of these methods has been limited 
due to dedicated instrumentation requirements (Silva et al., 2013). 
Several types of scan mode can be performed by tandem mass spectrometers (Niessen, 
1999). The basic and the most commonly used scan mode is the product ion scan, where a 
specific precursor ion is selected during the first stage of the mass analysis, and the product 
ions generated from its fragmentation are detected during the second stage of mass 
analysis (Niessen, 1999). Product ion scans are used to infer peptide sequences and hence 
identify the proteins in a biological sample (Glish & Vachet, 2003). However, if a group of 
compounds share a common and specific product ion, then precursor ion scans can be used 
for their identification. Precursor ion scanning involves specifying a target product ion to 
be monitored in the second mass analyser while the first mass analyser scans all the 
precursor ions that decompose to produce the specified product ion (Glish & Vachet, 2003, 
Niessen, 1999). Neutral loss scanning is another scan mode can that be performed by some 
instruments, here the instrument is set to transmit only ions where a specific neutral mass 
loss is observed in product ion populations. The m/z offset corresponds to the mass of 
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neutral loss. For example; 18 Da loss to identify precursor ions losing a water molecule 
(Glish & Vachet, 2003, Niessen, 1999). Precursor ion and neutral loss scans are sensitive 
and specific techniques for the identification of modified peptides (Salzano & Crescenzi, 
2005, Larsen et al., 2006). Finally, selected reaction monitoring scans are typically used for 
quantification. Both the precursor and product ion m/z values are specified here, and the 
detection takes place only when the precursor ion selected by the first mass analyser 
fragments to produce a given product ion (Glish & Vachet, 2003, Niessen, 1999). Figure 3-
3 summarise the different MS/MS scan mode. 
Q-TOF instruments can be operated with product ion scan, precursor ion scan (however, 
with much lower sensitivity than to triple quadrupoles); (Chernushevich et al., 2001), and 
selected reaction monitoring-like experiments by utilising software to algorithmically 
extract the targeted signals from full or partial product ion scans (Bereman et al., 2012). 
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Figure 3-3 Tandem mass spectrometry scan types. Product ion scan: MS1 select precursor 
ion and MS2 scan production. Precursor ion scan: MS1 scan precursor ion and MS2 monitor 
specific product ion. Neutral loss scan: MS1 scan precursor ion and select ions with a 
neutral loss in MS2. Selected reaction monitoring: MS1 select precursor ion and monitor 
specific product ions in MS2. MS and CID stand for mass spectrometer and collision-induced 
dissociation, respectively 
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3.1.7 Identification of peptides 
Once acquired, the MS/MS dataset (containing product ion spectra and precursor ion m/z 
values) have to be analysed. The peptide sequence can be determined from the 
fragmentation spectrum by calculating the mass shift between adjacent fragment peaks 
and determining any match between mass increments and amino acid masses (Aebersold 
& Goodlett, 2001). If a specific PTM modifies the analysed peptide ion, the type of 
modification and the location of the modified reside may be similarly determined from the 
mass increment (Mann & Jensen, 2003). However, this is only possible if the PTM remains 
intact during the fragmentation process with adequate fragment ions covering the peptide 
sequence (Mann & Jensen, 2003). A number of known PTMs show high lability under CID 
conditions, including phosphorylation and glycosylation (Kim & Pandey, 2012). 
The large, complex datasets generated during tandem mass spectrometry experiment are 
highly amenable to bioinformatics analysis, as peptide fragmentation processes are 
predictable; the presence of modifications (post-translational, chemicals or accidental) 
further increases the complexity of sequence determination. Various algorithms have been 
developed for the automatic interpretation of tandem mass spectra. These algorithms fall 
into two types (Nesvizhskii & Aebersold, 2004): de novo sequencing algorithms; these 
identify peptide sequences directly from the tandem MS data based on amino acid masses 
e.g. PEAKS algorithm (Zhang et al., 2012), and database searching algorithms, which 
compare MS/MS spectra in the experimental dataset against theoretical fragmentation 
spectra of peptides generated from in silico digestions of protein sequence database 
entries (Helsens et al., 2007). The output of such comparisons is the identity of the peptides 
with a score or expectation value to quantify the degree of similarity between the 
compared spectra (Nesvizhskii & Aebersold, 2004). Examples of these algorithms are 
Chapter 3: Revealing the glycation sites of in vitro glycated C-reactive protein
  Introduction 
110 
 
Mascot (Perkins et al., 1999), Sequest (Eng et al., 1994), and X!Tandem (Craig & Beavis, 
2004). 
Mascot, which is developed by Matrix Science, is a probability-based scoring system which 
supports PMF, sequence query, and MS/MS ions search (Perkins et al., 1999). Mascot has 
been extended to include a modified peptides search, where PTMs such as glycation can 
be included as variable modifications during the search (Creasy & Cottrell, 2002). It should 
be noted that identifications of modified peptides are often less precise than unmodified 
peptides, mainly when more than one modification is present, because of the increase in 
the search space involved in variable searching with modifications (Mann & Jensen, 2003). 
MS/MS spectra from peptides with labile modifications are often less informative due to 
neutral loss being the predominant fragmentation. Nevertheless, these difficulties can be 
overcome by validation of the tandem mass spectrum against possible modified peptides 
predicted from the putative sequence (Mann & Jensen, 2003). 
3.1.8 Fragmentation behaviour of glycated peptides under CID condition 
Glycated peptides have characteristic fragmentation patterns distinct from those of normal 
non-modified peptides when using CID or HCD (Rabbani et al., 2016, Frolov et al., 2006). 
When the peptide is modified by glycation, the intramolecular vibrational energy resulted 
from the collision redistributes to include the peptide side chain modification, causing 
dissociation of weakest bonds on side chain modifications before the amide bond cleavage 
(Zhang et al., 2008). The labile Amadori product tends to lose up to three molecules of 
water to generate pyrylium ions and loses three water molecules with additional loss of 
formaldehyde to form furylium and immonium ions (Jerić et al., 2002). Consecutive loss of 
four water molecules has also been reported, attributed to the five-membered furanose 
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ring form, which can lose up to four water molecules (Frolov et al., 2006). The 
fragmentation of glycated peptides under CID or HCD conditions and the proposed 
structures of the fragment ions mentioned above are illustrated in figure 3-4. The signals 
of the successive neutral losses dominate the MS/MS spectra of glycated peptides; glycated 
b- and y-ions signals are usually very poor or even undetectable (Frolov et al., 2006). The 
characteristic product ions can be used to demonstrate the presence of a glycated peptide 
(Wang et al., 2014, Leblanc et al., 2016, Frolov et al., 2006). 
 
Figure 3-4 Fragmentation of Amadori compounds under CID conditions. Fragmentation of 
Amadori compounds by CID results in the formation of oxonium, pyrylium, furylium and 
immonium ions. Reproduced from Rabbani et al., 2016. 
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3.1.9 Other technologies and strategies to characterise glycated peptides 
Glycated peptides have been demonstrated to generate a number of low mass ions related 
to modified lysine immonium ion species including: glucose-derived lysine immonium ion, 
pyrylium-derived lysine immonium ion and furylium-derived lysine immonium ion (246.2, 
192.1, and 162.1 Da respectively when considering the mass of 84.1 Da for the unmodified 
lysine immonium ion signal); (Frolov et al., 2006, Priego-Capote et al., 2014). The presence 
of such ions in product ion spectra is a good indicator that a given peptide is modified by 
glycation. However, among the modified lysine immonium ions, the pyrylium-derived 
lysine immonium ion generates the most intense signal (Frolov et al., 2006). Precursor ion 
scanning experiments for pyrylium-derived lysine immonium ion at m/z 192.1 have been 
used to identify the glycation peptides of the glycated bovine serum albumin using Q-TOF 
MS; the peptide sequence was determined based on the abundant signals from the 
pyrylium and furylium glycated fragments ions (Frolov et al., 2006). 
Under CID conditions, neutral loss of an entire glucose molecule (-162) is also observed in 
addition to the neutral loss of multiple water molecules in the product ion spectra of 
glycated peptides. Neutral loss-triggered product ion scans based on characteristic neutral 
loss of -162 Da have been used to determine the glycation sites of human serum albumin 
using Q-TOF MS. The neutral loss scan experiment was composed of two segments; in the 
first segment the glycated peptides are identified based on their neutral loss of 162 Da, and 
in the second segment, the identified glycated peptides were fragmented at higher collision 
energy to obtain the amino acid sequences and the sites of glycation (Gadgil et al., 2007). 
Data-dependent neutral loss triggered MS3 (NLMS3), and multi-stage activation tandem 
mass analysis (MSA) are similar advanced CID techniques that can also be applied to 
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identify glycation sites (Zhang et al., 2008). In NLMS3 experiments, product ions produced 
on CID via neutral loss of 3 H2O or 3 H2O + HCHO are selected for MS3 analysis. In MSA, the 
neutral loss products are subjected to MS3 without isolation step, and in the presence of 
the other fragments of the precursor ion (Zhang et al., 2008). 
The neutral loss phenomena associated with glycated peptides under CID condition can be 
avoided by using alternative fragmentation methods such as ETD (Zhang et al., 2007). ETD 
provides more extensive sequence fragmentation and retains the Amadori compound 
intact (Zhang et al., 2007). ETD has been applied successfully for sequencing of glycated 
peptides in several studies, where it outperformed CID by producing abundant and almost 
complete series of c- and z-type fragment ions enabling direct and confident identification 
of modification sites (Zhang et al., 2007, Zhang et al., 2008). However, ETD based MS/MS 
also has limitations; it is less effective for ions with m/z over 850 and doubly charged ions 
(Good et al., 2007), and ETD capability is less widely available (Zhang et al., 2008). 
3.1.10 Experimental Aims 
The present study aimed to identify the potential glycation sites of CRP, exposed to 1 M 
glucose concentration over a time course of six days, by enzymatic digestion and tandem 
mass analysis with the Q-TOF-MS. The second aim was to identify the favourable glycation 
site of the protein when exposed to the lower glucose levels. A computational-based 
method to calculate the distance from the potential glycation sites to the nearby acidic and 
basic residues in the 3D structure of the protein, as well as the exposed surface area of the 
potential glycation sites and their pKa values, were used to understand the 
microenvironment of the potential glycation sites. The information gained from this study 
were utilised to investigate the effect of diabetic glucose levels on CRP in vivo. 
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3.2 Materials & Methods 
3.2.1 Glycated CRP samples used in this study 
From the in vitro glycated samples prepared in section 2.2.2, samples incubated for 19 h, 3 
days, and 6 days with 1 M glucose solution were selected for the tandem mass 
spectrometry analysis. The rationale for selecting the samples incubated with the highest 
glucose concentration was to maximise the observation of glycation sites. 
Additional samples were also prepared to determine the primary amino acid site modified 
by glycation. This group included CRP samples incubated with decreasing concentration of 
glucose; 200, 100, 50 and 30 mM, for 19 hours. The incubation time of the CRP sample 
exposed to 30 mM was also extended to 3 days. The sample preparation was according to 
the method described in section 2.2.2. In addition to the in vitro glycated samples, a CRP 
sample prepared under the same condition but without the addition of glucose was used 
as a control. The final concentration of all CRP samples was 1 µg/µL (43.4 pmol/µL) in 50 
mM ammonium bicarbonate, pH 7.4. The samples were stored at 4 °C until analysis. 
3.2.2 Sample pre-treatment and protein digestion 
The in vitro glycated CRP samples and the non-glycated CRP control (see section 3.2.1) were 
all treated and digested using the same reagents, protocol, and the same equipment to 
minimise variations in digestion process due to alterations in the experimental conditions. 
HPLC grade water was used in the preparation of ammonium bicarbonate buffer (50 mM, 
pH 8), dithiothreitol (100 mM) and iodoacetamide (100 mM). 
CRP samples were first denatured by addition of, MS-compatible detergent, Rapigest 
(Waters) to enhance the enzymatic digestion of the protein. Rapigest (lyophilised powder, 
1 mg) was reconstituted in 100 µL of 50 mM ammonium bicarbonate buffer to give a stock 
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solution of 10 g/L; this solution is stable for up to 1 week at 4°C. To a 50 µL aliquot of each 
sample (containing 50 µg of the protein), Rapigest was added to a final concentration of 2 
g/L then incubated at room temperature for 30 minutes. 
Protein disulfide bonds were reduced by the addition of dithiothreitol (DTT, Sigma-Aldrich) 
to a final concentration of 10 mM. The solutions were heated to 99.5 °C for 5 min, then 
kept at 60 °C for 30 min. Upon cooling and gentle vortexing, iodoacetamide (IAA, Sigma-
Aldrich) was added to a final concentration of 15 mM to prevent disulfide bonds from 
reforming. The samples were then incubated in the dark for 1 hour. The alkylation reaction 
with IAA was stopped by further addition of DTT to reach 25 mM. A sufficient quantity of 
50 mM ammonium bicarbonate was added to reduce the Rapigest concentration to 1 g/L 
in a 125 µL reaction volume. Finally, each CRP solution was divided into two equal portions 
(each contains ≈25 µg of the protein), the first portion to be used for trypsin digestion, 
while the second portion to be digested with endoproteinase Glu-C. 
Both trypsin (proteomics Grade, Sigma-Aldrich) and Glu-C (protease V8 Sequencing Grade, 
Roche) were freshly reconstituted. For trypsin, the lyophilised product (20 µg) was 
dissolved in 20 µL of 1 mM HCl, while Glu-C (50 µg) was dissolved in 50 µL HPLC grade 
water. Trypsin and Glu-C stock solutions can be stored at 2–8 °C for 2 weeks and 1-2 days, 
respectively. Aliquots of the stock enzyme solutions were diluted with 50 mM ammonium 
bicarbonate to 0.1 µg/µL. The working solution of trypsin (0.1 µg/µL) was then added to 
the first portion of each CRP sample to give substrate to enzyme ratios of 30 to 1, an equal 
volume of Glu-C working solution (8.3 µL of 0.1 µg/µL) was added but to the second portion 
to give the same substrate to enzyme ratio. The solutions were incubated for 24 hours at 
37 °C with gentle agitation. A second application of each enzyme was added to the 
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corresponding aliquot after 8 hours of incubation to enhance protein digestion. The 
digestion was stopped by lowering the pH to less than two by adding TFA to a final 
concentration of 0.5%. The acidified solutions were then incubated at 37 °C for 30-45 min 
before centrifugation and removal of the supernatant for analysis. The digestion products 
(80 µL samples) were stored frozen (-20 °C) until analysis. 
3.2.3 LC-ESI-MS/MS Analysis of Protein Digests 
Before MS/MS analysis, the CRP peptide digests were desalted using C18 Zip-tips 
(Millipore). The zip-tip was wetted ten times with a 10 µL portions of 100% ACN, and then 
equilibrated ten times with a 10 µL portions 0.1% F.A solution. A 10 µL aliquot of CRP digest 
(containing ≈ 3 µg of the protein) was adsorbed onto the reversed-phase medium by 10 
repeated aspirate-dispense cycles of sample loading. The tip was washed immediately with 
100 µL of 0.1% F.A. Finally, A 10 µL portion of 80% ACN in 0.1% F.A solution was placed into 
a microcentrifuge tube, and peptide elution was performed by passing this solution 
through the Zip-tips with three aspirate-dispense cycles. The eluted peptides (≈10 
pmole/µL assuming 80% recovery from the Zip-tip) were diluted with HPLC grade water to 
a final concentration of 1 pmol/μL. Samples were centrifuged for 3-5 minutes to remove 
precipitate, then transferred to autosampler vial (Waters Corporation). The vials were 
loaded onto autosampler, and an aliquot of solvent A was also loaded to be used as a blank. 
The sample run was performed after three blank runs to ensure that the LC-MS system is 
stable before samples analysis. Moreover, two blank runs were added between samples to 
minimise observation of system contamination and carryover. The same LC-MS equipment 
described in 2.2.5 was used for peptide analysis but employing C18 trapping column 
(Acclaim PepMap100, ID 0.3 mm, length 5 mm, particle size 5 μm, pore size 100 Å, Dionex) 
and C18 analytical column (Acclaim PepMap100, ID 75 μm, length 15 cm, particle size 3 μm, 
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pore size 100 Å, Dionex). The HPLC solvents consisted of 0.1% F.A, 5% ACN, as solvent A, 
and 0.1% F.A, 95% ACN for solvent B. 
For each HPLC separation, digested protein (2 pmol) were loaded onto C18 trap column 
throughout 5 minutes using 95% solvent A, 5% solvent B at 30 µL/min to desalt and 
concentrate the peptides. After the trapping period, the peptides were separated on a C18 
analytical column at a flow rate of 0.35 µL/min. The HPLC gradients consisted of 2 ramping 
steps; a 35 minutes ramp from 5% to 60% solvent B, followed by a 10 minutes ramp to 95% 
solvent B then preserving on 95% B for additional 5 minutes before returning to the initial 
starting conditions at the end of the run. 
After separation, peptides eluting from the HPLC column were delivered to a Q-TOF mass 
spectrometer and introduced into the gas phase through the nanoESI source by applying a 
DC potential of 1-2 kV to the sample solution within the nano-spray emitter capillary. 
Survey spectra were acquired in positive ion mode over the m/z 400–1600, with data-
dependent product ion analysis of multiply charged precursors where intensity >50 counts 
per scan, m/z 50 to 1600. The collision offsets used during the CID-MS/MS analyses were 
preset according to precursor m/z. Data were collected using MassLynx version 4.1 (Waters 
Ltd., Manchester, UK). 
3.2.4 Collection and analysis of mass spectrometry data 
Raw peptide mass values from each whole mass spectrometry file were extracted as text 
formatted mgf files using Mascot Distiller (Matrix Science, London). The mgf files were 
subjected to database searching using Mascot database search engine (Matrix Science, 
London, UK). A custom database, comprising the CRP sequence and common laboratory-
observed contaminants was used for these searches with the following parameters: 
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enzyme: trypsin or V8-E, missed cleavages: ≤two, fixed modifications: carbamidomethyl 
(C), variable modifications: oxidation (M), Gln->pyro-Glu (N-term Q), glycation (K, R and N), 
mass values: monoisotopic peptide, mass tolerance= ±100 ppm, MS/MS tolerance= ±0.6Da. 
MS/MS spectra of the precursors whose m/z values were assigned to glycated CRP peptides 
through Mascot were further analysed manually to interpret unassigned peaks within the 
spectrum and identify the glycation site. The m/z values that did not correspond to any 
peptide sequence in the selected database during the Mascot search were considered as 
possible CRP glycated peptides and further analysed as follows: the experimental masses 
of these m/z values were compared with a table model containing hypothetical molecular 
weight values of all possible glycated CRP peptides bearing up to three glucose molecules. 
The data table was generated by performing a theoretical digestion of CRP using 
ProteinProspector tool MS-Digest (http://prospector.ucsf.edu/prospector/cgi-
bin/msform.cgi?form=msdigest) with the following parameters: enzyme: trypsin or V8-E, 
missed cleavages: ≤two, fixed modifications: carbamidomethyl (C), variable modifications: 
oxidation (M), Gln->pyro-Glu (N-term Q), peptide mass values: 500-5000 Da, minimum 
peptide length = 5. Subsequently, to the generated CRP peptide masses the mass increment 
due to glycation (by up to 3 glucose molecules) was added. When there was a match, within 
100 ppm mass threshold, then the product ion spectrum of the possible glycated peptide 
was manually processed. 
To facilitate the interpretation of the fragment ions in the spectrum of the matched m/z 
value (the possible glycated peptide), an in silico fragmentation of the possible glycated 
peptide were performed using the ProteinProspector tool MS-Product 
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(http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msproduct). Then the 
values are compared, and only the matches within 0.6 Da threshold were considered. 
3.2.5 Physicochemical properties of lysine and arginine residues in CRP 
Factors with the potential to impact the glycation process of individual lysine and arginine 
residues of CRP were analysed, these factors include the local pKa values of the lysine and 
arginine residues, the accessibility of the side chain amino group in these residues, and the 
nearby acidic (Glu and Asp) and basic (Lys, Arg and His) residues. 
The crystal structure of CRP in Protein Data Bank, PDB ID: 1B09, was used in this analysis. 
Local pKa values were estimated by using a protein pKa predictor (PROPKA 3.0), available 
on http://nbcr-222.ucsd.edu/pdb2pqr_2.0.0/ (Li, Hui et al., 2005). The fractional solvent 
accessible surface areas (FAS) of the side chain of lysine and arginine were calculated by 
using VADAR (Volume, Area, Dihedral Angle Reporter) algorithm, 
http://vadar.wishartlab.com (Willard et al., 2003). The location of lysine and arginine 
residues within the protein structure and the distance to the nearby acidic and basic 
residues were computed using PyMOL (http://www.pymol.org). The distance from lysine 
or arginine residue to acidic residues (Glu, and Asp) was calculated from the ε-NH+ group 
of lysine or the guanidino group of arginine to the free acid group of the side chain of the 
acid residues (γ-COOH group of glutamate or β-COOH of aspartate). Similarly, the distance 
of lysine or arginine to basic residues was calculated from the ε-NH+ or guanidino group to 
the basic groups of the side chain of the basic residues (ε-NH+ of lysine, guanidino group of 
arginine, or the imidazole group of histidine). Only residues within 10 Å distance in tertiary 
structure or within three residues distance in the primary structure was included in this 
calculation.  
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3.3 Results 
The non-glycated and the in vitro glycated CRP samples prepared according to section 3.2.1 
were enzymatically digested by trypsin and Glu-C separately, and the resulting digests were 
analysed by LC-nESI-QqTOF-MS/MS. The obtained data were submitted to Mascot, which 
allowed identification of CRP peptides. The product ion spectra of putative glycated 
peptides were further inspected manually to narrow down the likely glycation site(s). 
3.3.1 The sequence coverage of the non-glycated CRP control 
The sequence coverage obtained from the tryptic and Glu-C digests of the untreated non-
glycated CRP are summarised in Figure 3-5. Sequence coverage of 53% was achieved with 
trypsin, and 91% from Glu-C digest, combining the mapping results of both enzymes 
generated 100% sequence coverage thus covering all the probable glycation sites. 
 
 
Figure 3-5, Sequence coverage of the control CRP sample obtained from the tryptic and 
Glu-C digest. Residues in red represent coverage obtained from Glu-C digests, while the 
bold, underlined residues represent coverage obtained from trypsin digestion. 
  
1 QTDMSRKAFV FPKESDTSYV SLKAPLTKPL KAFTVCLHFY TELSSTRGYS 
51 IFSYATKRQD NEILIFWSKD IGYSFTVGGS EILFEVPEVT VAPVHICTSW 
101 ESASGIVEFW VDGKPRVRKS  LKKGYTVGAE ASIILGQEQD SFGGNFEGSQ 
151 SLVGDIGNVN MWDFVLSPDE  INTIYLGGPF SPNVLNWRAL KYEVQGEVFT 
201 KPQLWP 
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3.3.2 Tryptic digest of CRP preparations pre-exposed to 1 M glucose for 19 h, 3 and 6 days 
The data acquired from LC-MS/MS analysis of the tryptic digest of CRP samples exposed to 
1 M glucose for 18 hours, 3 days and 6 days were submitted to Mascot. The matched CRP 
peptides are summarised in Table 3-2.  
 
 
Table 3-2 Peptides identified in the tryptic digest of CRP samples incubated with 1 M 
glucose in the time course of the experiment. The duration of incubation were A: 19 hours, 
B: 3 days and C: 6 days. Incubated samples were analysed by LC-nESI-QqTOF-MS/MS, and 
the acquired data were searched against Mascot using database comprising CRP sequence 
and common laboratory-observed contaminants.  indicates the observation of a peptide 
in a given sample. Glycated peptides are underlined, and * represents the number of 
attached glucose moieties. All the identified peptides were within a mass tolerance of ±100 
ppm. 
Sequence Residues Experimental 
mass (Da) 
Charge 
state 
A B C 
KAFVFPK 7-13 835.49 2 
 
 
 
ESDTSYVSLK 14-23 1127.52 2 
 
 
 
ESDTSYVSLKAPLTKPLK 14-31 1976.03 3  
  
GYSIFSYATK 48-57 1135.53 2    
GYSIFSYATKR 48-58 1291.63 2, 3    
QDNEILIFWSK Gln->pyro-Glu (N-term Q) 59-69 1374.67 2    
QDNEILIFWSK 59-69 1391.68 2    
RQDNEILIFWSK 58-69 1547.79 2, 3    
YEVQGEVFTKPQLWP 192-206 1819.89 2    
ALKYEVQGEVFTKPQLWP 189-206 2132.1 2, 3    
DIGYSFTVGGSEILFEVPEVTVAPVH 
ICTSWESASGIVEFWVDGKPR 
70-116 5166.44 4    
KAFVFPKESDTSYVSLK* 7-23 2107.05 3, 4    
AFVFPKESDTSYVSLK* 8-23 1978.95 2, 3    
GYSIFSYATKR* 48-58 1453.70 2    
ALKYEVQGEVFTKPQLWP* 189-206 2294.15 3 
 
  
YEVQGEVFTKPQLWP* 192-206 1981.96 2 
  
 
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The sequence coverage obtained for samples incubated for 19 h, 3 and 6 days were found 
to be 54.4%, 54.4% and 50.5%, respectively. This sequence coverage included 10 out of 13 
lysine residues (K119, K122 and K123 were not covered) for the sample incubated for 19 h 
and 3 days; and 8 out of 13 lysine residues (K28, K31, K119, K121 and K122 were not 
covered) for the sample incubated for 6 days. 4 out of 6 arginine residues (R6, R47, R118, 
R188) were not covered by the sequence coverage of all the samples digested by trypsin. 
However, three of these arginines (R6, R47, and R188) were observed cleavage sites for 
trypsin. 
Peptides 7-23, 8-23 and 48-58 were found to be glycated with a single glucose moiety, 
these glycated peptides were identified in the tryptic digest of CRP samples exposed to 1 
M glucose for 19 h, 3 and 6 days (see table 3-2). If the trypsin cleavage site is discounted as 
a potential glycation site, then K13 is the only potential glycation site in the glycated 
peptides 7-23 and 8-23 while K57 is the potential glycation site of the peptide 48-58. 
The peptide comprising residues 189-206 includes two possible glycation sites, K191 and 
K201; this was modified with single glucose in the samples incubated for 3 and 6 days. The 
peptide comprising residues 192-206 has a single potential glycation site. K201 was 
modified by one glucose after all incubation time of 6 days. 
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3.3.3 Glu-C digest of CRP preparations pre-exposed to 1 M glucose for 19 h, 3 and 6 days 
The samples exposed to 1 M glucose for 18 hours, 3 days and 6 days were also digested by 
Glu-C endoproteinase, the resulting digests were analysed by LC-MS/MS, and the acquired 
data were submitted to Mascot. The results are summarised in table 3-3. 
 
 
Table 3-3 Peptides identified in the Glu-C digest of CRP samples incubated with 1M glucose 
in the time course of the experiment. The incubation times were A: 19 hours, B: 3 days and 
C: 6 days. Samples were analysed by LC-nESI-QqTOF-MS/MS, and the acquired data were 
searched against Mascot database using comprising CRP sequence and common 
laboratory-observed contaminants.  indicates the observation of a peptide in the 
samples. The glycated peptides are underlined, and * represents the number of attached 
glucose. All the identified peptides were within a mass tolerance of ±100 ppm. 
Sequence Residues charge 
state 
Experimental 
mass (Da) 
A B C 
QTDMSRKAFVFPKE Gln->pyro-Glu (N-term Q) 1-14 3 1665.8    
QTDMSRKAFVFPKESDTSYVSLKAPLT 
KPLKAFTVCLHFYTE Gln->pyro-Glu (N-term Q) 
1-42 6 4863.38  
 
 
  
LSSTRGYSIFSYATKRQDNE 43-62 3, 4 2322.05    
ILIFWSKDIGYSFTVGGSE 63-81 2 2118.05    
VTVAPVHICTSWE 89-101 2 1497.73    
FWVDGKPRVRKSLKKGYTVGAE 109-130 3, 4 2520.36    
ASIILGQEQDSFGGNFE 131-147 2 1810.83    
GSQSLVGDIGNVNMWDFVLSPDE 148-170 2 2478.12    
GSQSLVGDIGNVNMWDFVLSP 
DEINTIYLGGPFSPNVLNWRALKYE 
148-193 4 5124.48 
   
INTIYLGGPFSPNVLNWRALKYE 171-193 2, 3 2664.34    
VFTKPQLWP 198-206 2 1114.61    
ILIFWSKDIGYSFTVGGSE* 63-81 2 2280.11    
FWVDGKPRVRKSLKKGYTVGAE* 109-130 3, 4, 5 2682.40    
LSSTRGYSIFSYATKRQDNE* 43-62 3 2484.12      
INTIYLGGPFSPNVLNWRALKYE* 171-193 3 2826.42 
 
   
FWVDGKPRVRKSLKKGYTVGAE** 109-130 5 2844.45      
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Sequence coverage of 91.3% was obtained for the sample incubated for 19 h; this coverage 
included all the lysine and arginine residues in the primary sequence of CRP. Lower 
coverage (77.8%) was obtained from samples incubated for 3 and 6 days, all lysine and 
arginine residues except K23, K28 and K31, were included in this coverage. 
When the mapping results of both trypsin and Glu-C are considered, the total coverage 
increases to 100%, 94.7%, and 90.8% for the samples incubated for 19 h, 3 and 6 days 
respectively, this coverage included all the probable glycation sites, except the sample 
incubated for 6 days where K28 and K31 were not covered. 
Glu-C digestion products from samples incubated with 1 M glucose for 19 hours shows two 
peptides modified by one glucose molecule; residues 63-81 and residues 109-130. The 
peptide 63-81 have only a single lysine (K69), while the peptide 109-130 has 4 lysine and 2 
arginine residues. The same modified peptides were also detected after three days of 
incubation. However, after six days of exposure to 1 M glucose additional modified 
peptides were detected; peptides 43-62 and 171-193 both were modified by one glucose 
while the peptide 109-130 was seen modified by two glucose molecules. Residues 43-62 
cover K57 and R58, while residues 171-193 cover R188 and K191. 
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3.3.4 Interpretation of MS/MS spectra of the modified peptides 
Where multiple potential glycation sites were present within a single peptide, 
unambiguous assignment of the modified amino acid residue was inconsistently reported 
by Mascot. For this reason, the CID product ion of each glycated peptide was reviewed 
manually, looking for the unassigned peaks due to neutral losses, as well as identifying the 
glycation sites in each modified peptide. 
3.3.4.1  Glycation sites in CRP after 19 hours exposure to the 1 M glucose solution 
Based on the trypsin digest (table 3-1) and endoproteinase Glu-C digest (table 3-2), three 
tryptic and two GluC peptides were found modified by one glucose molecule after 19 h of 
incubation. 
Figure 3-6 displays the product ion spectrum of the glycated peptide KAFVFPKESDTSYVSLK 
at m/z 703.3473+. Several intense ions detected in this spectrum arise from neutral losses 
of water molecules from the fructosamine-containing product ions, mainly loss of 3 
molecules of water (-3 H2O), 4 molecules of water (-4 H2O) and loss of 84 Da (-3 
H2O+HCHO), in addition to the loss of entire glucose molecule (-C6H10O5). The presence of 
these neutral loss signals from the product ions y12 to y16, and b15, b10, and b8 confirmed 
not only the glycation status of the peptide but also allowed positive identification of the 
site of modification as K13. A similar finding was observed for the glycated peptide 
AFVFPKESDTSYVSLK at m/z 660.65+3 (Figure 3-7), which has the same sequence as the 
former peptide but without the N-terminus K7. The signals of fructosamine-containing 
product ions (such as y14, y12, y11, b11, b9, and b7) and the intense signals of the neutral loss 
from the product y-ions (y11 to y14) confirm that this peptide was also glycated at K13. 
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Figure 3-6 Assignment of product ion data for peptide sequence KAFVFPKESDTSYVSLK. A) 
nESI product ion mass spectrum of the precursor at 703.34+3 m/z, combined spectra were 
smoothed/centroided using MassLynx 4.1. B) Mascot identification of precursor ion at 
703.34+3 m/z, assigned to peptide sequence KAFVFPKESDTSYVSLK. The glycation site was 
identified by manual interpretation of the spectrum. K13 is the glycation site and indicated 
in the above sequence by (GL). bn and yn are N- and C-terminal fragment ion series, 
respectively. + is the number of charges, * indicates deamination. Neutral losses from the 
fructosamine-containing parent and fragment ions are indicated by  (loss of 1 H2O),  
(loss of 2 H2O),  (loss of 3 H2O),  (loss of 4 H2O),  (loss of -3 H2O+HCHO), and G (loss of 
C6H10O5). 
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Figure 3-7 Assignment of product ion data for peptide sequence AFVFPKESDTSYVSLK. A) 
nESI product ion mass spectrum of the precursor at 660.65+3 m/z, combined spectra were 
smoothed/centroided using MassLynx 4.1. B) Mascot identification of precursor ion at 
660.65+3 m/z, assigned to peptide sequence AFVFPKESDTSYVSLK. The glycation site was 
identified by manual interpretation of the spectrum. K13 is the glycation site and indicated 
in the above sequence by (GL). bn and yn are N- and C-terminal fragment ion series, 
respectively. + is the number of charges, * indicates deamination. Neutral losses from the 
fructosamine-containing parent and fragment ions are indicated by  (loss of 1 H2O),  
(loss of 2 H2O),  (loss of 3 H2O),  (loss of 4 H2O),  (loss of -3 H2O+HCHO), and G (loss of 
C6H10O5). 
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The second glycation site identified in the tryptic digest of CRP samples incubated with 1 
M glucose for 19 h and more extended periods is K57 (Figure 3-8).  
 
 
Figure 3-8 Assignment of product ion data for peptide sequence GYSIFSYATKR. A) nESI 
product ion mass spectrum of the precursor at 727.84+2 m/z, combined spectra were 
smoothed/centroided using MassLynx 4.1. B) Mascot identification of precursor ion at 
727.84+2 m/z, assigned to peptide sequence GYSIFSYATKR. The glycation site was identified 
by manual interpretation of the spectrum. K57 is the glycation site and indicated in the 
above sequence by (GL). bn and yn are N- and C-terminal fragment ion series, respectively. 
+ is the number of charges, * indicates deamination. Neutral losses from the fructosamine-
containing parent and fragment ions are indicated by  (loss of 1 H2O),  (loss of 2 H2O),  
(loss of 3 H2O),  (loss of 4 H2O),  (loss of -3 H2O+HCHO), and G (loss of C6H10O5). 
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The MS/MS spectrum of the glycated peptide GYSIFSYATKR at m/z 727.84+2 shows 
abundant signals corresponding to mass losses of 3 H2O, 4 H2O and 3 H2O+HCHO from the 
parent ion confirming the glycation status of the peptide, while the fructosamine-
containing product ions and their correlated neutral losses identify the glycation site as 
K57. 
Additional glycated peptides were identified in the Glu-C digests of CRP samples incubated 
with 1M glucose for 19h and more extended periods: ILIFWSKDIGYSFTVGGSE, which has a 
single modification site (K69), and FWVDGKPRVRKSLKKGYTVGAE, with six possible 
modification sites. 
Mascot assigned the doubly charged peptide at m/z 1141.0617+2, ILIFWSKDIGYSFTVGGSE, 
to the MS/MS spectrum in Figure 3-9. y-ion and b-ion series corresponding to the entire 
peptide chain was observed, with a robust b-ion series showing mass shifts of +162 Da 
corresponding to glycated peptide fragments and assign the glycation to K69. The neutral 
loss patterns in MS/MS observed, but the major losses observed was -18 Da corresponding 
to the loss of 1 H2O. Other kinds of loses were also detected but with lesser intensity. 
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Figure 3-9 Assignment of product ion data for peptide sequence ILIFWSKDIGYSFTVGGSE. A) 
nESI product ion mass spectrum of the precursor at 1141.06+2 m/z, combined spectra were 
smoothed/centroided using MassLynx 4.1. B) Mascot identification of precursor ion at 
1141.06+2 m/z, assigned to peptide sequence ILIFWSKDIGYSFTVGGSE. The glycation site 
was identified by manual interpretation of the spectrum. K69 is the glycation site and 
indicated in the above sequence by (GL). bn and yn are N- and C-terminal fragment ion 
series, respectively. + is the number of charges, * indicates deamination. Neutral losses 
from the fructosamine-containing parent and fragment ions are indicated by  (loss of 1 
H2O),  (loss of 2 H2O),  (loss of 3 H2O),  (loss of 4 H2O),  (loss of -3 H2O+HCHO), and G 
(loss of C6H10O5). 
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The MS/MS spectra of triply, quadruply or the quintuply charged glycated peptide 
FWVDGKPRVRKSLKKGYTVGAE shows only limited sequence information that does not help 
to assign the modification to any of the 6 possible modification residues in the sequence. 
Figure 3-10 shows the fragmentation spectrum of the quadruply charged peptide at m/z 
671.61+4. 
 
 
Figure 3-10 Assignment of product ion data for peptide sequence 
FWVDGKPRVRKSLKKGYTVGAE. Combined spectra of the precursor at 671.61+4 m/z were 
smoothed/centroided using MassLynx 4.1. The product ion data were manually assigned 
to the peptide sequence FWVDGKPRVRKSLKKGYTVGAE with one glucose molecule. The 
fragmentation spectrum did not provide enough information to identify the glycation site. 
bn and yn are N- and C-terminal fragment ion series, respectively. Neutral losses from the 
fructosamine-containing parent and fragment ions are indicated by  (loss of 1 H2O),  
(loss of 2 H2O),  (loss of 3 H2O),  (loss of 4 H2O),  (loss of -3 H2O+HCHO), and G (loss of 
C6H10O5). 
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The parent ion is observed as abundant signal shifted by +162 and associated with peaks 
of varied intensity corresponding to neutral losses of 1 to 4 molecules of water, loss of 84 
Da (3 H2O+HCHO) and 162 Da (C6H10O5). The glycated product ions y20 and y21 were 
identified and associated with signals corresponding to all described neutral losses ( H2O, 2 
H2O, 3 H2O, 4 H2O, 3 H2O + HCHO, and C6H10O5); however, the ions corresponding to the 
loss of 3 molecules of H2O was most abundant. Moreover, signals corresponding to neutral 
losses of 3 H2O from fructosamine-containing product ions b18 and b20 were observed. 
Despite this information confirming the presence of glycation but any attempt to identify 
the glycation site with such information-weak fragmentation spectra are likely to result in 
false positives. 
3.3.4.2 Glycation sites in CRP after 3 days exposure to 1 M glucose solution 
Increasing the incubation time to 3 days allowed the glycation on K191 besides on the 
previously recognised glycation sites. The MS/MS spectrum of the tryptic glycated peptide 
ALKYEVQGEVFTKPQLWP- at m/z 765.724+3 (Figure 3-11) afford a series of product ions 
corresponding to most of the peptide chain. Although this peptide has two potential 
glycation sites, K191 and K201, the presence of unglycated y-ions from y6 to y15 and 
glycated b-ions b4 and from b6 to b12 suggest the modification to be predominantly 
associated with K191 rather than K201. Consecutive losses of water and formaldehyde 
from the glycated b-ions species (mainly from b9 to b12) further suggest glycation of K191. 
The signals corresponding to the loss of three water molecules were the strongest among 
the other neutral loss signals. 
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Figure 3-11 Assignment of product ion data for peptide sequence ALKYEVQGEVFTKPQLWP. 
A) nESI product ion mass spectrum of the precursor at 765.72+3 m/z, combined spectra 
were smoothed/centroided using MassLynx 4.1. B) Mascot identification of precursor ion 
at 765.72+3 m/z, assigned to peptide sequence ALKYEVQGEVFTKPQLWP. The glycation site 
was identified by manual interpretation of the spectrum. K191 is the glycation site and 
indicated in the above sequence by (GL). bn and yn are N- and C-terminal fragments, 
respectively. + is the number of charges, * indicates deamination. Neutral losses from the 
fructosamine-containing parent and fragment ions are indicated by  (loss of 1 H2O),  
(loss of 2 H2O), (loss of 3 H2O), ( loss of 4 H2O),  (loss of -3 H2O+HCHO), and G (loss of 
C6H10O5). 
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3.3.4.3 Glycation sites in CRP after 6 days exposure to 1 M glucose solution 
K201 seems to be glycated only after increasing incubation to 6 days. The MS/MS spectrum 
of the doubly charged tryptic peptide at m/z 991.9854+2, YEVQGEVFTKPQLWP.-, confirmed 
the glycation on this residue, Figure 3-12. The presence of the Amadori y- and b- product 
ions shifted by +162 Da together with the unglycated ions, cover the majority of the 
glycated peptide sequence, and allowed the identification of the modification site. Signals 
corresponding to the loss 1 H2O, 3 H2O and -C6H10O5 were the most recognised losses from 
the fructosamine-containing product ions. 
During this incubation period, the peptide FWVDGKPRVRKSLKKGYTVGAE was observed 
with a m/z value consistent with glycation by two glucose molecules. The product ion 
spectrum showed very few product ions sufficient to confirm the presence of the two 
glucose molecules, however, these fragments are inadequate to confirm or even to exclude 
any of the potential modification sites. 
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Figure 3-12 Assignment of product ion data for peptide sequence YEVQGEVFTKPQLWP. A) 
nESI product ion mass spectrum of the precursor at 991.98+2 m/z, combined spectra were 
smoothed/centroided using MassLynx 4.1. B) Mascot identification of precursor ion at 
991.98+2 m/z, assigned to peptide sequence YEVQGEVFTKPQLWP. The glycation site was 
identified by manual interpretation of the spectrum. K201 is the glycation site and indicated 
in the above sequence by (GL). bn and yn are N- and C-terminal fragments, respectively. + 
is the number of charges, * indicates deamination. Neutral losses from the fructosamine-
containing parent and fragment ions are indicated by  (loss of 1 H2O),  (loss of 2 H2O), 
(loss of 3 H2O), ( loss of 4 H2O),  (loss of -3 H2O+HCHO), and G (loss of C6H10O5). 
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Some of the glycated residues were identified in the digest of both enzymes. Figure 3-13, 
shows the fragmentation spectrum of the glycated peptide LSSTRGYSIFSYATKRQDNE at m/z 
829.04+3 from the Glu-C digest, the modification was assigned to the residue K57. This 
glycated residue (K57) was already identified in the glycated peptide GYSIFSYATKR from the 
tryptic digest of CRP exposed to glucose solutions for 19 h and more extended periods. 
 
 
Figure 3-13 Assignment of product ion data for peptide sequence LSSTRGYSIFSYATKRQDNE. 
Combined spectra of the precursor at 829.04+3 m/z were smoothed/centroided using 
MassLynx 4.1. The product ion data were manually assigned to the peptide sequence 
LSSTRGYSIFSYATKRQDNE with one glucose molecule. K57 is identified as the glycation site 
and indicated in the above sequence by (GL). bn and yn are N- and C-terminal fragment ion 
series, respectively. + is the number of charges. Neutral losses from the fructosamine-
containing parent and fragment ions are indicated by  (loss of 1 H2O),  (loss of 2 H2O), 
 (loss of 3 H2O),  (loss of 4 H2O),  (loss of -3 H2O+HCHO), and G (loss of C6H10O5). 
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Furthermore, K191 is identified as glycation site in the glycated Glu-C peptide 
INTIYLGGPFSPNVLNWRALKYE; the fragmentation spectrum is shown in Figure 3-14. The 
same residue was identified in the tryptic glycated peptide ALKYEVQGEVFTKPQLWP. 
 
 
Figure 3-14 Assignment of product ion data for peptide INTIYLGGPFSPNVLNWRALKYE. A) 
nESI product ion mass spectrum of the precursor at 943.14+3 m/z, combined spectra were 
smoothed/centroided using MassLynx 4.1. B) Mascot identification of precursor ion at 
943.14+3 m/z, assigned to peptide INTIYLGGPFSPNVLNWRALKYE. The glycation site was 
identified by manual interpretation of the spectrum. K191 is the glycation site and indicated 
in the above sequence by (GL). bn and yn are N- and C-terminal fragments, respectively. + 
is the number of charges, * indicates deamination. Neutral losses from the fructosamine-
containing parent and fragment ions are indicated by  (loss of 1 H2O),  (loss of 2 H2O), 
(loss of 3 H2O), ( loss of 4 H2O),  (loss of -3 H2O+HCHO), and G (loss of C6H10O5). 
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3.3.4.4 Unmatched m/z values after Mascot search 
Due to the fragmentation behaviour of the glycated peptides, m/z values corresponding to 
glycated CRP peptides may not be assigned to CRP during the Mascot search. For this 
reason, all the unmatched m/z values during the Mascot search were considered as 
possible CRP glycated peptides and further explored as detailed in section 3.2.4. 
After analysis, two m/z values were found to have a match with a glycated CRP peptide 
within 100 ppm threshold. The species at m/z 829.04+3, which present in Glu-C digest of 
CRP sample incubated for 3 days, match the glycated peptide LSSTRGYSIFSYATKRQDNE. 
The fragmentation spectrum of this peptide assigns the modification to K57. This 
modification site is already identified in the tryptic digest of CRP incubated for 19 h (Figure 
3-8) and longer periods, and in the Glu-C digest but only in the sample incubated for 6 days, 
see figure 3-13. 
The second matched peptide, which presents in the tryptic digest of CRP sample incubated 
for 3 days, has m/z 713.7105+3 and corresponds to glycated peptide ESDTSYVSLKAPLTKPLK, 
Figure 3-15. The fragmentation spectrum of this triply charged peptide shows a high-quality 
series of fragment ions shifted by +108 Da and +78 Da corresponding to the formation of 
pyrylium and furylium ions from the fructosamine-containing product ions y9 to y17, while 
the conventional glycated y fragments (M+162) were missing. Pyrylium and furylium ions 
fragments confirmed the presence of glycation and provided enough information to cover 
most of the peptide sequence. The strong signals of the unglycated fragments y8, y7 and a 
detectable signal of y5 ions localised the glycation site on K23 and excluding K28. 
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Figure 3-15 Assignment of product ion data for peptide sequence ESDTSYVSLKAPLTKPLK. 
Combined spectra of the precursor at 713.71+3 m/z were smoothed/centroided using 
MassLynx 4.1. The product ion data were manually assigned to the peptide sequence 
ESDTSYVSLKAPLTKPLK with one glucose molecule. K23 is identified as the glycation site and 
indicated in the above sequence by (GL). bn and yn are N- and C-terminal fragment ion 
series, respectively. Neutral losses from the fructosamine-containing parent and fragment 
ions are indicated by  (loss of 1 H2O),  (loss of 2 H2O),  (loss of 3 H2O),  ( loss of 4 H2O), 
 (loss of -3 H2O+HCHO), and G (loss of C6H10O5). 
 
3.3.5 Determination the most reactive lysine residue 
CRP samples were incubated with decreasing concentration of glucose to determine the 
most reactive lysine residue. The samples were enzymatically digested by trypsin and Glu-
C separately, and the resulting digest was analysed by LC-nESI-QqTOF-MS/MS. The data 
obtained were submitted to the Mascot search engine which allowed identification of 
glycated CRP peptides. The m/z values that did not match any peptide sequence during the 
Mascot search were considered as possible CRP glycated peptides and further analysed as 
explained in section 3.2.4. The results are summarised in Table 3-4. 
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Table 3-4 The Glycated peptides identified in the tryptic and Glu-C digests of the CRP 
samples incubated for 19 hours with a varying concentration of glucose. The incubation 
time of the CRP sample exposed to 30 mM of glucose was also extended to 3 days. The 
samples were analysed by LC-nESI-QqTOF-MS/MS, and the acquired data were searched 
against the Mascot using a database comprising the CRP sequence and common 
laboratory-observed contaminants. The peptide sequence was confirmed by manual 
interpretation of its fragmentation spectrum. 
Glucose concentration/ 
incubation time 
Peptide sequence Observed 
m/z value 
Experimental 
mass 
Mass error 
ppm 
200 mM/ 19 h KAFVFPKESDTSYVSLK 703.3563 2107.0471 -12.05 
100 mM/ 19 h KAFVFPKESDTSYVSLK 703.3604 2107.0595 -6.17 
50 mM/ 19 h - - - - 
30 mM/ 19 h - - - - 
30 mM/ 3 days KAFVFPKESDTSYVSLK 703.3459 2107.0157 -26.95 
 
CRP exposed to 200 mM of glucose for 19 h shows one glycated peptide, 
KAFVFPKESDTSYVSLK, at m/z 703.36+3 with the glycation site in a mid-chain position 
corresponding to K13 of CRP as confirmed by manual interpretation of the product ion 
spectrum. This glycated peptide was identified in the tryptic digest of the protein while no 
modified peptide was observed in the Glu-C digest. The same result was obtained after 
reducing the glucose to 100 mM for the same incubation time. However, no glycated 
peptide can be identified (in both tryptic or Glu-C digest) in the CRP samples exposed 
glucose concentration less than 100 mM for 19 h, while the sample exposed to 30 mM of 
glucose but for 3 days reveal the same glycation site on K13. 
3.3.6 Characteristics of glycated lysine residues 
The proximity of acidic and basic groups to the lysine and arginine residues in the primary 
or tertiary structure of CRP, the local pKa value of arginines and lysines in CRP sequence, 
and the fractional accessible surface (FAS) of the side chain of these residues were 
calculated and presented in Table 3-5. This information was utilised to inform our 
understanding of observed differences in lysine residue glycation, and also to predict the 
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most likely modification sites within a glycated peptide bearing more than one potential 
modification site. 
When comparing the glycated residues detected in the present study (group A in Table 3-
4) with the unglycated lysine and arginine residues (group C in Table 3-4), it was noted that 
glycated lysines are located in closer proximity to acidic residues, with the acidic residue is 
mainly situated C-terminally to the glycation site. 
All glycated lysines except K191 are located adjacent to carboxylate groups within distances 
<4 Å. The glycated lysine K191, observed only after three days of incubation, is 9.7 Å distant 
from Glu 193. However, this lysine has the highest FAS (0.692) compared to other glycated 
residues. On the other hand, K201 has the lowest FAS (0.232) compared to the other 
glycated lysines and was found modified only after 6 days of incubation. 
The modified lysines that have been detected after 19 h incubation times (K13, K57 and 
K69) share the property of having an acidic residue in the C-terminal side, and shorter 
distance between the ε-NH+ group of the glycated residue to the carboxylate group of the 
acidic residues; the distance did not exceed 3.6 Å to the nearest free acid group. 
Group B in the Table 3-4 summarise the properties of the lysine and arginine residues of 
the FWVDGKPRVRKSLKKGYTVGAE peptide. This peptide was modified with up to two 
glucose molecules. However, the fragmentation spectrum did not provide enough 
information to identify the glycation sites. The arginens in this peptide (R116 and R118) has 
the highest pKa values and lowest FAS compared to the lysines of the same region. In 
contrast, K114 has relatively low pKa value (10.38) and the greatest FAS (0.832) compared 
to the other residues. With the other three residues (K119, K122, K123), the pKa and FAS 
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were either both low or both high. For example, K199 which has the lowest pKa value (9.61) 
it has the smallest FAS (0.24) compared with the other lysines in the same sequence. 
Table 3-5 Physicochemical characteristics of CRP lysine and arginine residues. Lysine and 
arginine residues were divided into three groups; group A included the glycated lysine 
detected in this study, B: the lysine and arginine residue of the glycated peptide 
FWVDGKPRVRKSLKKGYTVGAE, C: unglycated lysine and arginine in this study. The distance 
to the nearby acidic and basic residues was computed using PyMOL, the local pKa values 
were estimated by using PROPKA 3.0, The FAS of the side chain of lysine and arginine were 
calculated by using VADAR. The * represents residues on the adjacent protomer. 
 
Group Residue Distance to basic 
residues in Å 
Distance to acidic 
residues Å 
Estimated 
pKa 
Estimated 
FAS 
 
 
 
 
A 
K13 6.6 to K123* 3.3 to E197, 
12.1 to E14, 
14.8 to D16 
10.684 0.556 
K57 9.1 to R58 3.1 to E130, 
14.6 to D60 
11.27 0.55 
K69 
 
3.6 to D70 10.88 0.44 
k191 
 
9.7 to E193 10.352 0.692 
K23 9.5 to K191 3.8 to E193 10.798 0.516 
k201 6.3 to R118 3.1 to E101*, 
6.5 to E108* 
10.466 0.232 
 
 
 
 
B 
K114 11.1 to R116 8.1 to D112 10.38 0.832 
K119 8.3 to R116 3.9 to E42*, 
5.6 to E85 
9.614 0.24 
K122 14.3 to K123 7.6 to E62 10.16 0.364 
K123 6 to K13*, 
14.3 to K122 
9.7 to E101, 
2.8 to E197* 
11.204 0.472 
R116 8.3 to K119, 
11.1 to K114 
4.6 to E42* 12.218 0.194 
R118 6.3 to K201, 
15 to R116 
9.3 to E101, 
2.8 to D155* 
13.296 0.008 
 
 
 
 
C 
K7 11.6 to R6 6.6 to D3 10.392 0.454 
K28 8.5 to K31  8.3 to D163 10.432 0.876 
K31 8.5 to K28 8 to E101 10.25 0.694 
R6 8.7 to H38, 
11.6 to K7 
5.4 to D169*, 
10 to D3 
12.82 0.686 
R47 
 
2.9 to E14, 
9.5 to D16 
11.942 0.216 
R58 9.1 to K57 8.2 to E130, 
10.2 to D60 
12.49 0.928 
R188 
 
5.1 to D3 12.456 0.576 
Chapter 3: Revealing the glycation sites of in vitro glycated C-reactive protein
  Discussion 
143 
 
3.4 Discussion 
The goal of the present study was to characterise the putative glycation sites of CRP 
exposed to glucose, using tandem mass spectrometry and to determine the most reactive 
residues for glycation in order to extrapolate the generated information to the in vivo 
situation. The general strategy employed in the study may be summarised as follows: CRP 
digestion with trypsin and Glu-C, tandem mass spectrometry analysis of digests, Mascot 
searching of data against customised database comprising the CRP sequence and common 
laboratory-observed contaminants, manual validation of the MS/MS spectra that were 
assigned to glycated CRP peptides through Mascot and interpretation of unassigned 
product ions, analysis of the m/z values that did not match any peptide sequence in the 
selected database during the Mascot analysis. 
3.4.1 C-reactive protein and enzymatic digestion 
Protein digestion is the most critical step in the sample preparation for tandem mass 
spectrometry analysis (Hustoft et al., 2012). CRP preparations were digested with trypsin 
due to its advantage in preparing peptides of appropriate mass range for MS sequencing 
(Hustoft et al., 2012). Since the cleavage sites of trypsin could be involved in the glycation 
reaction (Lacinová et al., 2010), endoproteinase Glu-C was also used as an alternative single 
protease to enhance protein sequence coverage. 
CRP has been found to be relatively resistant to enzymatic digestion. After several digestion 
trials with low-efficiency cleavage (data are not shown), it was found that additional 
denaturation steps, higher CRP: enzyme molar ratio and longer incubation times with 
proteases were required to improve its degradation. Taylor et al. demonstrated that CRP 
in its native pentameric form is highly-resistant to enzymatic digestion, both degradation 
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to its monomeric form and the use of high enzyme: CRP molar ratio is required to achieve 
digestion with trypsin (Taylor & Van Den Berg, 2007). Monomerisation of CRP can be 
achieved either by heat or by denaturation with a chelating agent (Taylor & Van Den Berg, 
2007, Potempa et al., 1987). It found that one hour of heating at 70 °C is required to achieve 
complete monomerisation of CRP in the presence of calcium (Taylor & Van Den Berg, 2007). 
However, in the absence of calcium abbreviated incubation times can achieve the same 
results (Potempa et al., 1983), because removal of calcium decreases the stability of the 
CRP pentamer and increases susceptibility to proteolysis and denaturation (Shrive et al., 
1996). Using chelating agents to remove calcium from the solution is not recommended 
with trypsin digestion (Nord et al., 1956). 
In this work, CRP preparations were denatured by using the combination of a mild 
denaturant (Rapigest) to unfold the protein and reveal the inaccessible cleavage sites 
(Huang et al., 2009), and by heating the samples near 100 °C for 5 min followed by 30 
minutes heating at 60 °C. Furthermore, the digestion time was extended to 24 h, with two 
additions of the enzyme at 30:1 to promote complete protein digestion. Combining the 
mapping results of both trypsin and Glu-C digested peptides resulted in high sequence 
coverage sufficient for the analysis of the N-terminus, all arginines, and at least 11 out of 
13 lysine residues on CRP in all of the samples that were studied. 
3.4.2 Fragmentation behaviour of glycated peptides 
Glycated peptides lose water molecules from the glycated lysine residues during CID as a 
result of dissociation of the most labile bonds in the peptide side chain modification (Zhang 
et al., 2008). The MS/MS spectra of glycated CRP peptides showed a high abundance of 
peaks reflecting these multiple neutral losses from the glucose-containing parent and 
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fragment ions at a characteristic intensity distribution. Similar findings have been 
previously observed with glycated peptides analysed by CID (Lapolla et al., 2004, Frolov et 
al., 2006, Mennella et al., 2006). The characteristic neutral losses observed with CRP 
glycated peptides, analysed by Q-TOF instrument, include consecutive elimination of 1 H2O, 
2 H2O, 3 H2O, 4 H2O, 3 H2O + HCHO, and neutral loss of the entire Amadori product 
(C6H10O5). The most intense neutral loss signal commonly arose from pyrylium ions (neutral 
loss of 3 H2O) while the second most intense neutral loss signal typically derives from the 
furylium ions (neutral loss of 3 H2O + HCHO). Interestingly, pyrylium ions were observed 
from all glycated peptides studied here, frequently followed by the furylium ion signal, 
indicating that observation of pyrylium and furylium ions is strongly suggestive of the 
presence of a glycated peptide. The neutral loss of entire Amadori product was also 
observed in glycated y-ion series. The conventional Amadori b- and y-ions were very weak 
or even undetectable, while the non-modified product ions do not show any neutral loss, 
but the typical y- and b-ions. 
Although this fragmentation pattern has been previously reported (Lapolla et al., 2004, 
Frolov et al., 2006, Mennella et al., 2006), unambiguous assignment of the modified amino 
acid residue was not consistently reported by Mascot. This was especially the case where 
multiple potential glycation sites were present on a single peptide. For instance, the 
glycated tryptic peptides KAFVFPKESDTSYVSLK and AFVFPKESDTSYVSLK share the same 
sequence except for a missed cleavage site at the N-terminus of the first sequence. Mascot 
confirmed the glycated peptide K7AFVFPK13ESDTSYVSLK sequence but assigned a higher 
probability score for glucose condensed on K7 than K13; this is less plausible, as lysine 
glycation should obstruct trypsin cleavage (Wa et al., 2007, Zhang et al., 2003). Since the 
glycated b- and y-ions were very weak or missing, the majority of product ions used by 
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Mascot in the assignment of the glycated residue are those not involved in Amadori 
product formation, while the signals from successive neutral losses, including the strong 
signals of pyrylium and furylium ions were neglected, resulting in confounding the 
automatic sequence assignment and glycation site identification by Mascot. 
Manual assignment of the unmatched neutral losses provides the missing piece of 
information and reveals the ambiguity of the modification site. Although neutral losses of 
H2O and 2 H2O can also occur from other peptide functional groups, such as neutral loss of 
H2O from peptides containing hydroxyl or carboxylic acid residues (Zhang et al., 2008), 
neutral losses of 3 H2O, 4 H2O, 3 H2O + HCHO and C6H10O5 are significantly less common 
and characterise the Amadori-modified peptides (Zhang et al., 2008, Zhang et al., 2008b). 
Identification of these fragment ions confirmed the presence of glycation and allowed 
positive determination of the site of modification. Furthermore, besides the glycated 
product ions, the presence of surviving precursor ion of glycated molecular weight and 
neutral loss products from precursor also confirm the presence of a glycated peptide. When 
all potential neutral losses from the product and precursor ions were considered in the 
MS/MS spectra analysis, the majority of the backbone ions can be determined, and the 
modification site can be identified and localised (Frolov et al., 2006). Considering the 
neutral loss signals from the glycated product ions confidently shows that both peptides, 
KAFVFPKESDTSYVSLK and AFVFPKESDTSYVSLK, were glycated at K13 (see Figure 3-6 and 3-
7). Another example showing the utility of neutral loss peaks in assigning the modification 
site is the tryptic glycated peptide ALKYEVQGEVFTKPQLWP- at m/z 765.724+3, bearing two 
possible glycation sites; K191 and K201 (see Figure 3-11). Here, the strong pyrylium and 
furylium ion signals derived from glycated b-ion species allowed positive determination of 
the primary glycation site at K191 rather than K201. The precursor peptide ion at 
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713.7105+3 did not find any match against CRP sequence via Mascot searching as no 
glycated b- and y- ions were observed. The MS/MS spectrum of this peptide shows a high-
quality series of fragment ions with mass shifts of +108 amu and +78 amu vs their 
unmodified counterparts, corresponding to the formation of pyrylium and furylium ions 
from the glycated residue, confirming the presence of glycation. When these ions are 
utilised together with the unglycated fragments, the majority of the peptide sequence can 
be covered, and the glycation site can be localised to K23 (see Figure 3-15). 
3.4.3 Glycation sites of the in vitro glycated C-reactive protein 
The potential glycation sites of CRP include 13 lysines, 6 arginines and the N-terminal 
amine. These sites are primarily clustered at the outer boundaries of each subunit in the 
tertiary structure of CRP as shown in Figure 3-16. 
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Figure 3-16 Crystal structure of CRP highlighting putative glycation sites. CRP structure PDB 
entry 1B09, showing one protomer (Top; ligand recognition face, bottom; the effector 
face). Lysine residues (K) are coloured red, arginine residues (R) are coloured blue 
 
Based on trypsin and Glu-C experiments (Tables 3-2 and 3-3) and after manual validation 
of the MS/MS spectra for each glycated peptide, three glycation sites were identified in 
CRP preparations exposed to 1M of glucose for 19 hours; these are K13, K57 and K69. 
Occupation of the same glycation sites was also observed after increasing the incubation 
time to 3 and 6 days, suggesting that these residues are favourable glycation sites at this 
glucose concentration. After 3 days of incubation, K191 (which is also seen after 6 days) 
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and K23 were modified, while K201 was observed as being modified only after 6 days of 
incubation. This finding suggests that glycation is not randomly occurring, and the free 
amino groups of CRP differ in their rates of glycation (Zhang et al., 2008). Besides the 
glycation sites mentioned above, the peptide FWVDGKPRVRKSLKKGYTVGAE was found to 
be glycated by one glucose molecule after 19 h, and by two glucose after six days of 
exposure to 1M glucose concentration. The MS/MS spectrum of this peptide shows limited 
sequence information, sufficient to confirm the presence of the glucose moiety, but 
insufficient to localise the precise modification sites. In addition to the weak fragmentation 
pattern of glycated peptides under CID condition (Zhang et al., 2008), the presence of 6 
basic amino acids residues in the middle of this 22 residues peptide resulted in localised 
high positive charge density, which might be why simple peptide fragmentation is 
prevented (Xue et al., 2015). It is worthy of mention that several residues of 
FWVDGKPRVRKSLKKGYTVGAE peptide are involved in inter-subunit interactions with the 
neighbouring protomer in the CRP pentamer including the following amino acid pairs; K119 
of one protomer with E42 of the next protomer, K123 with E197 of the next protomer, 
R118 with D155 and P202 from the next protomer (Thompson et al., 1999, Shrive et al., 
1996). K201, which seen after 6 days of incubation, is also known to form a salt bridge with 
E101 from the next protomer (Shrive et al., 1996). 
Positively, the results of the tandem mass analysis are comparable with the result of intact 
mass analysis for the same samples. The number of condensed glucose molecules as 
determined intact mass analysis were 3, 5 and 8 molecules for samples incubated with 1 M 
of glucose for 19 h, 3 days and 6 days respectively (see Figures 2-6, 2-7 and 2-8). This 
corresponds closely to the total number of glycation sites identified in these samples; 
where 3 glycation sites plus one further site in 109-130 peptide were identified in sample 
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treated with1M glucose for 19 h, 5 glycation sites plus one further site in 109-130 peptide, 
and 5 glycation sites plus two further sites in 109-130 peptide in the sample exposed to 6 
days. 
To identify the most reactive lysine residues towards glycation, CRP were exposed to lower 
concentrations of glucose for 19h. We observed that only the glycation site on K13 could 
be identified at a glucose level of 200 and 100 mM suggesting that this residue is more 
susceptible to glycation than other lysines. CRP incubated glucose levels less than 100mM 
for 19h incubation showed no evidence of glycation, suggesting that the extent of glycation 
was insufficient to be detected under our experimental conditions. However, increasing 
the incubation time, even at 30 mM glucose, allows observation of K13, as the glycation is 
directly proportional to the exposure time. 
3.4.4 Factors affecting glycation site specificity 
Factors known to influence the reactivity of lysines or arginines towards the glycation 
reaction were investigated to understand why some of these residues are more prone to 
glycation or glycated at a faster rate than the others. The investigated factors were the 
position of the modified residues and their proximity to the nearby charged residues within 
the primary or tertiary structure, FAS, and pKa values of the side chain of the of the 
potential glycation sites (Shapiro et al., 1980, Garlick & Mazer, 1983, Rabbani et al., 2016). 
All the identified glycation sites were lysine residues located at the outer surface of the 
protein, excepting K201, a residue which is implicated in intersubunit interaction with 
adjacent protomer (Shrive et al., 1996). Because the formation of Schiff bases requires the 
free amino groups to be unprotonated to carry out the nucleophilic addition or 
substitution, lysine or arginine residues with lower pKa values would be expected to be 
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more susceptible to glycation reactions (Watkins et al., 1985, Johansen et al., 2006). 
However, the pKa values of the glycated lysine residues alone cannot directly explain the 
observed specificity (Shapiro et al., 1980, Garlick & Mazer, 1983, Silva et al., 2018). For 
instance, K57 has the highest pKa value among the lysine residues of CRP but is found to 
be glycated even during the shortest incubation period. 
FAS and the properties of nearby amino acids been proposed to play a significant role in 
determining glycation site specificity (Rabbani et al., 2016, Johansen et al., 2006). In CRP, 
the potential glycation sites were all located close to carboxylate groups within the primary 
and/or tertiary structure, principally situated C-terminally to the putative glycation site. For 
the most reactive lysine residues that have been detected after 19h of incubation (i.e. K13, 
K57 and K69), the distance between the ε-NH+ group of the glycated residue to the nearest 
carboxylate group was below 3.6 Å. These residues, K13, K57 and K69, all share the 
property of having an acidic residue C-terminally namely; E14, D60 and D70, respectively. 
A similar finding has been previously observed with other glycated proteins (Shapiro et al., 
1980, Casey et al., 1995, Watkins et al., 1985, Johansen et al., 2006). The proximity of 
carboxylate group to lysine in either the primary or tertiary structure catalyses the Amadori 
rearrangement (Casey et al., 1995, Garlick & Mazer, 1983), the rate-limiting step in 
glycation, by providing a conjugate base to promote the removal of a proton from the Schiff 
base and hence accelerates the rate of glycation at these residues (Rabbani et al., 2016). 
K201 is found glycated only after 6 days of incubation. The slower reactivity of K201, 
despite its proximity to E101, can be explained by the small FAS (0.232) of the side chain of 
this residue meaning less access to free glucose compared to the other glycated residues 
located on the surface of the protein. 
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The microenvironment of the potential glycation sites, pKa and the FAS have also been 
utilised to identify the possible glycation sites in the FWVDGKPRVRKSLKKGYTVGAE peptide. 
This peptide includes 6 possible glycation sites (2 arginines and 4 lysines) adjacent to each 
other. The presence of arginine or another lysine near the lysine either in the primary or 
the tertiary structure has also been proposed to catalyse the glycation of the lysine (Chen 
et al., 2012, Johansen et al., 2006), suggesting that these glycations sites could catalyse 
each other during the glycation process (Wang et al., 2013). Up to 2 glucose molecules 
could be condensed on this peptide after 6 days of incubation with glucose. The arginines 
(R116 and R118) of this peptide are the less probable glycation sites, because they have 
the highest pKa values and lowest FAS compared to the lysines on the same peptide 
(FWVDGKPRVRKSLKKGYTVGAE). Among the 4 lysines residues, K114 has the highest 
probability of being modified, based on a favourable combination of pKa and FAS (10.38 
and 0.832 respectively) compared to other lysines. D112 which situated proximal to K114 
in the primary sequence, can accept the proton from the Schiff base and accelerate the 
rate-limiting Amadori rearrangement step (Rabbani et al., 2016). K114 is part of putative 
C1q-binding site of CRP and play a role in modulating the reactivity of CRP with C1q 
(Agrawal et al., 2001, Agrawal & Volanakis, 1994). Thus, K114 glycation could have an 
impact on the CRP function. For the remaining lysines residues, K119, K122 and K123, the 
combination of pKa and FAS were either both low or both high. For example, K119 has the 
lowest pKa value (9.61) but the smallest FAS (0.24) compared with the other lysines in the 
same sequence, meaning it is less exposed to glucose despite its high reactivity. Moreover, 
K119 and K123 are implicated in the intersubunit interaction (Thompson et al., 1999, Shrive 
et al., 1996) which could partially shield the glycation of these lysines (Johansen et al., 2006, 
Ito et al., 2011). 
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3.4.5 Conclusion 
MS/MS spectra of glycated CRP digest recorded by the Q-TOF shows multiple neutral losses 
from the glucose-containing parent and fragment ions at a characteristic intensity 
distribution; this characteristic fragmentation pattern was independent of the peptide 
sequence and could be applied to confirm the occurrence of glycation as well as to localise 
the glycation site. Six glycation sites have been identified in the CRP digest treated with 
glucose for a period up to 6 days. These are K13, K57, K69, K191, K23 and K201, in addition 
to two ambiguous glycation sites among six possible residues within one peptide 
(FWVDGKPRVRKSLKKGYTVGAE). Based on the combined contribution of pKa and FAS to the 
lysine microenvironment, K114 could be an additional glycation site. Among the identified 
residues, K13 is the more reactive lysine. The common feature between the glycated lysines 
are their proximity to an acidic residue which, principally situated C-terminally to the 
glycated lysine. The established protocols/procedures and the results obtained from this 
study are a good starting point to investigate the presence of these glycation sites in human 
plasma from diabetic patients  
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Chapter 4: Analysis of human serum samples from diabetic patients 
 
4.1 Introduction 
4.1.1 Overview 
The high levels of circulating blood sugar found in diabetic patients can cause protein 
glycation. While we have established that CRP can be glycated in vitro as illustrated in 
chapter two, and the putative glycation sites were identified (chapter three), the effect of 
the glycation reaction on CRP, in vivo, remains unexplored. Glycation of proteins impacts 
on their structure and consequently may alter the physical and functional properties of the 
protein which may impact physiologically. In addition, recent studies showed that 
monomeric isoform of CRP (mCRP), formed as a result of a dissociation process of CRP, can 
play a harmful pro-inflammatory role in the progression of diseases (Wang et al., 2015). 
There is however a consensus that this isoform is preferentially expressed in tissues 
(Eisenhardt et al., 2009, Ji et al., 2009). The aim of this study is first seeking, then 
quantifying these modified forms of CRP (glycated and/or monomeric) in the serum of 
diabetes mellitus patients with elevated CRP levels. The serum samples utilised in our study 
were obtained from 24 diabetic patients with either type I (n=4) or type II (n=20) diabetes, 
and markedly raised levels of CRP (>100 mg/L). CRP was isolated from human serum by 
affinity chromatography. The glycated form and the site(s) of glycation were identified 
using our established protocols/procedures by mass spectrometry. The monomeric form 
of the protein was purified from serum then characterised based on size exclusion 
chromatography, ELISA and mass spectrometry. Any emergent relationship between the 
clinical condition and modified and clinically assayed CRP levels was investigated.  
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4.1.2 Diabetes mellitus 
Diabetes mellitus (DM) is a metabolic disorder characterised by chronic hyperglycaemia 
with disturbance of carbohydrate, fat and protein metabolism resulting from defects in 
insulin secretion, insulin action or both (American Diabetes Association, 2014). DM is one 
of the most serious and chronic diseases in the world, currently affecting ~8.5% of the adult 
population (World Health Organization, 2016). The vast majority of diabetes falls into two 
main types; type 1 DM, is usually caused by autoimmune destruction of the pancreatic islet 
β-cells, rendering the pancreas unable to synthesise and secrete insulin (Castano & 
Eisenbarth, 1990), while type 2 DM, is caused by a combination of insulin resistance and 
inadequate insulin secretion and is the most common form, accounting for 90% of diabetes 
cases (Sacks & McDonald, 1996). In both types of diabetes, hyperglycaemia can lead to 
severe microvascular complications such as retinopathy, neuropathy, and diabetic 
nephropathy. However, the major complication in diabetes is macrovascular complications, 
mostly atherosclerosis, that are associated with increased risk of developing CVD such as 
coronary artery disease, stroke, and peripheral artery disease (Fowler, 2008, Messier et al., 
2004). In fact, people with DM are at two-to three-fold increased risk of developing CVD, 
and this represents the major cause of mortality in patients with diabetes (Jousilahti et al., 
2011, Sarwar et al., 2010). Protein glycation and formation of AGEs, as a result of persistent 
hyperglycaemia, plays an important role in the development of diabetic complications 
(Singh et al., 2014). The levels of glycated proteins in diabetic patients are much higher 
than those of non-diabetic individuals (Rondeau & Bourdon, 2011). Although both types of 
DM could enhance protein glycation, the rate of increase may be different. Yoshiuchi et al. 
(2008) demonstrated that the higher level of glycaemic fluctuation and deviations seen in 
type 1 DM could be responsible for the increase in protein glycation relative to type 2 DM 
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(Yoshiuchi et al., 2008). On the other hand, anti-type 2 diabetes drugs such as metformin 
and pioglitazone have been found to inhibit the non-enzymatic glycation of proteins, 
possibly by trapping highly reactive intermediates generated during glycation (Rahbar et 
al., 2000). The consequences of glycation vary, depending upon the product formed and 
the molecular structures involved. In general, it could be said that glycation compromises 
normal molecular structure, function and/or half-life. Add to this the fact that glycated 
structures are also targets of specific clearance receptors whose ligation promotes 
inflammation, then one may quickly conclude that glycation can have considerable effects 
(Brownlee, 2000, Cloos & Christgau, 2002, Stern et al., 2002). The effect of glycation has 
been described in many proteins such as haemoglobin, albumin, ferritin, apolipoprotein, 
collagen, insulin, histone, IgM, IgG, glucose-6-phosphate dehydrogenase, aldehyde 
reductase, glutathione reductase, Cu-Zn superoxide dismutase and the lens protein 
crystallin (Arasteh et al., 2014, Ansari & Ali, 2011, Hunter et al., 2003). To the best of our 
knowledge, there is no work described in the literature studying the effect of non-
enzymatic glycation of CRP in vitro or in vivo. The results of our in vitro study show that CRP 
can be glycated to various extents, depending on both glucose concentration and exposure 
time; putative glycation sites were determined. 
4.1.3 Monomeric C-reactive protein within the human body 
Although pentameric CRP is extremely stable under physiological conditions, there is 
increasing evidence to suggest a pro-inflammatory role for mCRP (Eisenhardt et al., 2009, 
Ji et al., 2009). In vitro, native pCRP can dissociate irreversibly upon treatment with acid, 
urea-chelation, or heating in the absence of calcium into mCRP (Potempa et al., 1987). 
mCRP displays new epitopes (neoepitopes) which are normally concealed in pCRP, and has 
distinct physiochemical, antigenic and biological activities (Ablij & Meinders, 2002, 
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Potempa et al., 1987). Recently, strong evidence has been presented that pCRP dissociation 
can take place under physiological conditions after binding to the cell membrane (Ji et al., 
2007, Eisenhardt et al., 2009). Conversely, other studies report independent mCRP 
synthesis upon the cell surface (Salazar et al., 2014). It has also been proposed that mCRP 
imposes pro-inflammatory effects throughout the human body, contributing to various 
auto-inflammatory diseases. The binding of mCRP to either native LDL or oxidised LDL (ox-
LDL) is an effective method of activating the classical complement pathway, causing an 
intensified state of inflammation at localised sites throughout the body (Ji et al., 2009). 
Endothelial cell activation and dysfunction have also been linked with mCRP. Incubation of 
human vascular endothelial cells with mCRP resulted in an increase in the secretion of 
monocyte chemoattractant protein (MCP-1), IL-8, and increased expression levels of the 
cell adhesion molecules ICAM-1, VCAM-1 and E-selectin (Khreiss et al., 2004). Up-
regulation of P-selectin by mCRP in a study carried out by Molins et al. 2008, demonstrated 
the ability to further increase and stabilise platelet-platelet and platelet-leukocyte 
interactions (Molins et al., 2008). Coupled with increased tissue factor expression and 
alteration of fibrin formation and clotting properties, mCRP may be a contributing factor 
towards the prothrombic events routinely seen in cardiovascular disease (Molins et al., 
2008, Li et al., 2012). In addition to the activation of endothelial cells, mCRP has also been 
linked to the activation of circulating platelets within atherosclerotic lesions (Eisenhardt et 
al., 2009). Lipids present on the surface of activated platelets have been shown to mediate 
the binding and dissociation of pCRP into mCRP (Eisenhardt et al., 2009). Proposed modes 
of action have been put forward, hypothesising a dissociation mechanism and explaining 
how mCRP may contribute to disease throughout the circulation, but there is still no clear 
biological role for a monomeric form of CRP (Eisenhardt et al., 2009, Verma et al., 2004). 
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Upon activation, lipid membranes undergo rapid changes in their membrane composition, 
resulting in the shedding of microparticles (MPs); (Owens & Mackman, 2011). Recent 
evidence has demonstrated that these MPs, following severe cardiovascular events, can 
bind and dissociate pCRP (Habersberger et al., 2012). This evidence provides an in vivo 
explanation for the generation and transportation of mCRP, which can thus interact with 
other cells in the body and provide a pro-inflammatory stimulus (Habersberger et al., 2012). 
Although it is not entirely clear what is the role of mCRP within the human body, 
experimental evidence provided in the literature indicates a potential pro-inflammatory 
role. Furthermore, this lack of understanding about mCRP has resulted in an incoherent 
generalisation throughout the literature of whether mCRP is primarily tissue bound or can 
be located within human serum. A recent pilot study carried out by Williams (2017) 
established that mCRP is located in human serum when circulating levels of CRP are high. 
In this study, the mCRP levels were observed to vary significantly, with some clear high and 
low outliers from the general distribution, between patients where the underlying 
aetiologies were unknown (Williams, 2017). In the current work, our aim is to investigate 
the presence of mCRP in diabetic patients who already have elevated CRP levels, not only 
to confirm or refute the previous finding of mCRP in patients with high clinically measured 
CRP levels, but also to establish where the mCRP levels for DM lie in relation to these. 
Another reason for selecting DM patients with elevated level of CRP is because the in vitro 
glycation trial of CRP shows that the stoichiometry of the glycation reaction is likely to be 
low, with difficulties associated with detecting a low abundance modification in the 
presence of other proteins in the serum. 
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4.1.4 Experimental aims 
While we have established that CRP can be glycated in vitro, the effect of the glycation 
reaction on CRP, in vivo, remains unexplored. Furthermore, recent evidence suggests that 
mCRP may be present in serum. The dissociation of pCRP to mCRP has been linked with 
proinflammatory processes and the progression of several diseases while the role and 
outcomes of CRP glycation remain unknown. The experimental aim of the research 
described in this chapter is to seek, then quantify, modified CRP in the serum of diabetes 
patients with elevated CRP levels and assess the relationship between pCRP, mCRP and the 
glycated isoforms. CRP was separated from human serum using affinity chromatography. 
The glycated form and the site(s) of glycation were detected using the established 
methodology that developed from our previous experimental research (chapter two and 
chapter three). The monomeric form of the protein was purified from serum then 
characterised based on chromatography, ELISA and western blot based on established 
procedures developed previously in the group (Williams, 2017). 
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4.2 Materials & Methods 
4.2.1 Reagents and consumables 
Reagents, solutions and proteins used in this chapter and their suppliers are summarised 
in Table 4-1. 
Table 4-1 Reagents, solutions and proteins used in the study. All substances were 
purchased in the highest possible purity from the following supplier 
Chemicals/proteins  Supplier 
3,3’,5,5’ tetramethylbenzidine (TMB) Sigma-Aldrich 
Acetonitrile (HPLC grade, 99.9%)  VWR International 
Ammonium bicarbonate Sigma-Aldrich 
Ammonium persulfate (APS) VWR International 
Anti-mouse IgG (whole molecule) peroxidase Antibody Sigma-Aldrich 
bovine serum albumin (BSA) Sigma-Aldrich 
Bromophenol blue VWR International 
Calcium chloride Sigma-Aldrich 
C-reactive protein (CRP, >99% pure) SCRIPPS Laboratories 
Dithiothreitol Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Formic acid (96%) Sigma-Aldrich 
Glu-C (Protease V8 Sequencing Grade)  Roche 
Glycerol Sigma-Aldrich 
Glycine Sigma-Aldrich 
InstantBlue™ Protein Stain Expedeon 
Iodoacetamide Sigma-Aldrich 
Low range molecular weight markers Bio-Rad 
Monoclonal anti-C-reactive protein antibody (Clone-8) Sigma-Aldrich 
Potassium chloride  Sigma-Aldrich 
Rapigest Waters 
Sodium azide Sigma-Aldrich 
Sodium chloride Sigma-Aldrich 
Sodium dodecyl sulfate SDS  Sigma-Aldrich 
Sodium phosphate dibasic (99%) Sigma-Aldrich 
Sodium phosphate monobasic (99%) Sigma-Aldrich 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
Trifluoroacetic acid (98%) Sigma-Aldrich 
Tris Fisher Scientific 
Trypsin (Proteomics Grade)  Sigma-Aldrich 
Tween Sigma-Aldrich 
Water (HPLC grade)  VWR International 
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4.2.2 Ethical Application 
Before starting the collection of human serum samples or any experimental procedure to 
take place, approvals from independent peer review and research ethics committee were 
required.  
A peer review form was submitted to the Independent Peer Review Committee (IPRC) at 
Keele University, the application was approved in October 2016. Following IPRC approval, 
an application to the Integrated Research Application System (IRAS) was submitted. IRAS is 
an online system for applying the permissions and approvals to Research Ethics 
Committees (REC) and the NHS Research & Development offices. This application was 
formally approved in April 2017 by NRES Committee West Midlands – Edgbaston under REC 
reference 17/WM/0150; Protocol reference: RG-0091-16-FNS and IRAS reference 211529, 
see appendix 1. 
4.2.3 Recruitment of Participants 
The identification of participants took place at the University Hospital of North Midlands 
(UHNM) considering the following inclusion criteria: 
I. Male or Female above the age of 18 years; 
II. They have type 1 or type 2 diabetes mellitus; 
III. They are a case with a raised CRP level of >100 mg/mL; 
IV. They are inpatients at University Hospitals of North Midlands; 
V. They are due to undergo routine blood testing as a part of their standard clinical 
care, and enough serum is left over for our study; 
VI. They are able to give informed consent. 
No exclusion criteria were applied to the participants beyond the inclusion criteria.  
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All the recruited participants were inpatients of UHNM, being investigated for a range of 
clinical situations requiring CRP monitoring as part of their routine patient care. Eligible 
participants were identified by a research nurse or research team member in UHNM. 
Research staff approached eligible participants and gave a brief verbal explanation of the 
study. All eligible participants who showed an interest in our study were then provided with 
a patient information sheet (PIS, see Appendix 2). The research nurse guided the 
participants through PIS, outlined the aims, benefits, and risks of the study and answered 
any questions the participant may have. The participants were informed that they were 
due to undergo a routine blood test as a part of their standard clinical care, and the leftover 
sample, which is routinely discarded, would be utilised for our research. The research nurse 
further explained that no additional procedures, not part of the routine clinical care, were 
required and the taken samples were to be anonymised; therefore, none of them would 
be identifiable. The participants were given as much time as necessary to decide whether 
they wished to take part in our study. If the participant agreed to take part in our study, 
they were given a participant consent form (PCF, see appendix 3), which they were asked 
to read through carefully, sign and date. The participant consent forms were stored under 
the standard NHS procedure. Access to PIS and PCF was only provided to NHS members of 
the research team or the participants' clinical care team at the hospital. Participants were 
informed that they have the right to pull out of the study at any given time, without reason, 
with their sample and consent form being destroyed immediately. Once sample 
anonymisation and analysis had taken place this would no longer be possible as the patient 
identifiers were unknown to the researcher. 
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4.2.4 Sample size calculation 
The sample size calculation was based upon an estimated percentage of mCRP that we 
anticipate to be found in the serum of type 1 & 2 diabetic patients with raised levels of CRP 
(>100 mg/L). To our knowledge there is no published experimental data in either of these 
fields, meaning we are unable to perform a standard sample size calculation. Based on 
recent work by Williams, who detected mCRP in the serum of different patients with a 
raised level of CRP (Williams, 2017), we estimated that the proportion of diabetic patients 
with detectable levels of mCRP would be as high as 75%. From this, we were then able to 
calculate the margin of error (ME) and the confidence interval at 95% confidence level for 
a chosen sample size, these were calculated with the following equations: 
Equation 4-1 The equations used to determine the margin of error ME (A) and the 
confidence interval (B) for a sample size. 
 
where p̂ is the expected proportion of samples with a detectable level of mCRP, n is the 
sample size and Z is the critical value at the 95% confidence level which is equal 1.96. 
It was calculated that with a sample size of 40 (20 of type 1 and 20 of type 2 diabetes) would 
be associated with a precision of ±13%, meaning that between 62% to 88% (25-35 samples) 
of the 40 serum samples may contain mCRP at 95% confidence level. 
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4.2.5 Acquisition of human serum samples 
After obtaining a signed and dated PCF, a qualified phlebotomist at UHNM drew venous 
blood from the recruited participant according to the hospital care protocol. A standard 
phlebotomy procedure was followed. The blood was collected in red cap BD Vacutainer 
serum separator gel tubes without anticoagulant. The tubes were left for up to 30 minutes, 
to allow the blood to coagulate, and then centrifuged at 3,500 x g for 10 minutes at room 
temperature to separate the serum from other blood components. The serum was then 
collected in a tube and stored at 4oC in the hospital cold room until the routine analysis had 
been carried out. Once the analysis had been completed, the volume remaining of the 
serum (near 1 mL) was transferred into a 1.5 mL cryovial tube and anonymised via a unique 
sample ID number (e.g., CRP01). The anonymised samples were then returned to in the 
cold room at 4oC until collection. Upon collection, the CRP level and where possible, calcium 
levels, were provided, via an Excel spreadsheet, linked to the unique sample ID number. 
The samples were transferred to Keele University, Life Sciences, Huxley building in a chilled, 
sealed container. Upon arrival, 0.02% (v/v) of sodium azide was added to all samples, then 
stored at 4 oC in the cold room (HTA approved) of the Structural Biology Research Lab at 
Keele University until analysis. All data generated from the study were stored securely on 
a password protected computer, linked to the Keele University server and managed by the 
CI. A detailed record of the samples involving: the sample ID, collection date, sample 
volumes, CRP and calcium concentrations and dates of when samples were discarded, were 
kept throughout the study. 
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4.2.6 Production of monomeric CRP 
Monomeric CRP, mCRP, was prepared in vitro from commercially available CRP to be used 
as a standard control in our study. Human native CRP (purity>99%), purchased from 
SCRIPPS Laboratories (San Diego, California, USA), was used to prepare mCRP by urea and 
chelator treatment. Native CRP at final concentration of 0.63 mg/mL was incubated in 
dissociation buffer containing 3 M urea, 10 mM EDTA, 20 mM Tris and 280 mM NaCl. 
Sodium azide was added at a final concentration of 0.01% to prevent bacterial and fungal 
contamination during the dissociation process. The resulting solution was incubated in the 
cold room for 10 weeks. After 10 weeks had been passed, the dissociated protein was 
subjected to size exclusion chromatography (see section 4.2.10) to separate mCRP. The 
eluted size exclusion fractions corresponding to mCRP were concentrated using a 
Vivaspin™ Turbo 15 mL centrifugal concentrator (Fisher Scientific), 10 kDa molecular 
weight cut-off (MWCO). The centrifugal concentrator was washed with deionised water 
(DW) at 1,000 x g, 4oC for 10 minutes. After the washing step, the eluted mCRP was then 
concentrated at 1,000 x g, 4oC for 15 minutes or until the final volume of 0.5 mL had been 
achieved. The protein concentration was determined by UV absorbance at 280 nm 
(Nanodrop 1000, Thermo Scientific). An extinction coefficient of 1.7 was used to give the 
concentration values in mg/mL (De Beer & Pepys, 1982). 
4.2.7 Calibration of the size exclusion column 
Size exclusion chromatography was used to separate the mCRP produced from dissociation 
of native pCRP in vitro, and to purify and separate both protein forms (mCRP and pCRP) 
from human serum samples. It was necessary to calibrate the size exclusion column before 
running the samples in order to accurately determine protein sizes via the reported elution 
volumes. HiLoad 16/60 Superdex 200pg column connected to the AKTA explorer 100 fast 
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protein liquid chromatography (FPLC) system (GE Healthcare) was used in this study. The 
system was controlled by UNICORN 5.11 software (GE Healthcare), and the elution volumes 
of the proteins were monitored by measuring the UV absorbance at 280 nm. 
Before calibration, the tubing, pumps and all valves of the system were purged with 30 mL 
of DW at 4 mL/min flow rate and bypassing the column. The column was stored in 20% 
ethanol before use, three column volumes (120 mL per column volume) DW were used to 
purge the ethanol storage buffer from the column at 1.5 mL/min flow rate. The column was 
then equilibrated using three column volumes of elution buffer (50 mM Tris, 150 mM NaCl, 
0.01% sodium azide). The elution buffer and DW used on the column were pre-filtered 
through a 0.2 µm cellulose acetate membrane filter (Sartorius Stedim Biotech, Goettingen, 
Germany) to remove particulate matter that may clog the system, and de-gassed to avoid 
introducing air into the column. 
The calibration was performed using a Gel Filtration Low Molecular Weight (LMW) 
Calibration Kit (GEHealthcare). The LMW kit contains 5 proteins with molecular weights in 
the range 6.5 kDa to 75 kDa, and Blue Dextran 2000 to determine the void volume of the 
column (Table 4.2). To further expand the molecular weight range of the kit, CRP (99% pure) 
purchased from SCRIPPS Laboratories (San Diego, California, USA) was used with the 
calibration standards. The calibration standards were provided in a lyophilised form and 
reconstituted to a 20 mg/mL stock solution using buffers recommended by the supplier. 
Two separate chromatography runs were performed, the first for the calibration standards 
including the CRP, and the second run for the Blue Dextran 2000 sample. Blue Dextran 2000 
was run separately because the fraction of Blue Dextran is broad and may overlap the 
calibration standard peaks. To achieve the best resolution, the volume of the sample 
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loaded on the column needs to be in the range of 0.1 to 2% of the total column volume. 
Therefore, the final volume of the sample solution was 1mL. The proper volumes of 
calibration standards and CRP were mixed together to achieve the concentration of the 
proteins listed in table 4.2, and the final volume was adjusted to 1mL with the elution 
buffer. For the Blue Dextran 2000 sample, a fresh solution containing 1 mg/mL was 
prepared, and the final volume was adjusted to 1mL using the elution buffer. 
Table 4-2 A table of the calibration standards and their respective molecular weights. The 
calibration standards were used to determine the calibration graph for the HiLoad 16/60 
Superdex 200 pg size exclusion chromatography column. The final concentrations of the 
calibration standards that were used in the calibration process are also provided. 
Protein Standard Molecular Weight (Da) Final concentration (mg/mL) 
Aprotinin 6500 3 
Ribonuclease A 13700 3 
Carbonic anhydrase 29000 3 
Ovalbumin 44000 4 
Conalbumin 75000 3 
CRP 115000 0.1 
 
The prepared sample solution (calibration standards or Blue Dextran sample) was loaded 
onto the column via a 2 mL sample injection loop while the elution buffer passed through 
the column at low speed. A buffer with a pH of 6–8 and an ionic strength ≥ 0.15 M is 
recommended for elution. The proteins were eluted with one column volume of elution 
buffer (150 mM NaCl, 50 mM Tris, and 0.01% sodium azide, adjusted to pH 7.20) at a flow 
rate of 1 mL/min and elution volumes of the proteins were monitored by measuring the 
UV absorbance at 280 nm. 
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4.2.8 Purification of the human serum samples by affinity chromatography 
CRP was purified from human serum samples by using a phosphocholine-bound affinity 
column (5 mL immobilised p-aminophenyl phosphocholine agarose gel) connected to 
ÄKTAexplorer 100 (GE Healthcare). The software used to operate the system was UNICORN 
5.11 (GE Healthcare). The buffers, solutions and DW used on the column were all filtered 
through a 0.2 µm cellulose acetate filter (Sartorius Stedim Biotech, Goettingen, Germany) 
to eliminate particulate matter that may clog the system, and de-gassed to avoid 
introducing air into the column. 
Before running the samples, the tubing, pumps and all valves of the system were first 
purged with 30 mL of DW at flow rate 4 mL/min, bypassing the column. The column was 
then re-connected and purged with 4 column volume (5 mL/ column volume) of DW at a 
flow rate of 1.5 mL/min to remove the equilibration buffer that filled the column during 
storage. 10 column volumes of regeneration buffers 1 & 2 (see table 4-3) were passed 
through the column at 1.5 mL/min flow rate, to clean the column from protein remnants 
that may present from the previous run, and to enable CRP present in the serum to bind. 
After regenerating the column, the column was equilibrated with 20 column volumes of 
equilibration buffer (see table 4-3) at a flow rate of 1.5 mL/min. After 20 column volumes 
had been passed, 0.9 mL of the serum sample was injected onto the column via a 2 mL 
sample injection loop while the equilibration buffer passed through the column at very low 
speed (0.1 mL/min). When the entire sample had been loaded to the column, the flow rate 
was adjusted to 0.5 mL/min, and the UV absorbance reading was blanked to a value of 0 
absorbance units. The column was washed with the equilibration buffer until all other 
unnecessary proteins pass through the column as a peak rise and flat-lined to zero again. 
When the UV absorbance reading had returned to its baseline value (usually after 15 mL), 
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the equilibration buffer was replaced with a chelating buffer (table 4-3) to elute the CRP 
that bound to the column. One column volume of chelating buffer was passed through the 
column at a flow rate of 0.5 mL/min with the absorbance measured at 280 nm. The 
fractions that correspond to eluted CRP were collected in 5 mL tubes. Once all CRP had 
been eluted, the column was washed with 20 column volumes of equilibration to be 
prepared for storage. 
Table 4-3 A table of the components of the buffers required to purify CRP from human 
serum samples using the phosphocholine-bound affinity chromatography column. 
Concentrations of each component used are also given 
Buffer (pH 7.4) Components 
Regeneration buffer 1 
• 0.5 M sodium chloride 
• 0.2 M tris 
• 0.01 M EDTA 
Regeneration buffer 2 
• 0.5 M sodium chloride 
• 0.05 M tris 
• 0.01 M calcium chloride 
Equilibration buffer 
• 0.01 M calcium chloride 
• 0.05 M tris 
• 0.15 M sodium chloride 
• 0.01% sodium azide 
Chelating buffer 
• 0.01 M EDTA 
• 0.05 M tris 
• 0.150 M sodium chloride 
• 0.01% sodium azide 
 
4.2.9 Concentrating the eluted fractions 
The eluted affinity chromatography fractions that correspond to CRP were concentrated 
using a Vivaspin™ Turbo 15 mL Centrifugal Concentrators (Fisher Scientific), 10 kDa MWCO. 
The centrifugal concentrator was initially washed with DW at 1,000 x g, 4 oC for 10 minutes. 
Chapter 4: Analysis of human serum samples from diabetic patients  Materials & Methods 
170 
 
After the washing step, the protein sample was then concentrated down at 1,000 x g, 4 oC 
for 15 minutes or until the desired volume of less than 1 mL had been achieved. 
4.2.10 Separation of pentameric and monomeric CRP by size exclusion chromatography 
Size exclusion chromatography was used to separate and purify the in vitro produced 
mCRP, and the pCRP and the potential mCRP from the human serum samples based on 
their elution volumes. The system, column and software used were the same as described 
in section 4.2.7, and the size exclusion column had been calibrated before running the 
samples in order to accurately determine protein sizes via their reported elution volumes. 
The elution volume of all the samples was determined by measuring the absorbance at 280 
nm. 
Before running the samples, the tubing, pumps and all valves of the system were purged 
with 30 mL of DW at 4 mL/min flow rate and bypassing the column. The column was stored 
in 20% ethanol, three column volumes (120 mL per column volume) DW were used to purge 
the ethanol storage buffer from the column at 1.5 mL/min flow rate. The column was then 
equilibrated using three column volumes of elution buffer continuing 280 mM NaCl, 20 mM 
tris, 5 mM CaCl2, 0.01% sodium azide. The pH of the elution buffer was adjusted to pH 7.4 
by the addition of HCl. The buffer and DW used on the column were pre-filtered through a 
0.2 µm cellulose acetate filter (Sartorius Stedim Biotech, Goettingen, Germany) to remove 
particulate matter that may clog the system, and de-gassed to avoid introducing air into 
the column. 
The samples subjected to size exclusion column were all the human serum samples that 
had been purified by affinity chromatography and concentrated to a volume of less than 1 
mL, and the in vitro produced mCRP dissociation sample which was in a final volume of 1 
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mL. The volume of samples was within 0.1-2% of the column volume (120 mL) which is 
recommended to achieve the best resolution. 
The sample was loaded onto the column (HiLoad 16/60 Superdex 200 pg column (GE 
Healthcare, 2011)) via a 2 mL sample injection loop while the elution buffer passes through 
the column at deficient speed. The proteins were eluted with one column volume of elution 
buffer at a flow rate of 0.5 mL/min while the absorbance was measured at 280 nm. The 
eluted proteins were collected as 5 mL fractions in 20 mL universal tubes. The pCRP 
containing fractions and the fractions thought to contain mCRP were concentrated, as 
described in section 4.2.9, to give final volumes ranging from 0.4 to 1.1 mL. The variation 
in the volumes of the purified samples was considered when determining the protein 
concentration of the sample. After the proteins were eluted, the size exclusion column was 
washed with 3 column volumes DW, followed by 3 column volumes of 20% ethanol to 
prepare the column for storage. 
4.2.11 SDS-PAGE of the size exclusion eluted fractions 
SDS-PAGE was performed to evaluate the purity and the protein content of fractions 
obtained from size exclusion chromatography. Size exclusion eluted fractions containing 
pCRP from the human serum samples labelled CRP01, 02, 06, 10, 11, 13, 14, 15, 17, 18, 21, 
22, 23 and 24 were selected and subjected to SDS-PAGE according to the previously 
described procedure (section 2.2.3). The gel was cast as described in section 2.2.3 with 
acrylamide content of 4% and 15% (v/v) in the stacking and resolving gels, respectively. The 
samples were mixed 1:1 (v/v) with non-reducing loading buffer and heated at 95 °C for 5 
minutes before being loading to the gel. A total volume of 20 µL was loaded to each well 
to maximise the amount of the protein. Low range molecular weight markers were run 
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beside the samples. Electrophoresis was run at 200 V for 45 min, and the samples were 
visualised by Coomassie Instant Blue stain. 
4.2.12 Enzyme-linked Immunosorbent assay of the eluted serum fractions 
Enzyme-linked immunosorbent assay (ELISA) was used to detect and quantify both pCRP 
and mCRP isoform in human serum samples. pCRP containing fractions and fractions 
thought to contain mCRP obtained from size exclusion chromatography (section 4.2.10) 
were tested separately. All ELISA analysis was carried out using 96-well flat-bottom plates 
with a low evaporation lid. A monoclonal anti-C-reactive protein antibody (clone-8), 
produced in a mouse, was used to detect both CRP isoforms. Anti-mouse IgG (whole 
molecule)-peroxidase antibody, was used as a secondary antibody. Both primary and 
secondary antibody was diluted as recommended by the supplier. The buffers and solutions 
used for ELISA experiments are detailed in Table 4-4. 
Table 4-4 Table of the components of the buffers and solution used in the ELISA 
experiments for the pCRP and mCRP containing fractions. The components concentrations 
are also given. 
Buffer/Solution Components 
PBS pH 7.4 with HCl Sodium chloride   137 mM 
Potassium chloride   2.7 mM 
Disodium phosphate   10 mM 
Monopotassium phosphate  2 mM 
Wash buffer (PBS – Tween) PBS    1 L 
Tween    0.5 mL 
Blocking solution (PBS-Tween with 3% BSA) PBS – tween   20 mL 
BSA    0.6 mg 
Calcium buffer pH 7.4 with HCl Tris     20 mM 
Sodium chloride   280 mM 
Calcium chloride   5 mM 
Primary monoclonal antibody 
(Dilution 1:40,000) 
Primary antibody   1 µL 
PBS–tween   up to 40 mL 
Secondary antibody 
(Dilution 1:40,000) 
Secondary antibody   1 µL 
PBS–tween   up to  40 mL 
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For the pCRP containing fractions ELISA assay, native pCRP from SCRIPPS was used to 
prepare the calibration standards. An aliquot was diluted to a concentration of 0.2 mg/L 
(20 ng in 100 ul). Subsequently, a serial dilution was carried out (eight dilutions) using 
calcium buffer (280 mM NaCl, 20 mM Tris, 5 mM CaCl2, 0.01% sodium azide), with the last 
dilution include only the calcium buffer (negative control). 100 µL of each dilution was 
added in triplicate to the columns 1 to 3, rows A-H (see table 4-5). Each pCRP containing 
fractions was first diluted in calcium buffer at 1:1000, and 100 µL of each serum sample 
was added, in triplicate, to a 96-well plate, see table 4-5. 
 
Table 4-5 The amounts of pCRP (ng) from SCRIPPS used in the preparation of the ELISA 
calibration standards. The dilution and the volumes of the pCRP containing samples added 
to the wells are also given 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 20 20 20 
Fractions thought to contain pCRP from 
human serum samples CRP01 to CRP24 
were diluted at 1:1000 and 100 µL were 
added in triplicate to the columns 4-12, row 
A-H. 
B 10 10 10 
C 6 6 6 
D 3.6 3.6 3.6 
E 2.16 2.16 2.16 
F 1.296 1.296 1.296 
G 0.778 0.778 0.778 
H 0 0 0 
 
For the mCRP containing fractions ELISA assay, the mCRP dissociated by 3 M urea was used 
to prepare the calibration standards. An aliquot was diluted to a concentration of 0.125 
mg/L (12.5 ng in 100 ul). Subsequently, a serial dilution was carried out (seven dilutions) 
using calcium buffer, with the last dilution includes only the calcium buffer (negative 
control). 100 µL of each dilution was added, in triplicate, to the columns 1 to 3, rows A-G 
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(see table 4-6). 100 µL of each mCRP containing samples was added without dilution, in 
triplicate, to a 96-well plate, see table 4-6. 
 
Table 4-6 The amounts of mCRP (ng), from 3 M urea dissociation experiment, used in the 
preparation of the ELISA calibration standards. The dilution and the volumes of the mCRP 
containing samples added to the wells are also given. 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 12.5 12.5 12.5 
Fractions thought to contain mCRP from 
human serum samples CRP01 to CRP24 
were added in triplicate to the columns 4-
12, row A-H. 
B 6.25 6.25 6.25 
C 3.125 3.125 3.125 
D 1.563 1.563 1.563 
E 0.781 0.781 0.781 
F 0.391 0.391 0.391 
G 0 0 0 
H 0 0 0 
 
Both plates were left to incubate overnight at 4oC on the rocker. After incubation, the 
following procedure was used for both plates. The plates were washed thoroughly for three 
cycles with washing buffer of phosphate buffered saline with tween, PBS-T (see Table 4-4). 
Each cycle the washing buffer was left in the well for 2-3 min then discarded by blotting the 
plate onto absorbent material. The plates were then blocked with 300 µL of a freshly 
prepared blocking solution (PBS-T supplemented with 3% of bovine serum albumin) for 2 
hours at 4oC on the rocker. The plates were washed three times with PBS-T, and each time 
the washing solution was left in the well for 2-3 min before being discarded. The primary 
monoclonal antibody solution was thawed before use. The primary monoclonal anti-C-
reactive protein antibody (clone-8) solution was diluted at 1:40,000 in wash buffer and 100 
µL of the diluted antibody solution was added to each well. The plate was incubated for 5 
hours at 4 oC on the rocker. The plates were washed three times with PBS-T, and each time 
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the washing solution was left in the well for 2-3 min before being discarded. The secondary 
antibody was thawed before use and diluted at 1:40,000 in wash buffer. 100 µL of the 
diluted secondary antibody was added to each well then incubated for 2 hours at 4 oC on 
the rocking machine. After incubation, the plates were washed again as with the primary 
antibody. Afterwards, the developing substrate (3,3’,5,5’ tetramethylbenzidine (TMB)) was 
added to each well (100 µL/well) and allowed to develop for 10 minutes at room 
temperature, or until the required colour intensity was reached. Finally, the reaction was 
stopped by adding 100 µL/well of 2 M sulfuric acid; the optical density for each sample was 
immediately determined at 450 nm using a BioTek EL800 plate reader operated by Gen5 
Software. The standard curves were then generated and used to determine the protein 
concentration in each sample, considering the variation in the initial sample volume. 
4.2.13 Intact mass spectrometry of the eluted fractions 
Purified samples containing pCRP, obtained from size exclusion chromatography described 
in section 4.2.10, were subject to LC-MS analysis to test for protein glycation as a function 
of the net gain in the molecular weight of the protein as a result of glucose conjugation. A 
portion from each sample was buffer exchanged and further concentrated to about half of 
its volume using Amicon ultra centrifugal filter devices (Millipore) fitted with a 10 kDa 
molecular weight cut-off membrane. The Amicon devices were first washed with 500 µL of 
DW at 1000 x g for 5 minutes. After the washing step, the sample was added, and the 
volume completed to 500 µL with solvent A (0.1% F.A, 5% ACN) and then concentrated at 
14000 x g for 15 minutes. This process (buffer exchanging and concentration) was repeated 
three times; the centrifugation steps were performed at 4 °C. 
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The LC-MS setup including the system, buffers, and the software is the same as described 
in section 2.2.5. For each HPLC run, 2 µL of protein solution (containing an average of >5 
pmole of pCRP) was injected into the 20 µL loop and loaded to the C4 guard column over 5 
minutes using 95% solvent A, 5% solvent B (30 µL/min). After the trap/wash period, the 
sample was loaded onto the C4 analytical column at a split flow rate of 0.35 µL/min. The 
gradient consisted of 2 ramps: 15 minutes (5% - 60% B), then, 5 minutes 60-95% B. The 
column was then washed at 95% B for 5 minutes before re-equilibration to the starting 
conditions. Sample runs were bracketed by blank runs to allow full equilibration of columns 
and to minimise system carryover and consequent column contamination. The HPLC 
column was coupled online to the Q-TOF mass spectrometer via nanoESI, with typical 
capillary voltages of 1-2 kV being applied. The Q-TOF was operated in MS only mode. The 
Q-TOF parameters were the same as described in section 2.2.5. The scan m/z range started 
at 500 and ended at 2500 in positive ion mode, scan time 1 s, 0.1 s interval. Data were 
collected and processed using MassLynx V4.1 (Waters). The multiply-charged electrospray 
spectra were deconvoluted (after background subtraction) using the Maximum Entropy 1 
package of the MassLynx software, with a resolution of 1 Da/channel, a uniform Gaussian 
width at half height of 0.5 Da, and minimum intensity ratios of 33%. 
In addition to pCRP samples, the mCRP containing samples with high protein content, as 
revealed by ELISA, were also analysed by LC-MS as an additional measure to confirm the 
identity and the mass of the isolated isoform. The mCRP containing fractions from human 
serum samples labelled CRP04, CRP17, and CRP21 were selected. 200 µL from each 
selected sample was buffer exchanged into solvent A and concentrated down to 40 ul using 
Amicon ultra centrifugal filter devices, then 5 µL was injected into the system and analysed 
as with pCRP samples. 
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4.2.14 Bottom-up mass spectrometric analysis of pCRP containing samples 
Purified pCRP containing samples were digested with trypsin and Glu-C and subjected to 
bottom-up mass spectrometric analysis with the aim to identify glycation, if any, at the 
peptide level. Purified pCRP containing samples from all 24 human serum samples were 
treated, digested and analysed using the same reagents, protocol, and equipment 
described in section 3.2.2 and 3.2.3. The purified pCRP samples were in calcium buffer (see 
section 4.2.10) with an average protein content of 0.04 µg/µL as determined by ELISA. An 
aliquot (200 ul) from each sample was concentrated, using Amicon ultra centrifugal filter 
devices, to a final volume of 50 µL (assumed to contain an average of 8 ug of protein). The 
concentrated pCRP samples were denatured with Rapigest, reduced with DDT, and 
alkylated by IAA as described in section 3.2.2. The treated samples were divided into two 
equal portions (each containing ≈4 µg of the protein). The first portion was used for the 
trypsin digestion while the second portion was digested with endoproteinase Glu-C. 
Both trypsin (proteomics grade, Sigma-Aldrich) and Glu-C (protease V8 sequencing grade, 
Roche) were freshly reconstituted, and working solution of 0.1 µg/µL was prepared as 
described in section 3.2.2. Trypsin (at 0.1 µg/µL) was added to the first portion of each CRP 
sample to give substrate to enzyme ratios of 30 to 1, and an equal volume of Glu-C (at 0.1 
µg/µL) was added but to the second portion to give the same substrate to enzyme ratio. 
The solutions were incubated for 24 hours at 37 °C with gentle agitation. A second 
application of each enzyme was added to the corresponding aliquot after 8 h of incubation, 
this to aid complete protein digestion. The digestion was stopped by lowering the pH to <2 
by adding TFA to a final concentration of 0.5% (v/v). The acidified solutions (≈65 µL samples) 
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were then incubated at 37 °C for 30-45min before centrifugation and removal of the 
supernatant. 
The CRP peptides digests were then desalted and concentrated using C18 Zip-tip (Millipore) 
and the same protocol described in section 3.2.3. The zip-tip was wetted ten times by 10ul 
portions of 100% ACN and then equilibrated ten times by a 10 µL portions 0.1% F.A solution. 
A 30 µL aliquot of CRP digest (assumed to contain ≈1 µg of the protein) was absorbed onto 
the reversed-phase medium by 10 repeated aspirate-dispense cycles of sample loading. 
The tip was washed immediately with 100 µL of 0.1% F.A. Finally, A 10 µL portion of 80% 
ACN in 0.1% F.A solution was placed into a microcentrifuge tube, and peptide elution was 
performed by passing this solution through the Zip-tips with 3 aspirate- dispense cycles. 
The desalted and concentrated protein digest (with an average concentration of 3 
pmole/µL if assuming 80% recovery from the zip-tip process) were then transferred to 
autosampler vial inserts (Waters Corporation). 
The vials were loaded onto HPLC autosampler, and an aliquot of solvent A was also loaded 
to be used as a blank. The samples run was performed after three blank runs to ensure that 
the LC-MS system is stable before samples analysis. Moreover, two blanks run was added 
between the samples as well to minimise system contamination and carryover. The LC-MS 
setup including the system, buffers, and the software is all the same as described in section 
3.2.3. For each HPLC separation, digested protein (typically 2 µL) were loaded onto C18 trap 
column throughout 5 minutes using 95% solvent A, 5% solvent B at 30 µL/min to desalt and 
concentrate the peptides. After the trapping period, the peptides were separated on a C18 
analytical column at a flow rate of 0.35 µL/min. The HPLC gradients consisted of 2 ramping 
steps; a 35 minutes ramp from 5% to 60% solvent B, followed by a 10 minutes ramp to 95% 
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solvent B then preserving on 95% B for additional 5 minutes before returning to the initial 
starting conditions at the end of the run. After separation, samples eluting from the HPLC 
column were delivered to a Q-TOF mass spectrometer and introduced into the gas phase 
through the nanoESI source by applying a DC potential of 1-2 kV to the sample solution 
within the Nano-spray emitter capillary. The Survey spectra were acquired in the positive 
ion mode over the mass range of 400–1600 amu, with data-dependent product ion analysis 
of multiply charged precursors as described in 3.2.3. 
The data were collected using MassLynx version 4.1 (Waters Ltd., Manchester, UK). The 
collected data were extracted as text formatted mgf files using Mascot Distiller (Matrix 
Science, London). The mgf files were subjected to database searching using the Mascot 
search engine (Matrix Science, London, UK) as described in section 3.2.4. The MS/MS 
spectra of the m/z values assigned to glycated CRP peptides through Mascot, if present, 
were analysed manually to interpret unassigned peaks within the spectrum and confirm 
the glycation site. The m/z values that did not correspond to any peptide sequence in the 
selected database during the Mascot search were considered as possible CRP glycated 
peptides and further analysed as described in section 3.2.4. 
4.2.15 Statistical Analysis 
All graphs and tables produced from the data collected from the chromatographic 
separation and ELISA quantification of CRP isoforms were created by Microsoft Excel 365 
ProPlus. Statistical analysis including descriptive statistics and Mann-Whitney test was 
carried out in Minitab® Statistical Software (Version 18). Central tendencies are reported 
as mean ±SEM for normal data and median + interquartile range (IQR) for non-normal data. 
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4.3 Results 
4.3.1 Experimental design 
The primary aim of the study was to establish whether modified forms of CRP (glycated 
and/or monomeric) are present in the serum of diabetic patients with raised levels of CRP 
(>100 mg/L). After the required approvals were in place, the participant recruitment 
process was started. All the participants were inpatients at UHNM with markedly raised 
levels of CRP (>100 mg/L) and classified as having type 1 or type 2 diabetes. During the time 
available for the sample collection, it was possible to recruit 24 diabetic patients; 20 
patients with type II diabetes and only 4 patients with type I diabetes, since type 1 diabetes 
is less common in adults than type 2 (Hex et al., 2012). With a sample size of 24 patients, 
the ME increases from ±13% (when n=40) to ±17% (with n=24), meaning that the modified 
form of CRP would be expected to be identified in 14 to 22 (58%-92%) serum samples at 
95% confidence level. A full list of the sample IDs, type of diabetes and the initial CRP 
concentrations (mg/L) as provided by UHNM can be found in Appendix 3.  
The methodology used for the analysis of human serum samples is summarised in Figure 
4-1: CRP was first purified from human serum via affinity chromatography, followed by 
separation of CRP isoforms (pCRP and mCRP) using size exclusion chromatography. The 
pCRP containing fractions were quantified by ELISA and subjected to LC-MS and LC-MSMS 
analysis to test for the glycated isoform of CRP. The mCRP containing fractions were 
subjected to LC-MS and ELISA for mCRP identification and quantification, respectively. 
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Figure 4-1 A flow diagram of the methodology used for the analysis of human serum 
samples. Unless otherwise indicated, each experimental method was performed on all 
samples 
 
4.3.2 Calibration of the size exclusion chromatography column 
Prior to the use of size exclusion chromatography, the column was calibrated with known 
molecular weight proteins including: aprotinin (6.5 kDa), ribonuclease A (13.7 kDa), 
carbonic anhydrase (29 kDa), ovalbumin (44 kDa), conalbumin (75 kDa), in addition to CRP 
(115 kDa) to further expand the molecular weight range of the calibration standards. Figure 
4-2 shows the chromatography trace for the molecular weight standards; the sample was 
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injected into the column at 0 mL, and six peaks were observed at elution volumes of 70.93, 
75.64, 81.47, 89.12, 96.99 and 105.92 mL for CRP, conalbumin, ovalbumin, carbonic 
anhydrase, ribonuclease A and aprotinin, respectively. 
 
 
Figure 4-2 A size exclusion chromatography trace of the molecular weight standards. Peak 
1, CRP (115 kDa), has an elution volume of 70.93 mL. Peak 2, conalbumin (75 kDa), has an 
elution volume of 75.64 mL. Peak 3, ovalbumin (44 kDa), has an elution volume of 81.47 
mL. Peak 4, carbonic anhydrase (29 kDa), has an elution volume of 89.12mL. Peak 5, 
ribonuclease A (13.7 kDa), has an elution volume of 96.99mL. Peak 6, aprotinin (6.5 kDa), 
has an elution volume of 105.92 mL. 
 
A second chromatography run was performed with Blue Dextran, a high molecular weight 
glucose polymer, in order to determine the column void volume. The chromatography trace 
of Blue Dextran shows a single sharp peak with maximal absorption at 44.98 mL; which 
represents the column void volume (see Figure 4-3). 
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Figure 4-3 A size exclusion chromatography trace for Blue Dextran. Single sharp peak is 
observed at 44.98 mL elution volume. Absorbance was measured at 280 nm. 
 
The elution volumes of the protein standards obtained from the chromatography trace in 
Figure 4-2 were used to calculate the proportion of pores available for each protein 
standard (Kav) using the following equation: 
Equation 4-2 The equation used to calculate Kav value for the protein standards 
 
In equation 4-2, Ve is the elution volume for the protein standard, Vo is the column void 
volume (44.98 mL from Figure 4-3), Vt is the total column volume, which was calculated to 
be 120.63 mL (π x radius x length). 
The calculated Kav values for each of the protein standards are presented in Table 4-7 in 
addition to the log10 of the molecular weight of each protein standard. The calibration 
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graph was constructed by plotting the Kav versus the log10 of their molecular weights as 
shown in figure 4-4. 
Table 4-7 A table of the calculated Kav values for the molecular weight protein standards. 
The molecular weights, elution volumes, and log10 of molecular weights for all standards 
are also shown. 
Protein Molecular 
Weight (kDa) 
Elution 
Volume (mL) 
Kav log10 of 
Molecular 
Weight 
Aprotinin 6.5 105.92 0.806 3.813 
Ribonuclease A 13.7 96.99 0.688 4.137 
Carbonic anhydrase 29 89.12 0.583 4.462 
Ovalbumin 44 81.47 0.482 4.643 
Conalbumin 75 75.64 0.405 4.875 
pCRP 115 70.93 0.343 5.061 
 
 
Figure 4-4 Calibration graph of the Kav values of the molecular weight standards versus the 
log10 of their molecular weight. The R² value is 0.9961, and line equation for the graph is 
y=-0.3763x+2.244 
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The calibration graph displays an inverse relationship between log10 molecular weight and 
Kav meaning that the larger the Kav (representative of elution volume), the smaller the 
molecular weight of the protein. The high R2 value of 0.9961 indicates the strong 
correlation between the two data sets. The line equation of the calibration graph (y=-
0.3763x+2.244) describes the inverse relationship between Kav and log10 of the molecular 
weight of the proteins. From this equation, the molecular weight of the proteins in the 
sample can be determined based on their elution volumes from the size exclusion column. 
The ability to estimate the molecular weight of the eluted proteins based on their elution 
volumes enable reliable identification of CRP forms (whether mCRP or pCRP form) in the in 
vitro-produced mCRP sample or the purified human serum samples. 
4.3.3 Purification of in vitro prepared monomeric C-reactive protein 
mCRP was prepared in vitro from the dissociation of native pCRP using 3 M urea in the 
presence of EDTA as calcium chelator (see section 4.2.6). After 10 weeks of incubation in 
dissociation buffer, size exclusion chromatography was used to separate mCRP from 
residual undissociated pCRP. Figure 4-5 shows a size exclusion chromatography trace of the 
dissociation trial; two peaks are observed on the chromatography trace, labelled peak 1 
and peak 2. Peak 1 is broad in shape and small, eluted at volume   ̴73 mL with absorbance 
not exceeding 2.9 mAU. Applying the calibration equation (figure 4.4), the elution volume 
of peak 1 represents a protein with a molecular weight of 95.2 kDa. Peak 2 is sharp and 
significantly larger with an absorbance of 73.6 mAU and elution volume of 89.9 mL (peak 
start-end; 86-93 mL). Peak 2 represents fraction with molecular weight 24.2 kDa, consistent 
with the molecular weight of mCRP. Fractions corresponding to the mCRP (peak 2) were 
collected and concentrated to 0.5 mL. The concentration was measured by Nanodrop and 
found to be 0.4 mg/mL. The protein was stored at 4 oC for further experimental analysis.
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Figure 4-5 A Size exclusion chromatography trace of CRP treated with 3 M urea in the presence of EDTA for 10 weeks. Peak 1 has an elution 
volume of   ̴73 mL and UV absorbance of 2.9 mAU. Peak 2 is significantly larger with UV absorbance of 73.6 mAU, and elution volume of 89.9 mL 
consisting with the elution volume of mCRP. The sample was injected at 0 mL and the UV absorbance was measured at 280 nm.
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4.3.4 Purification of the human serum samples by affinity chromatography 
Affinity chromatography was performed on collected serum samples to purify CRP from 
other serum constituents. Samples were passed through a phosphorylcholine (PC) affinity 
column in the presence of calcium to enable CRP binding to its natural ligand, PC, while the 
other constituents were washed out. The CRP bound to the column was then eluted by 
using an EDTA-containing buffer. All 24 samples were purified by the same method. A 
representative trace for the purification of human serum by affinity chromatography is 
shown in Figure 4-6. All results obtained from affinity chromatography followed the same 
trend. 
After loading the sample, while the calcium buffer passes through the column at a low flow 
rate, a peak started to develop just after 2.7 mL of the calcium buffer (peak 1 in the figure 
4-6). This peak reached an absorbance reading of 3060.9 mAU at 6.7 mL, with absorbance 
reading not returning to 0 mAU until 15.9 mL of calcium buffer had passed. Peak 1 is due 
to the elution of serum constituents that were unable to bind to the column. The calcium 
buffer was allowed to run through the column for an additional time after the absorbance 
reading had returned to the baseline level to aid removal of unbound constituents. The 
calcium buffer was then replaced with the calcium chelator as indicated by the marker at 
the volume point of around 41 mL. A second peak started to develop after several mL of 
the calcium chelator passed through the column, and extended for around 4.5 mL with 
absorbance reading reached 73.9 mAU (see peak 2 in the Figure 4-6). Peak 2 on the 
chromatography trace is due to the elution of CRP from the PC-column due to the removal 
of calcium by EDTA since the calcium removal results in elution of calcium-dependent PC-
bound proteins, such as CRP. The slight background increase that seen before peak 2 in the 
magnified section of the Figure 4-6 is due to loading of the chelator buffer to the column.
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Figure 4-6 A chromatography trace of human serum passed through PC-bound affinity column. Peak 1 eluted at 6.7 mL when the calcium buffer 
passes through the column, this peak represents the serum constituents which did not bind to the column. Peak 2 was eluted after addition of 
the chelating buffer, it has an absorbance reading of 73.96 mAU and represents elution of the calcium-dependent PC-bound CRP. 
Calcium buffer 
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4.3.5 Isolation of CRP isoforms by size exclusion chromatography 
The calcium-dependent proteins from human serum samples retained by PC-bound affinity 
column were subjected to size exclusion chromatography to further purify and separate 
the potential CRP isoforms based on their sizes. Affinity chromatography fraction from peak 
2 of the chromatography trace in Figure 4-6 was collected, concentrated to 1 mL volume, 
and loaded onto a size exclusion column. A representative trace for the results acquired 
from the size exclusion chromatography is shown in Figure 4-7. Three peaks are observed 
on the chromatography trace and labelled peaks 1, 2 and 3. Peak 1 was eluted before the 
column void volume at 39.6 mL with an absorbance of 1.9 mAU. Peak 2 was sharp and 
larger than peaks 1 and 3 with an absorbance reading of 9.5 mAU. Peak 2 had an elution 
volume of 71.8 mL (peak start-end; 69.5-76.7 mL). Based on the calibration graph equation, 
peak 2 represents a protein with a molecular weight of 105 kDa which is consistent with 
the molecular weight for pCRP. Peak 3 was eluted at   1̴09.5 mL with an absorbance reading 
of 2.3 mAU. Based on the calibration graph equation, the elution volume of peak 3 
represents a protein with a molecular weight of 4.98 kDa. 
For all the samples, a peak corresponding to elution of pCRP was observed, with an elution 
volume around 72 mL and UV absorbance in the range of 4.89-15.23 mAU with a median 
of 10.34 mAU. The vast majority of the samples (18 out of 24) show a chromatography 
trace typical to the example presented here with three peaks; one eluting before the 
column void volume, a second peak corresponding to pCRP, and a third peak at   1̴10 mL. 
Three of the studied samples show only one peak corresponding to pCRP, while the other 
three samples showed two peaks: one peak at pCRP elution area and another peak either 
before the column void volume or at   1̴10 mL. The peaks that were eluted before the 
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column void volume or at   ̴110 mL are outside of the column resolution and were not 
subjected to further experimental analysis and disregarded. 
Based on calibration graph and the size exclusion run of the in vitro produced mCRP (Figure 
4-5), mCRP isoform should be eluted at a volume of   ̴90 mL (90 mL elution volume 
represent a protein with the molecular weight of around 24 kDa). However, with all 
samples, the absorbance reading remain around the baseline level with no evidence of any 
peak at the region that correspond to the elution of mCRP. 
The fractions containing pCRP (typically from elution volume of 65 to 80 mL), in addition to 
fractions at elution volume between 85 to 95 were collected separately, concentrated, and 
stored at 4 oC for further experimental analysis. The reason behind collecting the fractions 
eluting between 85 to 95 mL, although no peak was observed, is to exclude mCRP levels 
being too low to be detected the UV absorbance detector and inducing an elution peak.
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Figure 4-7 Size exclusion chromatography trace of the proteins from human serum sample retained by the PC-bound affinity column. The 
presented trace represent the typical image of the purified human serum samples when subjected to size exclusion column. Three peaks were 
observed: the largest peak (labelled 2) displayed an elution volume of 71.8 mL and corresponds to pCRP, peaks labelled 1 and 3 displayed elution 
volumes of 39.6 mL and 110 mL, respectively.
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4.3.6 Monitoring size exclusion chromatography by SDS-PAGE 
SDS-PAGE was carried out to determine the presence and purity of CRP in the fractions 
obtained from size exclusion chromatography. Only the pCRP fractions were tested, as we 
anticipated, based on prior data, that the amount of mCRP would be insufficient to be 
detected by SDS-PAGE. Figure 4-8 shows the SDS-PAGE result of the size exclusion fractions 
from fourteen human serum samples. All tested samples produced a single band at a 
molecular weight of ~23 kDa, confirming the presence of CRP in the eluted fractions. For 
all the samples, no bands other than the CRP band were observed. Staining intensity 
indicated varying protein concentration. 
 
Figure 4-8 SDS-PAGE analysis of pCRP containing fractions after size exclusion 
chromatography separation. Lane 1 represents the molecular weight markers, while the 
lanes from 2 to 15 are the eluted fractions that thought to contain pCRP from the fourteen 
human serum samples. A total volume of 20 µL of each sample was loaded to the gel, and 
the gel was stained with Coomassie brilliant blue. 
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4.3.7 Enzyme-linked immunosorbent assay of the eluted serum fractions 
Fractions obtained from size exclusion chromatography corresponding to the elution 
volume of pCRP (typically from elution volume of 65 to 80 mL) or mCRP (typically from 
elution volume 85 to 95) were concentrated and subjected to ELISA analysis in order to 
detect and quantify the levels of these isoforms, if present, in the corresponding fractions. 
Analysis via ELISA offers an increased level of sensitivity to detect a level of the protein 
which may be too low to be detected by the UV detector of the size exclusion column. 
Fractions contain pCRP were tested in triplicate with samples also triplicated upon the 
plate. Known amounts of pCRP, purchased from SCRIPPS, were analysed beside the pCRP 
containing fractions to produce a calibration curve. Figure 4-9 shows the calibration graph 
generated from plotting the known concentrations of pCRP versus their absorbances. The 
calibration graph displays a strong positive correlation between the concentration of the 
protein and its absorbance as indicated by R2 value 0.9987. The line equation of the 
calibration graph (y=0.0378x+0.0225) was used to determine the respective pCRP 
concentrations in the tested samples. 
The result of ELISA analysis for the pCRP containing fractions is presented in Figure 4-10. 
The concentration of the protein samples is expressed in term of mg/L, and the values have 
been corrected to account for pCRP sample volume post purification process to give an 
estimate concentration of pCRP in the human serum samples (see 4.2.10 and Appendix 4). 
The average value of pCRP across all 24 human serum samples was calculated to be 30.03 
mg/L (with SD equal to 13.85, and SE ±2.83), the lowest recorded pCRP value was 4.09 mg/L 
(CRP05) and the highest recorded value 57.75 mg/L. 
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Figure 4-9 The calibration graph for pCRP ELISA assays. The line equation is 
y=0.0378x+0.0225 and the R2 = 0.9987 
 
 
Figure 4-10 Pentameric CRP concentrations purified from serum samples as determined by 
ELISA. The fractions containing pCRP were diluted at 1:1000 and tested in triplicate over 3 
separate ELISA assays. The primary and secondary antibody dilutions were 1:40,000, the 
samples were developed with TMB and measured at 450 nm. The bars represent the 
average concentrations in term of mg/L; the error bars are the SEM for each sample. Darker 
bars are samples from type 1 diabetic patients, paler are from type 2 diabetic patients. 
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The results of the ELISA quantification of pCRP-containing samples indicates a significant 
loss of protein post purification compared to the initial sample concentrations, where all 
samples were over 100 mg/L. The initial samples concentrations, as provided by UHNM, 
were plotted against the pCRP concentrations obtained via the ELISA analysis to provide an 
overview of the relationship between these two data sets. This comparison is shown in 
Figure 4-11. The correlation coefficient between the two data set is 0.6 (p-value 0.002), 
indicating a moderate positive correlation between the purified pCRP concentration and 
the initial CRP concentration. 
 
 
Figure 4-11 A comparison of the pCRP concentrations obtained from the ELISA analysis of 
purified pCRP against the data provided from UHNM as whole serum CRP levels. A 
moderate positive correlation between the data sets was found with a correlation 
coefficient of 0.6 
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Size exclusion fractions corresponding to the elution volume of mCRP were analysed in the 
same way, with samples being triplicated upon the ELISA plate. Known amounts of mCRP, 
produced in vitro from native pCRP by urea and chelator treatment, were included 
alongside mCRP-containing samples to produce the calibration curve. Figure 4-12 shows 
the calibration graph generated from plotting the mCRP standards versus their 
absorbances. The calibration graph displays a strong positive correlation between the 
concentration of the protein and its absorbance as indicated by R2 value 0.9961. The line 
equation of the calibration graph (y=0.0616x-0.0174) was used to determine the respective 
mCRP concentrations in the tested samples. 
 
Figure 4-12 Calibration graph for mCRP ELISA assays. The line equation is y=0.0616x-0.0174 
and the R2 = 0.9961 
 
The result of ELISA analysis for the mCRP-containing fractions is presented in Figure 4-13. 
The concentration of mCRP in the samples is expressed in term of mg/L, and the values 
have been corrected to account for the mCRP sample volume post purification process to 
give an estimate concentration of mCRP in the serum samples (see 4.2.10 and Appendix 3). 
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The entire 24 human serum samples show a detectable level of mCRP, with an average 
mCRP content of 0.093 mg/L (SD of mean equal to 0.0461, and SE mean ±0.0094). The 
lowest recorded mCRP value was 0.043 mg/L and the highest recorded value 0.219 mg/L. 
The median value across all 24 samples was calculated to be 0.079 mg/L, IQR 0.058-0.109 
mg/L. For all total 24 human serum sample, all mCRP values were significantly lower than 
those for pCRP. 
 
 
Figure 4-13 Monomeric CRP concentrations purified from human serum samples as 
determined by ELISA. The fractions containing mCRP were measured in triplicate. The 
primary and secondary antibody dilutions were 1:40,000, the samples were developed with 
TMB and measured at 450 nm. The bars represent the average concentrations in term of 
mg/L, the error bars are the SEM for each sample. Darker bars are samples from type 1 
diabetic patients, paler were type 2 diabetic patients. 
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Since the serum samples were collected from both type 1 and type 2 diabetes participants, 
the differences in the level of mCRP between the two groups were investigated. Type 1 
diabetes group comprised 4 participants with a median mCRP value of 0.084 mg/L, while 
the type 2 diabetes group comprised 20 participants with a median mCRP value of 0.080 
mg/L. Comparing the mCRP levels between the two groups using the Mann-Whitney test 
for not normally distributed data, show no significant difference between the groups (P 
>0.908). However, due to the small sample size of the groups, particularly that of type 1 
diabetic participants, it is not possible to draw a meaningful predictive conclusion. 
The differences in the level of pCRP between the two groups (type 1 and type 2) were also 
investigated using Mann-Whitney test, no significant difference in the level of pCRP were 
found between type 1 and type 2 diabetes groups (P >0.7). 
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The correlation between the levels of mCRP and pCRP within the serum sample for the 
entire 24 participants was also investigated. No correlation was found between levels of 
mCRP and pCRP as illustrated in Figure 4-14 with R2 = 0.0574, P > 0.26. 
 
 
Figure 4-14 Scatter plot illustrating the correlation between the pCRP and mCRP levels 
purified from human serum samples as determined by ELISA. The line equation is y= 
0.0008x +0.0685, with R2 = 0.0574 showing no correlation between levels of mCRP and 
pCRP P > 0.26. The concentration for each sample is expressed in terms of mg/L. 
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4.3.8 Intact mass analysis of mCRP in diabetic serum samples 
Monomeric CRP samples with high protein content, as revealed by ELISA, were also 
subjected to LC-MS analysis at the intact level to demonstrate the identity and the mass of 
the isolated isoform. The mCRP-containing fractions from three human serum samples 
were tested. All three samples produced very similar spectra. An example is shown in figure 
4-15. 
 
Figure 4-15 Mass spectra of mCRP purified from human serum sample and measured by 
nESI-QTOF-MS in positive ion mode. A, combined m/z spectrum after LC-MS analysis of 5 
ul of mCRP isolated from a diabetic human serum sample. The charge states are indicated 
on the spectrum, and the intensities are scaled to the highest peak, B: Deconvoluted LC-
MS mass spectrum of mCRP based on the m/z spectrum presented in Figure A. 
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The low intensities of the peaks in m/z spectrum are due to the low mCRP concentration in 
the sample. The protein produced a charge state distribution similar to that produced by 
standard CRP preparation (figure 2-5). After software-assisted deconvolution of the 
spectrum, the mass spectrum depicted in Figure 14-5, B was obtained. The deconvoluted 
spectrum shows a mean species at 23,026 Da, which corresponds to the expected mass of 
unmodified monomeric CRP. 
4.3.9 Intact mass analysis of pCRP in human serum samples 
Mass spectrometry has been utilised to investigate the presence of a glycated form of CRP 
in diabetic serum samples; pCRP isolated from human serum samples were analysed by Q-
TOF mass spectrometer at the intact level. LC-MS analysis of pCRP shows a main peak at 
23027 Da corresponding to the expected mass of the unmodified CRP subunit. However, 
none of the samples shows any evidence of peak corresponding to the condensation of 
glucose molecules. All 24 human serum samples were tested and produced the same 
spectra as shown in Figure 4-16. Low-intensity signals, besides the main peak at 23027 Da, 
were seen with all analysed human samples but also found in the standard CRP preparation 
which analysed prior to running the human samples. These peaks are likely due to artefacts 
causing a mass shift of -18 Da, +17 Da, +34 Da and +221 Da to protein but not related to 
the protein glycation. 
Further LC-MS attempts were also carried out with five samples using SYNAPT G2-S mass 
spectrometer (Waters) which offers improved sensitivity than the MICROMASS Q-TOF 
premier (Waters) which was used in our study (Holčapek et al., 2012). However, near 
identical results were obtained (data not shown). 
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Figure 4-16 The deconvoluted mass spectrum of pCRP isolated from a diabetic serum 
sample. The main peak at 23027 Da corresponds to the expected mass of unmodified CRP 
subunit. No peaks corresponding to the condensation of glucose molecules were identified. 
 
4.3.10 Bottom-up tandem mass analysis of pCRP in human serum samples 
The investigation of the presence of the glycated form of CRP in the diabetic serum samples 
was extended to include bottom-up tandem mass analysis. The pCRP purified from diabetic 
human serum samples were enzymatically digested by trypsin and Glu-C separately, and 
the resulting digests were analysed by QTOF-MS/MS. The obtained data were submitted to 
Mascot, enabling identification of CRP peptides and, if present, the possible CRP glycated 
peptides. For most of the samples (16 out of 24), sequence coverage of >50% was achieved 
with trypsin alone, and >80% from the Glu-C digest alone (table 4-8). Combining the 
mapping results of both enzymes generated >90% sequence coverage in 17 out of 24 
samples. In 16 out of 24 samples, we were able to cover all the probable glycation sites, 
while the rest of the digested samples one or more of the lysine residues were not covered. 
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Table 4-8 Protein sequence coverage obtained after trypsin and Glu-C digestion of pCRP 
purified from diabetic serum samples, the lysine residues that were not covered by tryptic 
and Glu-C digest were also given. 
 
For all the 24 human serum samples, only non-glycated CRP peptides were identified 
through the Mascot search of the data obtained from the digest of trypsin and Glu-C 
enzymes, no CRP glycated peptide was identified. For each sample tested, the m/z values 
that did not correspond to any peptide sequence in the selected database during the 
Mascot search were considered as possible CRP glycated peptides and further analysed as 
explained in section 3.2.4. However, none of these unmatched m/z values corresponds to 
glycated CRP peptide.  
Sample 
ID 
% of sequence 
covered by 
tryptic digest 
% of sequence 
covered by 
Glu-C digest 
Total sequence 
coverage obtained 
from both trypsin 
and Glu-C digest 
Lysine residues that 
not covered in the total 
sequence coverage 
CRP01 52% 58% 96% K23 
CRP02 53% 94% 100% 
 
CRP03 58% 81% 100% 
 
CRP04 52% 62% 81% K7, 13 and 23 
CRP05 21% 39% 52% K7, 13, 69 and 191 
CRP06 28% 91% 97% 
 
CRP07 53% 94% 100% 
 
CRP08 58% 81% 100% 
 
CRP09 21% 46% 55% K28, 31 and 69 
CRP10 58% 91% 100% 
 
CRP11 52% 94% 100% 
 
CRP12 58% 91% 100% 
 
CRP13 62% 94% 100% 
 
CRP14 22% 46% 55% K23, 28 and 31 
CRP15 21% 57% 68% K69 
CRP16 35% 81% 97% 
 
CRP17 58% 91% 100% 
 
CRP18 52% 94% 100% 
 
CRP19 58% 91% 100% 
 
CRP20 26% 50% 65% K7 and 13 
CRP21 21% 46% 65% k7 and 13 
CRP22 52% 91% 100% 
 
CRP23 53% 94% 100% 
 
CRP24 58% 81% 100% 
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4.4 Discussion 
4.4.1 Production and Purification of Monomeric C-reactive Protein in vitro 
Treatment of the native pentameric CRP with urea, in the presence of a calcium chelator, 
yields a monomeric form of CRP (Potempa et al., 1987). While the high concentration of 
urea (8 M) can achieve dissociation in a short period (Potempa et al., 1987), a less harsh 
condition with lower urea concentrations can achieve complete dissociation after more 
extended exposure (Williams, 2017). In this work, mCRP was produced by treating the 
native pCRP with 3 M urea in the absence of calcium for 10 weeks, in order to minimise 
harsh conditions while producing mCRP. The size exclusion eluted fraction at   ̴73 mL 
corresponded to remaining undissociated protein, whereas the eluted fraction at 89.9 mL 
represents the in vitro produced mCRP (see figure 4-5) based on the calibration graph 
equation. Consistent with the recent study by Williams study (Williams, 2017), this 
treatment results in dissociation of >95% of CRP into mCRP (see Figure 4-5). 
It is necessary to remove calcium to achieve a high dissociation yield (Kresl et al., 1998). 
Removal of calcium results in conformational changes within the protein structure, 
whereby a large loop, composed of residues 140-150, moves away from the body of the 
protein, revealing hidden sites susceptible to proteolysis (Ramadan et al., 2002). It is 
possible that these conformational changes as a result of calcium removal promote 
pentamer instability and weaken the interprotomer contacts making the protein more 
labile to urea treatment. 
Urea is a powerful denaturant, commonly used in proteomic studies due to its ability to 
interact with both polar and nonpolar groups (Rossky, 2008, Zou et al., 1998). It is accepted 
that the denaturation of proteins by urea occurs through the direct interaction between 
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urea and the protein backbone and/or side chains via hydrogen bonds and other 
electrostatic interactions. This interaction will weaken the internal hydrogen bonds and 
promote protein unfolding. Upon unfolding and intrusion of urea into the hydrophobic 
core, both urea and water solvate the exposed hydrophobic, polar, and the peptide 
backbone (Hua et al., 2008, Rossky, 2008). Another possible mechanism is that urea may 
exert its effect indirectly by disturbing the water shell around non-polar groups in the 
protein, thereby weakening the hydrophobic effect of these groups, inducing protein 
unfolding (Zou et al., 1998, Vanzi et al., 1998). Although the direct interaction mechanism 
is more widely accepted, it is also plausible that both mechanisms are operating (Stumpe 
& Grubmüller, 2007, Vanzi et al., 1998). It is unclear by which mechanism urea induces 
dissociation of CRP, and what the modifications that may have on the function and 
structure of this protein. CRP units are held together by electrostatic intersubunit 
interactions (that is, salt bridges and hydrogen bonds); (Shrive et al., 1996). These 
interactions between CRP protomers may be targeted by urea, causing dissociation. 
Dissociation of CRP with a high concentration of urea (8 M) results in a loss of the capacity 
of the protein for calcium-dependent binding to the C-polysaccharide (Potempa et al., 
1983). In contrast, mCRP produced from the treatment of the native pCRP with 3 M urea 
over 10 weeks retains its ability to bind phosphocholine (Williams, 2017). It is worth 
mentioning that once CRP dissociates into its monomeric form, is able to re-associate even 
in the presence of calcium (Williams, 2017), perhaps because the ability of urea to 
carbamylate the free amino groups of protein (N termini of proteins or the ε-amino group 
of lysine and arginine residues); (Sun, S. et al., 2014). It is possible that interprotomer 
contacts become carbamylated by urea, preventing reassociation of subunits. 
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4.4.2 Purification and isolation of CRP isoforms from human serum samples 
Purification of CRP from human serum was carried out by using affinity chromatography 
based on the calcium-dependent binding of CRP to phosphorylcholine (PC) that has been 
immobilised on the chromatography column (Volanakis et al., 1978). The serum 
components that are unable to interact with PC pass freely through the column as 
represented by a significant peak in figure 4-6. Since the binding of CRP to 
phosphorylcholine is calcium-dependent, its elution could be achieved merely by chelating 
the calcium with EDTA (Volanakis et al., 1978). Upon addition of EDTA, a smaller peak was 
observed, which correspond to PC-bound proteins including CRP. A number of other serum 
proteins are known to bind PC or to PC-bound CRP (Volanakis et al., 1978, Christner & 
Mortensen, 1994). However, the bulk of the peak is thought to represent CRP because the 
serum samples had high CRP content (>100 mg/L). Since the in vivo generated mCRP retains 
its specificity to bind PC (Williams, 2017), the affinity-purified samples should contain both 
monomeric and pentameric CRP. 
Size exclusion chromatography further purified the affinity eluted samples and is able to 
isolate the different forms of CRP based on their elution volumes. All the 24 patient serum 
samples produced a peak at an elution volume of ~72 mL (figure 4-7). Based on the results 
of column calibration, coupled with the results of SDS-PAGE of the eluted fractions (figure 
4-8), it was concluded that this peak corresponds to elution of pCRP. Furthermore, SDS-
PAGE established the purity of the eluted fractions, by producing a single band per tested 
sample, and hence the efficiency of the purification process. The chromatography trace in 
figure 4-7 is a typical example of that seen for most human serum samples. Besides the 
peak that corresponds to pCRP, additional smaller peaks were commonly observed. Peak 1 
in figure 4-7 was eluted before the column void volume, suggesting a molecule with a large 
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molecular size, which could be a protein complex or CRP aggregate. However, peak elution 
before the column void volume may also be as a result of a carryover from a previous run, 
although this is less likely as the column was washed adequately before and after each 
sample application. The other peak commonly observed was the peak at elution volume of  
 ̴110 mL, based on the calibration graph equation the elution volume of this peak (peak 3 
in figure 4-7) represent a protein with a molecular weight of 4.98 kDa. Similar to peak 1, it 
was unclear what peak 3 may represent, fractions correspond to these peaks (peak 1 and 
3 in figure 4-7) were not pursued through additional experimental analysis. 
Based on the size exclusion column calibration equation, in addition to the result of 
purification of the in vitro produced mCRP (figure 4-5), the mCRP is expected to elute at 
~90 mL, and the peak could extend for 10 mL volume. However, none of the purified 
samples produced a peak for mCRP. This failure to produce a peak on the chromatogram 
could be as a result of mCRP levels being below the limit of detection. Therefore, the 
fractions eluting between 85 to 95 mL were collected for each serum sample and tested 
regardless. 
4.4.3 Enzyme-linked immunosorbent assay of the purified serum samples 
ELISA was carried out on the size exclusion eluted fractions corresponding mCRP, as well as 
pCRP-containing fractions. The mean level of pCRP across all 24 diabetic serum samples 
was calculated to be 30.03 mg/L, with the lowest recorded pCRP value of 4.09 mg/L and 
the highest recorded value of 57.75 mg/L. The results of the ELISA quantification of pCRP 
indicates a significant loss of protein during the purification processes as compared to the 
initial sample concentrations where all samples were over 100 mg/L. This loss is primarily 
attributed to the purification process which included multiple chromatographic and 
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concentrating steps to isolate CRP isoforms. Another factor that may have contributed to 
this loss, although to a lesser extent, is the fact that the ELISA reading represented only the 
levels of the pCRP portion, excluding other CRP isoforms, aggregates, or CRP complexed 
with other proteins that have different elution volumes. Although some of the samples 
displayed more significant losses than others, it was expected to find a significant positive 
correlation between the initial CRP levels and the levels of the purified pCRP (Figure 4-11) 
because the majority of CRP is pentameric (native) isoform. Williams (2017) used a similar 
methodology to purify CRP isoforms from human serum samples with initial CRP values 
above 100 mg/L. The percentage of yield for pCRP in the Williams study were ranged from 
5-30% of the initial sample concentrations, indicating a large protein loss during the 
purification process (Williams, 2017). 
Despite the loss that has been seen with pCRP-containing samples, the ELISA analysis of the 
purified mCRP-containing samples shows a detectable level of mCRP across all 24 diabetic 
serum samples, see figure 4-13. The levels of mCRP ranged from 0.043 mg/L to 0.219 mg/L, 
with mean value of 0.093 mg/L. The literature suggests that mCRP produced in vivo could 
originate from dissociation of pCRP when it binds to damaged membrane surfaces such as 
apoptotic/necrotic cells (Gershov et al., 2000), activated platelets (Eisenhardt et al., 2009), 
circulating microparticles (Habersberger et al., 2012, Van der Zee et al., 2010), liposomes 
containing lysophosphatidylcholine (LPC); (Ji et al., 2007), and oxidised low-density 
lipoprotein (Chang et al., 2002). The dissociation requires binding of circulating pCRP to the 
bioactive lipid; LPC, expressed on the membrane surface (Wu et al., 2015, Eisenhardt et al., 
2009). However, the curvature of the membrane and the hydrophobic microenvironment 
were also found to be additional factors affecting the binding and dissociation process of 
pCRP (Ji et al., 2007, Wang et al., 2012). In addition to the dissociation of pCRP on the 
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damaged membrane surfaces, independent mCRP synthesis may also be another source of 
this form. The expression of CRP mRNA has been identified in various extra-hepatic cells 
including vascular smooth muscle cells in atherosclerotic plaque and human adipose tissue 
(Yasojima et al., 2001, Devaraj et al., 2003, Jabs et al., 2003). However, whether the CRP 
that is synthesised by extra-hepatic cells is processed into pCRP or expressed as mCRP 
remains unclear (Eisenhardt et al., 2009). In fact, CRP mRNA in U937 macrophages is 
translated into mCRP rather than pCRP (Ciubotaru et al., 2005). Furthermore, studies have 
also indicated that pCRP can spontaneously dissociate upon binding to a fixed surface such 
as an ELISA plate (Eisenhardt et al., 2011). However, in this work, the tested samples were 
purified CRP isoforms, separated according to size by size exclusion chromatography. 
The levels of circulating mCRP are significantly low compared to the pCRP level of the same 
serum sample, this is likely because of the limited solubility of this isoform, rendering it 
tissue based protein rather than soluble serum-based protein (Molins et al., 2011). Indeed, 
mCRP was not identified in the peripheral circulation until recently (Habersberger et al., 
2012). In Habersberger et al.; (2012) study, the mCRP was qualitatively identified, by flow 
cytometry, on circulating microparticles of patients with acute myocardial infarction (AMI) 
(Habersberger et al., 2012). Another study by Wang et al.; (2015), the researchers were 
able to quantitatively identify mCRP in the plasma of the patients with AMI by using a 
monoclonal antibody specific for mCRP (Wang et al., 2015). However, Wang et al. did not 
give details of whether the circulating plasma mCRP reflects free mCRP or mCRP complexed 
with microparticles (Wang et al., 2015). The methodology used in this study included 
purification of CRP isoforms through both affinity and size exclusion chromatography 
before quantification by ELISA, suggested that the identified mCRP is a soluble free 
circulating form with a molecular size consistent with the size of a single monomer of CRP, 
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as demonstrated by intact mass analysis, see figure 4-15. The methodology used also shows 
that the circulating mCRP retains its ability to bind PC, which is consistent with the previous 
findings by Williams (Williams, 2017). 
The average value of mCRP determined in this study was considerably higher than those 
reported by Wang et al., where the mean level of mCRP in AMI group (n=101) was found 
to be 0.021 mg/L and significantly higher than the control group (Wang et al., 2015). In 
Wang et al. study, the pCRP levels of the analysed samples fall between 1.9-7.9 mg/L (Wang 
et al., 2015). In our study, however, only the patients with a high level of pCRP (>100 mg/L) 
were enrolled. Despite no correlation being found between pCRP and mCRP levels (as 
shown in Figure 4-14), it is still possible that the higher levels of pCRP result in increasing 
the chance of pCRP binding to the exposed bioactive lipid present on the surface of 
damaged membranes and microparticles, a process which is necessary for the conversion 
of pCRP to mCRP (Eisenhardt et al., 2009, Habersberger et al., 2012). In agreement with 
this assumption, Wang et al. study show that a proportion of patients with high pCRP levels 
(six patients out of 42 with a pCRP level ranged between 3-285 mg/L) displayed increased 
mCRP levels (Wang et al., 2015). In another study, Moran tested the presence of mCRP in 
the serum of patients with rheumatoid arthritis (RA) using a specific anti-human mCRP 
detection antibody (Moran, 2018). The results of mCRP in diabetic patients are comparable 
to those in RA patients of Moran’s study, where the mean level of mCRP in RA group was 
0.092 mg/L (range between 0.053 mg/L to 0.133 mg/L, n=30) with a significant difference 
from the healthy control participant (Moran, 2018). It worth mentioning that the average 
pCRP levels in the RA group of Moran study were also higher than the AMI group in Wang 
et al. study (22.85 mg/L vs 3.6 mg/L). On the other hand, the level of circulating mCRP 
determined in our study was considerably lower than the higher range reported by 
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Williams, who demonstrated mCRP levels fall between 0.04 mg/L and 3.52 mg/L in 40 
participants identified with high sera pCRP levels (>100 mg/L). The mCRP within Williams’ 
study was purified using the same methodology used in our study however, the underlying 
pathology of the enrolled participants was not known (Williams, 2017). 
Inflammation is the feature uniting the studies of mCRP in the circulation. Numerous 
studies hypothesised that chronic low-grade inflammation plays a role in the pathogenesis 
of both type 1 and type 2 diabetes, and moderately increased levels of serum CRP are found 
in both types of diabetes (Schalkwijk et al., 1999, Kilpatrick et al., 2000, Pickup & Crook, 
1998, Duncan et al., 2003). The increased levels of serum CRP in diabetes are not caused 
by the development or presence of microvascular complications but might precede these 
(Schalkwijk et al., 1999, Chase et al., 2004). Hyperglycaemia itself or through the formation 
of AGE are known to stimulate the release of the inflammatory cytokines including TNF-α 
and IL-6 from adipocytes, monocytes and other cells. These released cytokines, in turn, can 
affect the production of CRP in the liver (Ingle & Patel, 2011, Goh & Cooper, 2008). 
Moreover, diabetic individuals are at high risk of developing other inflammatory conditions 
including atherosclerosis and heart disease correlated to high levels of CRP (Messier et al., 
2004, Lee et al., 2015). Endothelial dysfunction and platelet activation together with 
increasing circulating microparticles are a common pathological features found in diabetic 
patients (Ingle & Patel, 2011, Ouviña et al., 2001, Tramontano et al., 2010), and are known 
to dissociate CRP, and may be responsible for the mCRP occurring in these patients 
(Habersberger et al., 2012, Eisenhardt et al., 2009). The resulting mCRP can mediate actions 
that are different from that produced by pCRP through activation of FcγRIII or integration 
into the lipid raft domain through a putative cholesterol binding domain that is hidden in 
the pentameric isoform (Ji et al., 2009, Khreiss et al., 2004). mCRP can induce pro-
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inflammatory effects on cells such as monocytes and endothelial cells. More specifically, 
mCRP has been shown to bind principally to the apical of endothelial cells surfaces that are 
enriched in lipid raft domains, promoting the release of proinflammatory cytokines, 
generation of reactive oxygen species, and adhesion molecule expression (Ji et al., 2009, Li 
et al., 2014). Crawford et al. (2016) suggest that mCRP mediates chronic inflammation by 
modulating the polarisation of monocytes and T lymphocytes migrating across the 
endothelial layer, promoting a Th1 response and M1 macrophage differentiation (Crawford 
et al., 2016). 
It was expected to find a positive correlation between mCRP and pCRP levels. However, the 
results show that mCRP does not correlate with pCRP levels with, an uneven distribution 
throughout the cohort. Several samples show higher levels of mCRP regardless of their 
pCRP levels as compared to other samples in the cohort. It is possible that these 
participants have one or more other underlying conditions or undiagnosed disease which 
account for an independent increase of mCRP form. Diabetes mellitus is usually 
complicated by other conditions, such as obesity, dyslipidemia, chronic kidney disease, 
cardiovascular disease and others conditions, which may play a leading role in providing 
the essential or synergistic conditions that enhance the conversion of pCRP to mCRP or 
possibly the expression of mCRP rather than pCRP. Moreover, in this work, only diabetic 
patients with raised levels of pCRP have been enrolled (>100 mg/L), suggesting the 
presence of underlying acute inflammation or infectious diseases in those patients. 
The absence of correlation between the circulating mCRP and the native pCRP was also 
reported in RA patients (Moran, 2018). In data published by Crawford et al. (2016), the 
circulating mCRP-bearing microparticles were also found not correlated to circulating pCRP 
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levels but strongly correlated with the amount of low-density lipoprotein cholesterol in 
patients with peripheral artery disease (Crawford et al., 2016). Another study by Schwedler 
et al. (2003) shows increased tubular mCRP staining with declining renal function and the 
severity of the histological lesions in patients with diabetic nephropathy. However, no 
correlation was evident between the tubular mCRP staining and serum levels of CRP 
(Schwedler et al., 2003), while in Wang et al. study, the circulating plasma mCRP levels were 
higher in deceased AMI patients than in living patients (Wang et al., 2015). In diabetes 
mellitus, the levels of mCRP could be also correlated to the prognosis and complications 
associated with diabetes mellitus rather than the pCRP levels. However, it must mention 
that the small sample size of the study and the protein loss during the purification process, 
which could be uneven through the samples, could also affect the correlation between 
mCRP and pCRP levels. 
Due to the potential for CRP losses during the purification process, the results of ELISA 
quantification of mCRP purified from diabetic serum samples could reflect mCRP lower 
than the actual levels in patient serum. Furthermore, the measured mCRP levels in this 
study represent the free unbound mCRP and did not count the mCRP bound to molecules 
such as MPs which could be lost during the chromatographic steps. 
4.4.4 Investigation of the glycated form of CRP using mass spectrometry 
Mass spectrometry has been used to investigate the presence of a glycated form of CRP in 
serum samples of diabetic patients. The investigation was carried out at the intact level of 
the protein with LC-MS and the peptide level with LC-MSMS. The results of intact mass 
analysis of all 24 human serum samples fail to show any evidence of glucose condensation 
on the protein in the form of mass increment of 162 Da per each attached glucose 
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molecule. Although the result of our in vitro study shows that CRP treated with 30 mM of 
glucose for a period equal to the half-life of the protein result in the formation of a mono-
glycated isoform of CRP (see Figure 2-6). However, the stoichiometry of the reaction was 
low, where only 3.7% of the treated protein was mono-glycated isoform (see figure 2-9). 
The glucose concentration, even in the poorly controlled diabetic patients, is typically 
rather lower than 30mM, suggesting that the in vivo glycation processes of CRP is too low 
to induce a peak corresponding to glycated CRP isoform. 
We have extended our investigation with trypsin and Glu-C enzymatic digestion of CRP 
containing samples with subsequent bottom-up tandem mass analysis of the resultant 
digestion products. Mascot search of the collected data against the customised database 
(comprising the CRP sequence and common laboratory-observed contaminants) and the 
manual inspection of the product ion spectra of the unmatched peptides could not identify 
any possible glycated peptide. The results of bottom-up tandem mass analysis of CRP from 
diabetic serum samples are consistent with our results of in vitro experiment; where the 
CRP incubated with glucose concentrations less that 100 mM for a period equal to the 
protein half-life in the circulation fail to show detectable glycated CRP peptides by tandem 
mass spectrometry (see table 3-4). However, when the incubation times were increased 
into three days, even with 30 mM of glucose, a single glycated peptide with glycation 
assigned to K13 was identified (see table 3-4). The glucose concentrations in diabetic 
patients and the exposure time of CRP to glucose which is limited by its half-life in vivo 
(Vigushin et al., 1993), were not enough to produce a detectable level of a glycated isoform 
of CRP.  
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Glycation reactions are, in general, relatively slow (Zhang et al., 2008). Kinetic experiments 
on glycation of human serum albumin with glucose showed that the rate of formation of 
the Amadori product is 0.25% of the protein per day for each 1 mM of glucose (Baynes et 
al., 1984), thus for the levels of glucose in well-controlled diabetes patients (<7.8 mM); 
around 1.9% of an individual protein could be glycated per day, so the longer the half-life 
of the protein the greater extent of glycation (Austin et al., 1987). The rate of glycation is 
not consistent for different proteins; the rate of haemoglobin glycation is much slower than 
that of albumin (Garlick & Mazer, 1983), while complement C3, despite a short half-life of 
2-5 days, shows moderate glycation as a result of its high intrinsic propensity for glycation 
(Austin et al., 1987). For CRP, 3.7% of the protein is glycated in vitro when incubated at 30 
mM glucose for 19h. If we hypothesise a linear relationship between the glucose 
concentration and extent of glycation of CRP, then <1% of the circulating CRP could be 
glycated in vivo when exposed to glucose levels of well-controlled diabetes patients 
(<7.8mM). This percentage (<1%) leads to a relatively small amount of glycated product 
when considering the low circulating concentration of CRP compared to other proteins 
such as albumin or complement C3 (Jolliff et al., 1982).  
Another possible reason for the failure to detect glycated CRP in the serum of diabetic 
patients is the significant CRP loss after the purification prosses. The results of ELISA 
quantification of the pCRP fractions showed a significant protein loss post-purification 
compared to the initial serum samples concentration (see appendix 4). This loss is primarily 
due to the multiple chromatographic and concentrating steps to isolate the CRP isoforms. 
Furthermore, CRP might be lost during the purification process due to its binding to serum 
microvesicles (Tendler et al., 2018, Van der Zee et al., 2010). Serum microvesicles such as 
microparticles (small vesicles, with a diameter of 100–1000 nm, released from cells by 
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shedding) and exosomes (smaller membranous-derived vesicles secreted from intracellular 
multi-vesicular bodies and range in size from 30 to 90 nm) are known to contain substantial 
amount of CRP, where CRP bound to its natural ligand on the surface of these circulating 
microvesicles (Tendler et al., 2018, Van der Zee et al., 2010). The ligand-bound CRP on the 
surface of microvesicles will resist the purification process as it cannot bind to the PC-
bound affinity column, therefore, will be lost during the affinity chromatography step. 
Another possible reason for failure to detect glycated CRP is that the glycation itself might 
affect the ability of CRP to bind to the PC-bound affinity column, however, this is less likely 
because the putative glycation sites, as determined in the in vitro glycation trails, were not 
involved in the phosphocholine binding site of CRP. 
The short half-life of CRP in vivo, the glucose level in diabetic patients, the low abundance 
of CRP in serum compared to other proteins, and protein loss during the purification 
process may cumulatively account for CRP glycation remaining undetected. 
4.4.5 Conclusion 
To our knowledge, there are no studies investigated the presence of modified forms of CRP 
(monomeric and/or glycated) in the serum of the patients with diabetes mellitus nor have 
quantified their presence. In the work described in this chapter, we demonstrate the 
presence of a freely circulating form of mCRP in the serum of diabetic patients with 
elevated levels of CRP. The identified mCRP has been demonstrated to be 23k Da in size via 
size exclusion chromatography and mass spectrometry. Furthermore, the circulating mCRP 
showed the ability to interact reversibly with phosphocholine, the natural ligand of pCRP, 
and this consistent with the recent finding of Williams (Williams, 2017). Both type 1 and 2 
diabetes showed detectable levels of mCRP with no significant difference between the two 
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groups. However, due to the small sample size, especially with type 1 diabetic group, it was 
difficult to draw a conclusion and predict whether this finding would be observed within 
the larger population. mCRP showed broad range of values among the patients. Moreover, 
the circulating mCRP were not correlated with the pCRP level; while the same result was 
found in other studies (Crawford et al., 2016, Schwedler et al., 2003), the absence of 
correlation suggests that mCRP levels could be correlated to the diabetic complications or 
other underlying conditions that the patients may have rather than the pCRP itself. 
We also investigated the presence of a glycated form of CRP in the serum of diabetic 
patients. We were unable to identify evidence for the presence of a glycated isoform in the 
serum of diabetic patients. While our in vitro study showed that CRP could be glycated after 
a 19h incubation period, the stoichiometry of the reaction was low, and glucose 
concentrations higher than those found in diabetic patients are required to produce a 
detectable level of glycated CRP isoform. The exposure time of CRP to glucose in vivo is 
limited by its half-life which is not enough to produce a detectable level of glycated CRP at 
glucose level of diabetic patients. This agrees with the results of the in vitro glycation trials 
where a longer incubation times or higher glucose concentrations are required to produce 
a detectable glycated CRP.  
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Chapter 5: Discussion, Conclusion and Future Work 
5.1 Overview 
C-reactive protein is an acute phase protein that has long been employed in clinical practice 
as a marker for the presence of infection, inflammation, or tissue damage, with plasma 
levels increasing from baseline 1-2 mg/L to up to 1000 fold in the presence of inflammation 
(Ablij & Meinders, 2002, Hirschfield & Pepys, 2003). It is believed that elevated baseline 
levels (>1-2mg/L) can be a reliable indicator of the development of CVD (Pepys & 
Hirschfield, 2003). Increased baseline CRP levels have been linked to an increased risk of 
thrombotic events, including myocardial infarction (Ridker et al., 2001, Kervinen et al., 
2001), and an increased risk of later development of diabetes (Barzilay et al., 2001, Pradhan 
et al., 2001). Furthermore, CRP levels are higher in people with diabetes compared with 
those without diabetes (Ford, 1999, Goldberg, 2000). Recent evidence suggests that CRP 
can dissociate to its monomeric subunit under physiological conditions after binding to the 
cell membrane (Ji et al., 2007, Eisenhardt et al., 2009). The dissociation has been linked 
with pro-inflammatory processes and the progression of the pathology commonly 
observed in inflammatory diseases (Wang et al., 2015, Zhang et al., 2012). Furthermore, 
the high level of glucose associated with diabetes mellitus results in glycation of serum 
proteins to varying extents, based on their half-life and glycability (Austin et al., 1987). 
Protein glycation adversely affects the normal molecular structure, function and/or half-
life (Brownlee, 2000, Cloos & Christgau, 2002, Stern et al., 2002). 
The two main aims of this research were to investigate the susceptibility of CRP to glycation 
in vitro and to clarify whether glycated and monomeric forms of human CRP were present,
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detectable and quantifiable within serum samples obtained from participants with 
diabetes mellitus. The research presents experimental evidence contributing to a greater 
understanding of CRP isoforms within the human body. 
5.2 Production & characterisation of in vitro glycated CRP 
Protein glycation has been recognised as an important post-translational modification due 
to its impact on the structure and consequent potential to alter the physical and functional 
properties of the protein and its physiological effects (Rondeau & Bourdon, 2011, McCarthy 
et al., 1998, Hunter et al., 2003). To our knowledge, no studies have been conducted so far 
to illustrate the effect of this reaction on CRP. The findings presented in chapters 2 and 3 
of this thesis shed light on CRP glycation in vitro with regard to the degree of glycation with 
different glucose concentrations and incubation times, the putative glycations sites, the 
microenvironment of the potential glycation sites (pKa, FAS, nearby acidic and basic 
residues), and the most susceptible residues toward glycation. 
To elucidate susceptibility of CRP toward glycation with glucose, CRP was exposed to 
different concentrations of glucose (30-1000 mM) for periods ranging from 19 h to 6 days, 
at 37 °C and pH 7.4. The glycation reaction was monitored by mass spectrometry as a 
function of a net increase in the mass of intact protein due to the addition of glucose, a 
principle that has been utilised in several previous studies dealing with the analysis of 
protein glycation by mass spectrometry (Farah et al., 2005, Lapolla et al., 1993, Goodarzi et 
al., 2004). The results of this in vitro study showed that CRP could be glycated, and higher 
states of glycation (number of attached glucose/CRP molecule) can be achieved with higher 
glucose concentrations as well as longer incubation times. Most importantly, CRP exposed 
to 30 mM glucose for a period equal to its half-life in vivo resulted in formation of a mono-
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glycated isoform. While this glucose level (30 mM) is still far from the normal physiological 
levels, or the levels in well controlled diabetic patients, it is not uncommon to find such 
glucose levels in poorly controlled diabetic patients (McCarthy et al., 1998). Identifying 
mono-glycated isoforms when treating CRP with 30 mM glucose for 19 h suggests the 
possibility of CRP glycation in patients with poorly controlled diabetes. However, based on 
the peak intensities of the MS spectra, the stoichiometry of the reaction is relatively low, 
where only 3.7% of the protein is estimated to be glycated. It is less likely that this degree 
of glycation could influence the biological functionality of CRP mainly because of the short 
exposure time of the protein to the glucose in vivo (Vigushin et al., 1993). Further glycation 
of CRP could be achieved, during the period of the protein half-life, by exposing the protein 
to higher glucose levels; increasing the glucose concentration beyond 30 mM results in a 
parallel increase in the extent of glycation to reach 48.8% of the unmodified protein when 
exposed to 1 M glucose level. It was observed that CRP favours the formation of mono-
glycated isoform despite increasing the glucose concentration to 1 M and extending the 
exposure time to 3 days, while other glycated isoforms with multiple condensed glucose 
molecules were also detected, their intensities were lower compared to mono-glycated 
CRP. When the incubation time was further increased to 6 days, a shift in the distribution 
of CRP glycoforms toward the highly glycated forms was observed in parallel with the 
increase in glucose concentration. Almost all the protein (97.6%) was glycated when 
exposed to 1 M glucose for 6 days, with an average of 3.6 glucose molecule/ CRP molecule, 
distributed between a mixture of species with varying glycation levels ranging from mono-
glycated to octa-glycated variants. It is clear from the result of this study that CRP glycation 
could be detected on the intact protein by mass spectrometry, which offered a direct and 
reliable approach for monitoring CRP glycation and provides an image of sample 
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heterogeneity. The results of this study also show that with increased concentration of 
glucose and incubation time, both the extent of CRP glycation and site occupancy increase. 
To elucidate the putative glycation sites, we have extended our study with trypsin and Glu-
C enzymatic digestion of the in vitro glycated CRP samples with subsequent bottom-up 
tandem mass spectrometric analysis of the resultant digestion product. In agreement with 
a previous study (Taylor & Van Den Berg, 2007), CRP was found to be relatively resistant to 
enzymatic digestion; additional denaturation steps, higher CRP: enzyme molar ratio and 
longer incubation times with proteases were required to improve its degradation. Tandem 
mass analysis of the in vitro glycated CRP samples, by Q-TOF, produced characteristic 
fragmentation spectra for glycated peptides as a result of multiple neutral losses from the 
glucose-containing parent and product ions. This phenomenon has been reported 
previously with other glycated peptides analysed by CID (Lapolla et al., 2004, Frolov et al., 
2006, Mennella et al., 2006). The most common and intense ions detected in the MS/MS 
spectra of the glycated peptides were those arising from neutral loss of 3 H2O (pyrylium 
ions) and 3 H2O + HCHO (furylium ions) from the glycated parent and fragment ions, 
observations of these ions was strongly suggestive of the presence of a glycated peptide. 
The neutral loss signals in the product ion spectra of the glycated peptides were associated 
with weak or even undetectable glycated b- and y-ions which in turn result in an ambiguous 
assignment of the modified amino acid residue by Mascot, especially when multiple 
potential glycation sites were present on the glycated peptide.  
Ambiguous modification site assignment by Mascot was revised and augmented by manual 
interpretation of the signals arising from successive neutral losses, including the strong 
pyrylium and furylium signals. Identifying the glycated peptide using Mascot followed by 
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manual interpretation/validation of the product ion spectrum allowed identification of the 
majority of the peptide backbone ions and positive demonstration of the site of 
modification. Furthermore, all peptides which Mascot failed to match were considered as 
possible glycated peptides and interpreted manually. The robust methodology used in this 
study allowed identification of three glycation sites in CRP preparation exposed to 1 M 
glucose for 19 hours these are K13, K57 and K69, in addition to one glycation sites among 
six possible residues within the peptide FWVDGKPRVRKSLKKGYTVGAE. Occupation of the 
same glycation sites was also observed after increasing the incubation time to 3 and 6 days, 
suggesting that these residues are favourable glycation sites at this glucose concentration. 
After 3 days of incubation with 1M glucose, K191 (also seen after 6 days) and K23 were 
modified, while K201 and two residues of the peptide FWVDGKPRVRKSLKKGYTVGAE were 
observed as being modified but after 6 days of incubation. This finding suggests that 
glycation is not randomly occurring, and the free amino groups of CRP differ in their rates 
of glycation (Zhang et al., 2008). All the identified glycation sites were lysine residues, and 
the common feature between the glycated lysines is the proximity to an acidic residue, 
principally situated C-terminally. For the most reactive lysine residues that have been 
detected after 19h of incubation (i.e. K13, K57 and K69); the distance between the ε-NH+ 
group of the glycated residue to the nearest carboxylate group was < 3.6 Å. Positively, the 
number of glycation sites identified in vitro glycated sample by tandem mass spectrometry 
is comparable to the number of condensed glucose molecules on the intact protein as 
determined by mass spectrometry. Among the identified glycation sites, K201 is involved 
in a salt bridge with E101 from the next protomer (Shrive et al., 1996); thus its glycation 
could affect the structure of pCRP. We were unable to precisely specify which residues in 
FWVDGKPRVRKSLKKGYTVGAE are glycated due to the limited sequence information in the 
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fragmentation spectrum, as a result of neutral losses and the localised high positive charge 
density in the middle of the peptide whic further affects its fragmentation (Xue et al., 2015). 
Based on the combined contribution of pKa and FAS to the lysine microenvironment, K114 
has the highest probability of being modified compared to other possible glycation sites in 
FWVDGK14PRVRKSLKKGYTVGAE. Moreover, the proximity of D112 to K114 in the primary 
sequence can accelerate the Amadori rearrangement by accepting the proton from the 
Schiff base (Rabbani et al., 2016). K114 is part of putative C1q-binding site of CRP and play 
a role in modulating the reactivity of CRP with C1q (Agrawal et al., 2001, Agrawal & 
Volanakis, 1994). Thus, K114 glycation could have an impact on the CRP function. It was 
observed that K13 is the most reactive residue toward glycation compared to other 
identified glycation sites in CRP; K13 was the only modified residue in CRP exposed to 100 
mM of glucose for 19 h. CRP incubated at glucose levels less than 100 mM for 19 h showed 
no evidence of glycation, suggesting that the extent of glycation was insufficient to be 
detected by tandem mass analysis. 
5.3 Analysis of human diabetic serum samples 
Serum samples were obtained from 24 participants with diabetes. These were tested for 
the presence of a monomeric and glycated form of CRP. All the tested samples were with 
high levels of pCRP (>100 mg/L) in order to maximise the chance of identifying CRP isoforms 
in the serum. A detectable level of mCRP was found across all the tested samples which 
included both type 1 and type 2 diabetes patients. To our knowledge, this is the first report 
for the presence of mCRP in the serum of diabetic patients, and one of the few studies of 
identifying a soluble circulating form of mCRP (Williams, 2017, Wang et al., 2015, Moran, 
2018). The result of this study is consistent with the previous findings, providing further 
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proof of the presence of a soluble circulating form of mCRP. A previous study by Wang et 
al. (2015) reported the presence of mCRP in the plasma of patients with myocardial 
infarction (Wang et al., 2015); likewise, more recent work by Moran detected mCRP in the 
serum of patients with rheumatoid arthritis (Moran, 2018). Both studies considered a 
specific anti-human mCRP antibody for detection. However, this raises a question of 
whether the identified mCRP is circulating free within the serum or bound to microparticles 
(Habersberger et al., 2012). In this work, mCRP was purified from serum by affinity and size 
exclusion chromatography before quantification by ELISA, thus confirming that the 
identified mCRP is a freely circulating isoform with reactivity against CRP antiserum, and 
molecular size of 23 kDa as further shown by intact mass analysis. The methodology used 
in our study to purify mCRP was adapted from Williams (2017) who identified the presence 
of mCRP in the serum of the patients with raised levels of CRP and unknown underlying 
disorders (Williams, 2017). In agreement with the Williams study (Williams, 2017), mCRP 
shows the ability to bind to PC, which further contributes towards the evidence supporting 
the ability of mCRP to bind to PC-containing cell membranes in vivo (Habersberger et al., 
2012, Eisenhardt et al., 2009). The monoclonal anti-CRP antibody (clone 8) used in the ELISA 
experiment was able to detect both mCRP and pCRP isoforms; therefore attention must be 
considered when explaining the results of standard ELISA tests or the automated systems 
used in clinical practice for measuring serum CRP levels, as they are likely unable to 
distinguish between the two isoforms (Williams, 2017). The literature suggests a pro-
inflammatory role for mCRP (Eisenhardt et al., 2009), with others suggesting increased 
levels of mCRP is related to the disease progression as in myocardial infarction (Wang et 
al., 2015), and diabetic nephropathy (Schwedler et al., 2003), therefore, distinguishing 
between the two isoforms is important and may result in better understanding of the 
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patient condition. No correlation was found between mCRP and pCRP levels in patients 
with diabetes mellites. The lack of correlation was also reported by other studies (Moran, 
2018, Schwedler et al., 2003, Habersberger et al., 2012), suggesting that other underlying 
conditions or undiagnosed disease may account for an independent increase of mCRP 
levels in some patients either through enhancing the conversion of pCRP to mCRP or 
increasing the expression of mCRP rather than pCRP. It was found that mCRP levels 
correlated more with the severity of the clinical condition rather than pCRP level. 
(Schwedler et al., 2003, Wang et al., 2015). 
The levels of mCRP determined in this study may represent lower than the actual levels in 
serum, this is because there is a potential for mCRP loss through the methodology used 
which involved several chromatographic and concentration steps. Furthermore, the mCRP 
measured in this study represent the freely soluble mCRP in serum and not counting the 
ligand-bound mCRP on the surface of circulating microvesicles such as MPs, which 
preferably lost during the purification process. 
Mass spectrometric analysis of pCRP failed to identify a glycated isoform of the protein in 
the serum samples of diabetic patients, suggesting that any in vivo glycation of CRP is too 
low abundance to be detected by the methods/instrumentation used in our study. Our in 
vitro experiments reveal that the stoichiometry of the glycation reaction is likely to be low 
during the period of the protein half-life in the serum. The short half-life of the protein and 
the relatively low quantity of pCRP in the serum compared to other protein in the serum, 
besides the significant loss of the protein post purification process may account for lack of 
detection of glycated CRP in the serum of diabetic patients. 
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5.4 Conclusion and Future Work 
The research described here, using ELISA and mass spectrometry, provides experimental 
evidence for a monomeric form and possibility of a glycated form of human CRP. The 
evidence from the in vitro glycation experiments implies the possibility of CRP glycation in 
patients with poorly controlled diabetes; however, at low stoichiometry and abundance, 
this could limit their detection. It is less likely that this degree of glycation influences the 
biological functionality of CRP in vivo. The glycation of CRP residues was not a random 
process; K13 was found more reactive for glycation when the glycating agent was reduced 
gradually in the reaction mixture. The reactivity of CRP lysine was found to be in the 
following order; K13> K57, K69 and one residue in the 109-130 peptide> K191 and K23> 
K201 and one residue in the 109-130 peptide. 
Based on the evidence of the in vitro glycation experiments, the failure to identify a 
glycated CRP in the serum of diabetic patients is the short half-life of CRP in vivo, which is 
insufficient to produce detectable levels of glycated CRP at glucose level of diabetic 
patients. The significant loss of protein during the purification process could be an 
additional reason for this failure. Additional future work on CRP glycation in the serum of 
diabetic patients should involve fewer purification steps and the use of multiple reaction 
monitoring (MRM) on triple quadrupole (QqQ) for more selective, and sensitive detection 
of glycated peptides in the serum. More, having a method to glycated CRP in vitro and 
hence a potential method for generating polyclonal antibodies against glycated CRP, could 
enable specific ELISA and other methods to be developed. 
The present study provides evidence for the presence of a freely circulating form of mCRP 
in the serum of diabetic patients (type 1 and 2) with elevated levels of CRP, thus adding to 
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the growing body of literature on the existence of serum mCRP. The molecular weight of 
mCRP was determined in this study by mass spectrometry and found to be consistent with 
the mass of CRP subunit. The levels of mCRP in diabetic patients were quantified and found 
not correlated to pCRP levels suggesting additional factors cause an independent increase 
of mCRP either through enhancing the conversion of pCRP to mCRP or increasing the 
expression of mCRP rather than pCRP. Factors such as diabetic complications, obesity, 
HbA1c levels, drug treatment or other underlying conditions may affect the levels of mCRP 
in diabetic patients; however, this research did not incorporate ethical approval for the 
correlation of mCRP with these factors. Also, the small sample size in this research did not 
allow reliable comparison between both types of diabetes. Future research should address 
these limitations. It is essential to determine what are the baselines levels of mCRP in larger 
group of population and what factors are involved in its rise in concentration. Furthermore 
what do the increased levels of mCRP correspond to, this lack of understanding, and the 
implications of the roles of mCRP in various pro-inflammatory scenarios, necessitates 
similar and further studies on mCRP. 
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PATIENT INFORMATION SHEET 
Study Title: < Modifications to C-reactive protein in Diabetes Mellitus >. 
 
Invitation 
You are being invited to consider taking part in the research study <Modifications to C-reactive 
protein in Diabetes Mellitus >. This project is being undertaken by <Dr A Shrive, Mr S. Mahmood, 
Dr S. Hart, Prof T. Fryer and Prof T Greenhough>. 
 
Before you decide whether or not you wish to take part, it is important for you to understand why 
this research is being done and what it will involve for you. One of the research team will go through 
the information sheet with you and will answer any questions you may have. We expect this should 
take no more than 15 minutes. If you are happy to participate we will ask you to sign a written consent 
form to acknowledge this. 
 
Aims of the Research 
The high blood sugar of patients with diabetes can cause sugar molecules to attach to proteins in a 
process called glycation. This happens to the protein, haemoglobin, which helps doctors assess how 
well controlled the diabetes is. We are interested in C-reactive protein (CRP). CRP is a protein which 
the body produces to help respond to infection and inflammation. Glycation of CRP is a neglected 
area of research and we aim to learn more about the role and consequences of glycation of CRP. The 
study will also aim to look in blood samples for the existence of a specific version of CRP known as 
monomeric CRP within the blood of patients who have already been identified as having high levels 
of CRP during routine blood tests. There is evidence suggest that this form of CRP may cause 
increased inflammation and the current blood tests for CRP do not include this version of the protein 
in their measurements. We therefore want to analyse blood samples for the existence of these possible 
modified forms of this protein. 
 
Why have I been invited? 
You have been invited to take part in this study because you have diabetes and your routine blood 
test has shown raised CRP levels. We aim to recruit 40 people. We would like to use the blood sample 
that is left over the following completion of your routine blood tests so the sample taken will be the 
sample normally taken for your routine blood tests and there will be no need to collect any extra 
blood from you. 
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Do I have to take part? 
You are free to decide whether you wish to take part or not. If you do decide to take part you will be 
asked to sign consent form and you should keep this information sheet for future reference. You are 
free to withdraw from this study at any time and without giving reasons, your sample and consent 
form will be destroyed immediately. Your medical care will not be affected in any way by this study. 
 
 
What will I have to do if I take part? 
You will not need to do anything other than sign the consent form. If you decide to take part you 
will: 
 
i. Agree to read through, sign and date our participant consent forms (2x copies) 
ii. Agree for us to use any leftover blood taken from your routine blood test procedure (that 
would normally be discarded), in order to test for other versions of CRP. 
You will not be required to undergo any procedure that is not already part of your routine clinical 
care at the hospital. This will complete your role within the study. 
 
What are the benefits (if any) of taking part? 
We don’t expect any direct benefit to you from taking part in this study. However, in the long run, 
the results obtained from the study will help us to determine whether different versions of CRP are 
present within the blood of people with diabetes and if any of these forms have any relationship with 
diabetes and its complications. 
 
What are the risks (if any) of taking part? 
Since you will not be required to undergo any procedure that is not already part of your routine 
clinical care at the hospital, we do not expect any or risks over and above that of normal clinical 
practice. 
Your name will be included in the consent form, but all other study information and data will be kept 
anonymised, confidential, and secure. You will be never identified by name in any communications 
or publications arising from this research. 
 
How will information about me be used? 
If there is any blood remaining after your routine blood tests it will be stored and sent to structural 
biology research group at Keele University. It will then be used by the Research Team to test 
experimental new blood tests for detecting different versions of CRP. We will not use these samples 
to test for anything that does not directly relate to this project. Once the study is completed, blood 
samples will be transferred back to the hospital and disposed off using the normal procedures. Your 
sample will remain anonymised and you will never be identified in any communications or 
publications from any research. Information generated from this study will be included within the 
thesis write up by Mr Sameer Mahmood, PhD student at Keele University, and any associate research 
publications. 
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Who will have access to information about me? 
Individuals who have taken part will not be identifiable in any way. All samples will be anonymised 
by a research team member at the University Hospital of North Midlands (UHNM). Each sample 
will be given a specific sample code at UHNM and then transferred to Keele University for analysis. 
Research team members at Keele University will therefore be unable to identify any patient samples. 
The reported results will be stored on a password protected computer database or in locked filing 
cabinets which only the research members have access to. 
 
Who is funding and organising the research? 
The project is funded by Keele University and under the supervision of Dr Annette Shrive. Her co-
investigators are Mr. Sameer Mahmood, Dr Sarah Hart, Prof T Greenhough (Keele University) and 
Prof T. Fryer (University Hospitals of North Midlands) and the laboratory test will be conducted at 
Keele University. 
 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you may wish to speak to the researchers who 
will do their best to answer your questions (contact details on the next page). 
If you remain unhappy about the research and/or wish to raise a complaint about any aspect of the 
way that you have been approached or treated during the course of the study please write to Dr Clark 
Crawford who is the University’s contact for complaints regarding research at the following address:- 
 
Dr Clark Crawford 
Head of Research and Clinical Governance 
Directorate of Engagement and Partnerships 
Innovation Centre 2 Building 
Keele University 
ST5 5NH 
E-mail: research.governance@keele.ac.uk 
Tel: 01782 733371 
 
Contact for further information 
Patients can contact the Patient Advise and Liaison service (PALS) by telephone on 01782 
676450/676455 or via e-mail to patient.advice@uhns.nhs.uk for an independent contact point where 
they can seek general advice about taking part in research. In addition, for further information about 
this study, patient can also contact the researcher listed below. 
 
 
Mr. Sameer M Mahmood Dr. Annette Shrive 
Postgraduate researcher Structural Biology Researcher and Senior 
Lecturer 
Huxley building, Keele university Huxley building, Keele university 
Keele Keele 
ST5 5BG ST5 5BG 
s.m.mahmood@keele.ac.uk a.k.shrive@keele.ac.uk 
Tel: 01782 734441 Tel: 01782 733419 
 
Thank you for your time reading this information sheet and for considering taking part in 
this study, please keep this information sheet for your records. 
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University Hospitals of North Midlands 
The Royal Stoke University Hospital 
Newcastle Rd, 
Stoke-on-Trent, 
Staffordshire 
ST4 6QG 
01782 715444 
 
PATIENT CONSENT FORM 
Title of Project: Modifications to C-reactive protein in Diabetes Mellitus 
 
Name and contact details of Principal Investigator: Prof Anthony A Fryer, 
 Professor of Clinical Biochemistry, 
 Department of Clinical Biochemistry 
 University Hospital of North Midlands 
 Tel: 01782 674245 
 Anthony.Fryer@uhns.nhs.uk 
 
 
Study Centre: Royal Stoke University Hospital / Keele University 
Study Number: CRP1 
Patient ID Number for this study: A001 
Please initial box if you agree with the statement 
 
1. I confirm that I have read and understood the information sheet dated 24/Jun/2016, version 
(1),for the above study and have had the opportunity to ask questions 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason and without my medical care or legal rights being affected. 
 
3. I understand that sections of my medical notes may be looked at by responsible individuals from 
regulatory authorities, the NHS trust or from the sponsor (Keele University), where it is relevant 
to my taking part in this research. I give permission for these individual to have access to my 
data. 
 
4. I understand that once the study has been completed, my serum sample will be transferred back 
to the Royal Stoke University Hospital and disposed off using the normal procedures. 
 
5. I agree to take part in the above study. 
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_______________________ 
Name of participant 
___________________ 
Date 
_____________________ 
Signature 
________________________  
Name of person taking consent  
___________________ 
Date 
____________________ 
Signature 
 
[Original to be filed in site file, copy to be given to patient; copy to be filed in patient’s medical records] 
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Concentrations of CRP in the initial samples provided by UHNM and in the purified 
samples of mCRP and pCRP, the volumes of purified mCRP & pCRP samples are also 
provided. 
 
Sample 
ID 
Type of 
diabetes 
Concentration 
of CRP 
provided by 
UHNM (mg/L) 
Volume of 
Purified 
pCRP 
Samples 
(mL) 
Concentration 
of pCRP in 
purified 
samples 
(mg/L) 
Volume of 
purified 
mCRP 
Samples 
(mL) 
Concentration 
of mCRP in 
purified 
samples 
(mg/L) 
CRP01 Type II 100.4 0.5 26.96 0.5 0.065 
CRP02 Type II 113.3 0.6 18.92 0.8 0.074 
CRP03 Type II 152.2 0.7 57.75 0.9 0.100 
CRP04 Type II 121.55 0.48 12.30 0.8 0.180 
CRP05 Type II 141.1 0.78 4.09 0.6 0.082 
CRP06 Type II 157.2 0.48 26.60 0.45 0.044 
CRP07 Type II 131.3 0.48 38.07 0.5 0.056 
CRP08 Type II 224.8 0.4 42.38 0.45 0.043 
CRP09 Type II 164.2 0.47 39.06 0.45 0.045 
CRP10 Type II 100.2 0.48 16.61 0.5 0.047 
CRP11 Type II 169.5 1 23.77 0.9 0.076 
CRP12 Type II 104.3 1 11.24 0.6 0.066 
CRP13 Type II 101.4 0.8 12.95 0.95 0.091 
CRP14 Type I 120.1 0.9 41.15 1.1 0.101 
CRP15 Type II 227.5 0.9 47.02 0.9 0.110 
CRP16 Type II 134.2 0.9 15.52 0.85 0.088 
CRP17 Type II 152 0.7 46.76 0.8 0.219 
CRP18 Type II 118 0.85 28.75 0.75 0.126 
CRP19 Type II 162.1 1 37.87 0.9 0.105 
CRP20 Type I 118 0.6 31.46 0.6 0.132 
CRP21 Type II 248.2 0.7 48.43 0.8 0.174 
CRP22 Type II 185.1 0.7 34.60 0.7 0.078 
CRP23 Type I 143 0.9 32.34 0.7 0.067 
CRP24 Type I 127.2 0.9 26.07 0.45 0.050 
 
 
 
 
